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Abstract
Cellular communication and the link between the extracellular and intracellu-
lar environments are in part mediated by signalling events from plasma mem-
brane proteins. Their tight regulation by a diverse array of post-translational
modifications (PTM) is essential to maintain the cellular integrity. Under-
standing these modifications would help with understanding cancer cell pro-
gression.
Dystroglycan is one of the plasma membrane proteins with both structural
and signalling properties, and is a core component of the dystrophin associ-
ated protein complex (DAPC). The nuclear localisation of dystroglycan and
some DAPC members suggests similar roles to those observed in the plasma
membrane. Dystroglycan is composed of an alpha and beta subunits that
are modified by different PTM. The altered glycosylation of alpha and the
phosphorylation of Y890 in beta, are triggering factors for the instability of
dystroglycan leading to the disruption of the DAP complex. In cancer studies,
it has recently been indicated that in addition to the above-mentioned PTM,
other signalling events such as additional phosphorylation sites and ubiqui-
tination, could mediate the rapid turnover of dystroglycan from the plasma
membrane and from the nucleus.
Here we show that beta-dystroglycan is susceptible to additional phospho-
rylation, and we were able to demonstrate its multiple ubiquitination. Further
experiments revealed that beta-dystroglycan is subject to intramembrane pro-
vii
teolytic events induced by increased cellular density and PDBu treatment.
Interestingly, we observed the translocation of beta- dystroglycan to the nu-
cleus due to high cell density growth. By enzymatic inhibition studies we
were able to identify gamma-secretase and furin as the enzymes responsible
for the shedding of beta-dystroglycan from both the plasma membrane and
nuclear envelope. Interestingly, we observed the preferential nuclear translo-
cation and degradation by the proteasome of the cytoplasmic fragment of
beta-dystroglycan. An interactome analysis by mass spectrometry techniques
revealed that beta-dystroglycan interacts with components of the ubiquitin-
proteasome system, the cell-cycle, and the nucleus.
This all together suggests that, the regulated intramembrane proteolysis
mediated by ubiquitination and phosphorylation PTM of beta-dystroglycan
triggers downstream nuclear signalling events. These findings provide more
ideas of the mechanisms implicated in the regulation of beta-dystroglycan and
importantly, of some nuclear processes wherein beta-dystroglycan is involved.
These insights may have further implications in the understanding of the pro-
gression of cancer and the development of useful therapies.
viii
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1
Generalities
1.1 Introduction
Humans are able to develop their daily activities thanks to the concerted func-
tions of their organs and systems. Within each organ, the activity performed
by every single cell is pivotal for maintaining a healthy status in the human
body, the so called, homeostasis. Furthermore, cellular integrity is dictated
by the correct synthesis, processing and interaction of its bio-molecules into
a complex network of signalling pathways in space and time. Although cells
are provided with specialized mechanisms to cope with possible alterations of
these pathways, sometimes these alterations are not detected by cells, leading
to detrimental effects which result in serious outcomes such as cancer.
1.2 Cancer
Normal cells are able to perform different activities throughout their lifespan,
but are always restricted by certain biological boundaries. Generally, nor-
mal cells are able to reproduce themselves at the right place and time and,
once their normal activities are culminated, they programme their own death.
Healthy cells are also coordinated by other cells and stop growing once they
touch another cell.
Cancer cells, on the other hand, do not exhibit the same characteristics as
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those present in normal cells. The main definition of cancer is the uncontrolled
growth of the cells, and this growth leads to the formation of tumours. The
increase in the tumour size can have different consequences: the deprivation
of nutrients to normal adjacent cells, the invasion and alteration of normal
functions of adjacent or distant tissues (metastasis), or the damage of adjacent
tissues by interfering in their physical space. Cancers are named according to
the source where the original deregulated cell comes from and therefore, there
are as many cancers as cells type in the human body. Cancers are complex
diseases, as multiple factors can contribute to their development including
a person’s environment and genetic background. These factors are usually
strong enough to damage critical biomolecules, such as DNA, which in turn
disrupts the normal functions of the cells ((Blanpain, 2013; Boland, 2003;
Merlo, Pepper, Reid, & Maley, 2006) and http://www.cancer.gov, http://
www.cancerresearchuk.org, http://www.who.int/cancer/en/).
Cancer cells have inherent features that distinguish them from normal cells,
termed ”hallmarks”. Hanahan and Weinberg classified these ”hallmarks” into
6 groups, plus two ”emerging hallmarks”. The ”hallmarks” of cancer are:
sustained proliferative signalling, evasion of growth suppressors, resisting cell
death, replicative immortality, induction of angiogenesis, and activation of in-
vasion and metastasis. Deregulating cellular energetics and avoiding immune
destruction account for the emerging hallmarks, and genome instability and
mutation, as well as tumour-promoting inflammation are enabling character-
istics of cancer (Hanahan & Weinberg, 2011; Lazebnik, 2010). The acquisition
of these characteristics may be a gradual process, involving multiple steps.
However, in the end, all these characteristics may be present within malignant
cells (Hainaut & Plymoth, 2013).
The growth of normal cells is restricted by their own and extracellular sig-
nals. In the case of growth signals, cancer cells may develop two mechanisms
to sustain proliferation, one dependent and one independent of growth factors,
in addition to the disruption of factors that control the cell cycle. In malignant
cells the production of growth factors may act in an autocrine or paracrine way
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to stimulate themselves or to stimulate neighbouring cells, or increase the con-
centration of growth factor receptors present at the cell membrane. Alterations
to the DNA, which lead to the constant activation of growth receptors and the
disruption of the mechanisms that decrease the signals of proliferation, account
for the mechanisms involved in sustaining proliferative signalling through the
growth factor independent mechanism (Hanahan & Weinberg, 2011).
Once cancerous cells have gained the ability to sustain proliferation, they
have to develop mechanisms in order to avoid growth suppressors. Al-
though there are many, retinoblastoma associated (RB) and TP53 are the two
canonical tumour suppressors. In cancer cells, as the RB and TP53 functions
are damaged, the cells are able to have a continued cell proliferation and to
escape apoptosis respectively. Additionally, cells are able to evade contact in-
hibition of growth and the antiproliferative effects of tumour growth factor β
(TGFβ) (Hanahan & Weinberg, 2011).
Apoptosis (programmed cell death) is one of the main characteristics
that differentiate normal cells from cancerous counterparts. In the case of
malignant cells, they develop mechanisms to bypass apoptotic events mediated
by TP53. Also, they are able to up-regulate or down-regulate the expression
of antiapoptotic or proapoptotic agents respectively. Autophagy and necrosis
are two mechanisms that can be advantageous to cancer cells. Autophagy
can provide metabolites to the fast growing cells, which require of a large
amount of nutrients, and necrosis, by releasing the cellular components to the
exterior, can have proinflammatory and tumour-promoting potentials (Fernald
& Kurokawa, 2013; Hanahan & Weinberg, 2011).
Whilst a normal cell is destined to programmed cell death upon completion
of its functions, a malignant cell has the potential of replicative immortal-
ity. This mechanism is sustained mainly by taking control of the enzyme
telomerase and up-regulating its functions. In this way, telomerases maintain
elongated telomeres, which in turn allow the cells to avoid senescence and
escape apoptosis (Hanahan & Weinberg, 2011).
The formation of new tumours requires a sustained supply of nutrients and
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also a way to dispose of metabolic waste. This is achieved by the formation
of new vessels (vasculogenesis) and the branching of the pre-existing
ones (sprouting), which remain active as the tumour grows and develops.
Additionally, pericytes and bone marrow-derived cells are important players
in tumour angiogenesis (Hanahan & Weinberg, 2011).
The progression of tumours into more malignant stages is in part achieved
by regional invasion and distant metastasis. The characteristic step into
this hallmark is the loss of cell-cell and cell-extracellular matrix contacts. Upon
the downregulation of cell adhesion proteins, among them E-cadherin, cancer-
ous cells are able to change their morphology and adhesive properties. This
series of events in turn leads to the up-regulation of adhesion proteins involved
in cell migration. The ”invasion-metastasis cascade” is a gradual event charac-
terised by regional invasion, intravasation into local blood and lymphatic ves-
sels, travelling through the lymphatic-haematic stream, exiting of cancerous
cells from vessels into new sites under colonisation (extravasation), formation
of micrometastasis and the colonisation of a new environment (growth of the
new tumour).
This cascade is regulated by a process called epithelial-mesenchymal tran-
sition (EMT). This mechanism is characterised by the loss of cell adhesions at
the adherens junctions with a consequent change in cellular morphology, syn-
thesis of enzymes in charge of degrading extracellular matrix, gain of mobility,
and the ability to evade apoptosis. EMT is commonly supported by neigh-
bour cells, such as macrophages, which are in charge of secreting enzymes
to help in the remodelling of the extracellular matrix. Once malignant cells
have colonised a new site, they can change their morphology to an epithelial-
like shape through a process called mesenchymal-epithelial transition (MET).
Following this, malignant cells will be required to adapt to the new environ-
mental conditions, ”or colonization” (Bogenrieder & Herlyn, 2003; Hanahan &
Weinberg, 2011; Lu, Weaver, & Werb, 2012; Yilmaz, Christofori, & Lehembre,
2007).
Additional hallmarks include the alteration of the energetic balance in or-
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der to support the continuing growth of the tumour, and escape of immune
system destruction, characteristics facilitated by two main mechanisms: the
alteration to the DNA (genomic instability) and tissue inflammation (Hanahan
& Weinberg, 2011).
1.3 Prostate cancer
The prostate is a small gland, part of the men’s reproductive system that
helps in the production of semen (http://www.cancer.org/index). Prostate
cancer is a very heterogeneous and complex disease, and is the second most
common malignancy in men. During the year 2012, approximately 1.1 million
male patients were diagnosed with prostate cancer around the world, which
represented 15% of all the cancers affecting men. In the same year, the 307,000
deaths attributed to prostate cancer, represented the 5th main cause of death
from cancer in men (http://globocan.iarc.fr/Default.aspx). According
to Cancer Research UK, older men have a higher probability of being diagnosed
with prostate cancer, with a median age of diagnosis above 70 years (http://
www.cancerresearchuk.org).
Prostate cancer tumours have particular characteristics. Prostate cancer
cells can be divided into two main groups, androgen dependent and androgen
independent, based on their capacity to respond to 5α-dihydrotestosterone.
Prostate tumours have a predilection to form metastases to skeletal bone,
lymph nodes, lung and liver. Prostate cancer cells express the antigen mark-
ers prostate specific antigen (PSA) and prostate-specific membrane antigen
(PSMA). Additionally, the interaction of the tumour with its microenviron-
ment seems to be of particular importance for the colonisation of new metastatic
sites (Morrissey & Vessella, 2007; Russell & Kingsley, 2003).
Hormone therapy, radical prostatectomy and radiation therapy are the first
choice therapies in prostate cancer. However, recurrence and resistance to-
wards hormone treatment, or invasion and metastasis are the main factors
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associated with the advanced stages of prostate cancer, and these factors usu-
ally subvert the previous therapies resulting in death (Balk & Knudsen, 2008;
Collins & Maitland, 2006; Morrissey & Vessella, 2007).
An understanding of the molecular mechanisms associated with the origin,
development and progression of prostate cancer is therefore required in order to
develop efficient therapies. The best way to explore the mechanisms associated
with prostate cancer progression is by using models that represent the human
body in order to mimic the same processes in prostate cancer progression.
Animal models represent a good option, however, the ethical issues and the
cost of their handling make them difficult models in the study of prostate
cancer and in the design of therapies (Sobel & Sadar, 2005).
Cell culture models have been developed to surpass this problem. The best
representative models of prostate cancer are the DU145, PC3 and LNCaP cell
lines. DU145 cells were derived from a central nervous system metastasis, are
not androgen responsive, do not express PSA and androgen receptor (AR) and
have a mutated p53. PC3 cells, were derived from a lumbar metastasis, have
a deletion in p53 and similar to DU145, are not androgen sensitive and do not
express PSA and AR (Russell & Kingsley, 2003; Sobel & Sadar, 2005).
LNCaP cells are a cell line that is androgen sensitive, expresses acid phos-
phatase, PSA and AR and have a silent mutation in p53. This metastatic
cell line was derived from a supraclavicular lymph node from a Caucasian
50-year-old male patient with prostatic adenocarcinoma and was first isolated
by Horoszewicz and colleagues (Horoszewicz et al., 1983; Russell & Kingsley,
2003; Sobel & Sadar, 2005).
Additional characteristics of this cell line include: an in vitro doubling time
of approximately 60 hours, an ability to develop tumours in athymic nude mice,
an ability to undergo functional differentiation, loose attachment to a substrate
unless poly-L-lysine is used, and once they reach high densities, they detach
forming clumps (Horoszewicz et al., 1983; Russell & Kingsley, 2003; Sobel &
Sadar, 2005).
The invasive potential of these cells suggests that some proteins involved in
10
1.4. THE DYSTROPHIN ASSOCIATED PROTEIN COMPLEX
attaching them to the cell surface in order to restrict their uncontrolled growth
may be damaged. Integrins are good candidates, however, components of the
dystrophin associated protein complex (DAPC) also play an important role
as ”potential tumours suppressors” (Lu et al., 2012; Sgambato & Brancaccio,
2005).
1.4 The dystrophin associated protein com-
plex
The dystrophin associated protein complex (DAPC) is a group of proteins
associated with dystrophin (Ervasti, Ohlendieck, Kahl, Gaver, & Campbell,
1990; Ervasti & Campbell, 1991). DAPC components can be divided into ex-
tracellular, transmembrane and cytoplasmic proteins. The main components
are: dystrophin/utrophin, dystroglycan, sarcoglycans, sarcospan, syntrophins,
dystrobrevin, syncoilin, nNOS (Figure 1.1) (Allikian & McNally, 2007; Con-
stantin, 2014; Ehmsen, Poon, & Davies, 2002).
In striated muscle the DAPC confers protection to the sarcolemma during
muscle contraction and relaxation, and serves as a physical connection be-
tween the cytokeleton and the extracellular matrix (Petrof, Shrager, Stedman,
Kelly, & Sweeney, 1993), the lack of which leads to necrosis of the muscle fi-
bres (Ibraghimov-Beskrovnaya et al., 1992), a triggering molecular factor in the
pathogenesis of muscular dystrophy (Ervasti et al., 1990). Some of the proteins
within the DAPC have signalling properties and for this reason it is believed
that the DAPC also plays a role in signalling events. Importantly, some pro-
teins can harbour motifs such as SH2, SH3, WW, PDZ binding targets, which
are implicated in protein-protein interactions, conferring the DAPC with scaf-
folding properties (Constantin, 2014). Each component within the DAPC
has critical roles, as the alteration of any of these can lead to varying and
severe outcomes: some resulting in embryonic lethality, others, in muscular
dystrophy-like phenotypes (Ehmsen et al., 2002; Whitmore & Morgan, 2014).
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1.5 Dystroglycan
1.5.1 Biosynthesis and structure of dystroglycan
Although later confirmed to be the same proteins (Smalheiser & Kim, 1995),
dystroglycan was originally termed cranin (Smalheiser & Schwartz, 1987), and
was first isolated from neural cells, and described as a 120 kDa glycoprotein
with laminin binding properties (Douville, Harvey, & Carbonetto, 1988; Smal-
heiser & Schwartz, 1987; Gee et al., 1993).
Human dystroglycan (dystrophin associated glycoprotein) is encoded by
the DAG1 gene, and was mapped to band 21 of the short arms of chromosome
3 (locus 3p21.1-21.31) by using skeletal muscle cDNA. The DAG1 gene has two
exons separated by an intronic region (Ibraghimov-Beskrovnaya et al., 1993).
In mice, Dag1 is located on chromosome 9 (Go´recki, Derry, & Barnard, 1994).
Pre-mRNA splicing of human DAG1 generates a transcript with the coding
sequence for an immature protein of 895 amino acids. The 97 kDa trans-
lated immature protein is further cleaved after amino acid 653 (Holt, Crosbie,
Venzke, & Campbell, 2000), to generate the 56 kDa core alpha- and 43 kDa
beta-subunits of dystroglycan. Although these subunits remain together on the
plasma membrane, they are not covalently attached. The primary structure of
mature dystroglycan, commencing on the extreme N-terminus, can be divided
in to three main sequences: 1) a hydrophobic fragment corresponding to a sig-
nal peptide; 2) alpha-dystroglycan, which harbours many amino acids prone to
post-translational modifications (PTM) such as N- and O-glycosylation; and
3) beta-dystroglycan, which has a potential residue that can be subject to
N-glycosylation, a transmembrane domain and a cytoplasmic fragment rich in
proline residues (Ibraghimov-Beskrovnaya et al., 1992) (Figure 1.2).
Depending on the tissue, mature alpha-dystroglycan is glycosylated to dif-
fering extents, leading to a variation in its size from approximately 120 kDa to
near 160 kDa (Ibraghimov-Beskrovnaya et al., 1992). Its structure consists of
N- and C-terminal globular domains separated by a central rod or mucin-like
domain (Brancaccio, Schulthess, Gesemann, & Engel, 1995, 1997). In com-
13
CHAPTER 1. GENERALITIES
Alpha/beta-dystroglycan precursor (97 kDa)  
1 29 654 895 750 776 316 486 
~30 kDa ~40 kDa (~120-200 kDa) ~41 kDa (~43 kDa) 
N MUCIN C N 
Alpha-dystroglycan Beta-dystroglycan 
SP TM NL
S 
PP
PY
 
774 808 892 
(a)
α 
β 
(b)
Figure 1.2: Biosynthesis of dystroglycan. (a) The schematic shows the struc-
tural organization of human dystroglycan. Alpha-dystroglycan harbours many
potential sites for N-glycosylation (branches) and O-glycosylation (black cir-
cles), beta-dystroglycan on the other hand is glycosylated to a lesser extent.
The transmembrane domain (TM), nuclear localisation signal (NLS) and the
PPXY motif are shown. Lightnings represent the approximate location of the
proteolytic cleavages by furin, autolysis and MMP. The known sites for palmi-
toylation, ubiquitination and phosphorylation are shown in orange, green and
yellow circles respectively. Numbers in parentheses represent the molecular
weight of mature proteins. (b) The mature protein is embedded in the plasma
membrane with alpha-dystroglycan facing the extracellular environment.
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parison, beta-dystroglycan has an unfolded N-terminal domain, followed by
a transmembrane fragment and a highly disordered C-terminal cytoplasmic
domain (Akhavan, Crivelli, Singh, Lingappa, & Muschler, 2008; Boffi et al.,
2001; Di Stasio et al., 1999) (Figure 1.2a).
Human dystroglycan functions may be diverse as it is highly expressed in
skeletal and heart tissues, and to a lesser extent in brain, placenta, lung, liver,
kidney, pancreas tissues (Ibraghimov-Beskrovnaya et al., 1993).
Dystroglycan has a high degree of homology and is expressed amongst dif-
ferent species including human (Ibraghimov-Beskrovnaya et al., 1993), mouse
(Go´recki et al., 1994), rabbit (Ibraghimov-Beskrovnaya et al., 1993, 1992), ze-
brafish (Parsons, Campos, Hirst, & Stemple, 2002), Drosophila (Deng et al.,
2003), dog (Leeb, Neumann, Deppe, Breen, & Brenig, 2000) and C. elegans
(Grisoni, Martin, Gieseler, Mariol, & Se´galat, 2002).
1.5.2 Dystroglycan, multiple signalling and protein-protein
interactions
Dystroglycan is on first inspection a passive protein whose function is to serve
as a bridge between the basal lamina and the dynamic cytoskeleton. However,
there are some internal characteristics within the structure of dystroglycan
that enable it to change from a static to a very dynamic status.
In the extracellular environment, alpha-dystroglycan is highly glycosylated.
This property allows its interaction with members of the extracellular matrix
such as laminin, agrin, neurexin, perlecan and pikachurin via LG domains
(Montanaro, Lindenbaum, & Carbonetto, 1999; Winder, 2001). The disruption
of this interaction, due to hypo-glycosylation, can lead to deleterious effects
such as muscular dystrophies.
Alpha-dystroglycan is also a receptor for Mycobacterium leprae (Rambukkana
et al., 1998) and Lassa fever and lymphocytic choromeningitis viruses (Cao et
al., 1998). Again, glycan groups on its surface are important for its interac-
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tion with the viruses (Kunz et al., 2005) (Figure 1.3). Importantly, a recent
hypothesis states that low levels of glycosylation on alpha-dystroglycan and
the proteolysis of beta-dystroglycan by MMPs could be a protective mecha-
nism against pathogenic infection (Emery, 2008; Sciandra et al., 2003). In this
regard, it should not be forgotten that alpha-dystroglycan is susceptible to a
proteolytic cleavage by furin (Singh et al., 2004). Then, it may be that all these
mechanisms, which affect the stability of dystroglycan, modulate the suscepti-
bility of cells to bacterial and viral infection. Furthermore, invasive processes
not only involve an interaction between dystroglycan and the pathogen, but
also downstream signalling events. Moraz and colleagues demonstrated that
the internalisation of Lassa virus triggered the phosphorylation of tyrosine
residues on beta-dystroglycan (other than Y892) and the disruption of the
interaction between dystroglycan and utrophin (Moraz et al., 2013).
From these examples, it is clear that the alteration of alpha-dystroglycan
can have consequences involving the beta subunit and other intracellular pro-
teins. Importantly, the same mechanism seems to be applicable to other situ-
ations, for example, in cancer.
Beta-dystroglycan is also a very enigmatic protein. This protein is particu-
larly promiscuous because it has been found interacting with different proteins
within different complexes. Additionally it is subject to a wide range of post-
translational modifications: it can be phosphorylated (Sotgia et al., 2001),
ubiquitinated (K. A. Lee et al., 2011), glycosylated (Ibraghimov-Beskrovnaya
et al., 1992), sumoylated (Steve J. Winder, personal communication), palmi-
toylated (Kang et al., 2008) and proteolytically cleaved (Yamada et al., 2001).
The cytoplasmic region has different motifs such as SH2, SH3 and WW (Fig-
ure 1.5). Furthermore, its localisation in compartments other than the plasma
membrane such as the nucleus and its expression in different cell types and
species, confer additional properties on beta-dystroglycan beyond those al-
ready known in skeletal muscle (Figure 1.4).
The extracellular domain of beta-dystroglycan mediates the interaction
with its partner alpha. This domain is also important because it is the site
16
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Figure 1.3: Alpha-dystroglycan binding partners. Alpha-dystroglycan is an ex-
tracellular protein that interacts with components of the extracellular matrix
(laminin-2, agrin, neurexin, perlecan and pikachurin). It is also an impor-
tant receptor for mycobacterias and arenaviruses. Alpha-dystroglycan binds
through its carboxy terminus to the N-terminal side of beta-dystroglycan.
Laminin G-like (LG) domains in laminin are shown in yellow.
where MMP-2 and -9 perform a proteolytic cleavage resulting in the generation
of a 31 kDa transmembrane anchored fragment (Yamada et al., 2001).
The transmembrane domain, which could seem to be immune to any mod-
ifications, has been suggested as the site where gamma-secretase could further
cleave the 31 kDa fragment of beta-dystroglycan to generate another, smaller,
26 kDa fragment presumably in a regulated intramembrane proteolysis (RIP)
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Figure 1.4: Beta-dystroglycan is subject to different PTM. Beta-dystroglycan
is glycosylated and cleaved by MMPs on its extracellular domain. In the TM
region, it is further cleaved and subject to palmitoylation. The cytoplasmic
fragment on the other hand is modified by ubiquitination, sumoylation and
phosphorylation.
manner (Hemming, Elias, Gygi, & Selkoe, 2008) (Figure 1.4).
The plasma membrane contains proteins with different topologies that de-
pending on their orientation are classified into two main groups, type-I and
type-II proteins. Type-I proteins display their N-terminus towards the extra-
cellular environment and their C-terminus faces the cytosol; type-II proteins,
on the other hand, have an opposite orientation. The cleavage of these proteins
for particular cellular purposes, such as turnover or signalling, is performed by
a process termed RIP. This mechanism is achieved within the hydrophobic
environment of the plasma membrane by three main families of proteases:
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metalloproteases, aspartyl proteases and serine proteases. Within each family
there are subgroups of proteases that have a specific affinity for type-I or type-
II substrates. Type-I proteins are cleaved by gamma-secretase and rhomboid,
whereas type-II proteins can be cleaved by S2P, SPP/SPPL and PARL (Kopan
& Ilagan, 2004; Lemberg, 2011).
The proteolysis performed by gamma-secretase, a GXGD-type aspartyl
protease, is usually initiated by the cleavage of proteins on their N-terminal
extracellular domain by extracellular proteases (e.g. MMP), which renders
truncated anchored plasma membrane proteins that are efficiently processed
by gamma-secretase. Gamma-secretase refers to a group of integral plasma
membrane proteins, and is composed of Nicastrin, presenilin, Aph-1 and Pen-
2. The mechanism starts with the recognition of the truncated cleaved protein
by Nicastrin. Following this, Aph-1 which functions as a central platform,
brings together Nicastrin, presenilin and Pen-2. In the core of this complex,
the proteolytic cleavage of the substrate is performed by presenilin. Given
the fact that the substrates for gamma-secretase are very diverse, there is still
not a consensus sequence where gamma-secretase exerts its proteolytic action.
RIP mediated by gamma-secretase has many biological implications, such as
in protein turnover and cellular signalling, the deregulation of which can lead
to disease, such as cancer and neurological problems (Kopan & Ilagan, 2004;
Lemberg, 2011; Selkoe & Wolfe, 2007; Steiner, Fluhrer, & Haass, 2008; Wak-
abayashi & De Strooper, 2008)
The primary sequence of the 26 kDa fragment of beta-dystroglycan is
flanked by a cysteine residue in its amino-terminus (C774) (http://www.ncbi
.nlm.nih.gov/protein/Q14118.2). A recent report, aimed to investigate
palmitoylated proteins in neurons, identified C774 below the transmembrane
domain as a potential site for palmitoylation (Kang et al., 2008). Palmitoyl
modification is usually associated with the retention of proteins in the plasma
membrane (Aicart-Ramos, Valero, & Rodriguez-Crespo, 2011). So far, no
more investigations have been carried out to investigate the role of this PTM
in beta-dystroglycan (Figure 1.4).
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After the C774 residue, there is a stretch of basic amino acids with some
known reported functions. Through this group of lysine and arginine residues,
beta-dystroglycan interacts with the cytoskeletal protein ezrin, a member of
the adaptor ERM (ezrin, radixin, moesin) group of proteins. The implications
of this interaction were related to the formation of microvilli and fillopodia-
like structures, due to the remodelling of the F-actin cytoskeleton (Spence,
Chen, et al., 2004). Additionally, it was observed that the activity of Cdc42
was required for the targeting of beta-dystroglycan-ezrin in complex with Dbl
to the plasma membrane, and the consequences were the same as the ones
described above (Figures 1.5 and 1.6) (Batchelor et al., 2007).
This group of amino acids seems to be a kind of ’hot spot’ within the
sequence of beta-dystroglycan. In addition to the previous interactions, it was
demonstrated that this domain functions as a nuclear localisation signal (NLS)
as it was required for the nuclear translocation of beta-dystroglycan (Lara-
Chaco´n et al., 2010; Oppizzi, Akhavan, Singh, Fata, & Muschler, 2008). Then,
this domain seems to have dual functions, as it is important for the formation
of beta-dystroglycan-ezrin complex, which in turn leads to the formation of
cellular protrusions, and also, it is important for the nuclear translocation of
this complex in an ezrin-dependent manner (Figures 1.5 and 1.6) (Va´squez-
Limeta et al., 2014).
An additional function of this domain in neuromuscular junctions was
demonstrated. It was observed that rapsyn functioned as a bridge between
the acethylcholine receptor and beta-dystroglycan, and again, the stretch of
basic amino acids in beta-dystroglycan was found mediating the interaction
(Apel, Roberds, Campbell, & Merlie, 1995; Cartaud, Coutant, Petrucci, &
Cartaud, 1998). This group of basic residues is also a point of convergence
for the ERK MAPK-dystroglycan-integrin signalling pathways. The interac-
tion between beta-dystroglycan and ERK is mediated by the same stretch of
basic amino acids that function as an NLS. Interestingly, the sequestering of
ERK and MAPK by beta-dystroglycan is performed in different compartments
within the cell (Figure 1.6) (Bao et al., 2009; Ferletta et al., 2003; Moore &
21
CHAPTER 1. GENERALITIES
Winder, 2010; Spence, Dhillon, James, & Winder, 2004).
The cytoplasmic region of beta-dystroglycan harbours other motifs that
could potentially mediate interactions with other proteins. It contains sites
for interactions with proteins containing PDZ, WW, SH2 and SH3 domains
(http://www.elm.eu.org) (Moore & Winder, 2010) (Figure 1.5).
A tyrosine (Y892 in humans) within the PPXY motif located in the very
carboxy terminus of beta-dystroglycan has gained special attention, because
(depending on its phosphorylated status) this tyrosine can interact with WW
or SH2 domains. An initial characterization showed that it is phosphorylated
by Src and that, upon phosphorylation, it was able to interact with c-Src,
Fyn, Csk, NCK and SHC SH2 domains (Sotgia et al., 2001). On the other
hand, the phosphorylation of Y892 prevents the interaction between the car-
boxy terminus of beta-dystroglycan and the WW domain in utrophin (James
et al., 2000) or dystrophin (Ilsley, Sudol, & Winder, 2001; Rentschler et al.,
1999). Importantly, the disruption of this interaction by phosphorylated ty-
rosine was reported to render an unstable beta-dystroglycan, which is sus-
ceptible to proteasomal degradation However, when prevented, components of
the DAPC were restored to the plasma membrane, and the dystrophic pheno-
type of the mdx mouse was improved (Miller et al., 2012). In a similar form
as with dystrophin/utrophin, caveolin-3 has been shown to bind to the non-
phosphorylated tyrosine within the PPXY motif; however, caveolin-3 competes
with dystrophin for this interaction (Figure 1.6) (Ilsley, Sudol, & Winder, 2002;
Sotgia et al., 2000).
Another motif, with the consensus sequence RXXXPXXP, is found in the
very carboxy terminus of beta-dystroglycan and overlaps with the PPXY men-
tioned previously (Moore & Winder, 2010) (Figure 1.5). This motif in beta-
dystroglycan was reported to be required for the interaction with the SH3
motif of the protein Grb2 (Cavaldesi et al., 1999; Russo et al., 2000; Yang et
al., 1995). An additional interaction mediated by this motif is that between
beta-dystroglycan and the third SH3 domain in vinexin in focal adhesions.
Vinculin was also found in the focal adhesion complex, however, the associ-
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ation with beta-dystroglycan was attributed to the interaction of vinculin to
the first and second SH3 motifs in vinexin (Thompson et al., 2010). It was
not conclusively demonstrated, but this motif may mediate the interaction of
beta-dystroglycan to the SH3 domain in the adaptor protein TKS5, in complex
with Src during the formation of podosomes (Figure 1.6) (Thompson et al.,
2008).
In Drosophila, the WW-domain binding motifs in beta-dystroglycan have
been suggested to have redundant functions towards their interaction to dys-
trophin (Yatsenko et al., 2009). However it has to be remembered that beta-
dystroglycan not only binds dystrophin, but several other proteins. Therefore,
whilst one WW-domain binding motif interacts with dystrophin, the other
may mediate an interaction with another protein (Figure 1.5).
Dystroglycan may be subject to ubiquitination (it has not been defined if
both subunits or only one subunit of dystroglycan is subject to ubiquitination),
however, the limited evidence regarding this PTM is introduced here.
As explained in this chapter, in muscular dystrophies and cancer diseases,
a reduction in the protein levels of beta-dystroglycan is frequently observed.
Of the different hypotheses explaining this reduction, ubiquitination within
the ubiquitin-proteasome system stands as the most plausible.
The evidence of a potential ubiquitination on dystroglycan comes from ex-
periments performed with the proteasome inhibitor MG-132. The local and
systemic treatment of mdx mice, a mouse model of Duchenne muscular dystro-
phy with MG-132 led to the restoration of components of the DAPC (alpha-
and beta-dystroglycan and alpha-sarcoglycan) to the plasma membrane. Im-
portantly, this restoration was able to improve the dystrophic phenotype of the
mdx mice (Bonuccelli et al., 2003). A similar approach using muscle explants
from patients with Becker and Duchenne muscular dystrophy showed compa-
rable results (Assereto et al., 2006). By employing the FDA-approved drug
velcade (also a proteasomal inhibitor), later experiments with the same objec-
tive demonstrated a restoration of the DAPC members to the plasma mem-
brane, further confirming the involvement of the ubiquitin proteasome system
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Figure 1.6: Binding partners of beta-dystroglycan. Beta-dystroglycan inter-
acts with multiple proteins through its stretch of basic amino acids and its
SH2, SH3 and WW protein binding domains. Other proteins were omitted,
however, they are further mentioned in the following chapters.
in their degradation (Bonuccelli et al., 2007; Gazzerro et al., 2010). This set of
results, although not showing the direct ubiquitination of beta-dystroglycan,
clearly suggest that beta-dystroglycan is subject to ubiquitination.
There are some research groups reporting ubiquitinated dystroglycan (K. A. Lee
et al., 2011; W. Kim et al., 2011). However, the significance of this PTM in the
turnover of dystroglycan is still unknown. Additionally, it is still not known
how this PTM regulates the interaction of dystroglycan with other proteins, or
what its potential implication is in muscular dystrophies and cancer. Sumoy-
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lation, a PTM with some homology to ubiquitination, is thought to modify
dystroglycan, however the data supporting this is limited (Steve J. Winder,
personal communication).
The combination of all the post-translational modifications, the motifs and
the disordered structure of the cytoplasmic fragment, make beta-dystroglycan
an enigmatic protein with still more roles to discover. In order to understand
how the alterations of dystroglycan can lead to disease, it is necessary first
fully understand its regulation in space and time. A major caveat of previous
research has been the focus on dystroglycan and its functions as isolated events
at the protein level. However, it has to be understood that there may be many
pools of dystroglycan within a cell that have different forms of PTMs at the
same time: whilst one form bridges the cytoskeleton to the plasma membrane,
the other regulates transcription, cell cycle progression, development or neural
transmission, as shown below (Bello et al., 2015; Bozzi, Morlacchi, Bigotti,
Sciandra, & Brancaccio, 2009; Moore & Winder, 2010; Winder, 2001).
1.5.3 Dystroglycan in human disease
Dystroglycan is indeed an enigmatic protein. It takes part in a multitude of
pathways due to its ability to interact with other proteins and to its flexibility
to adopt different post-translational modifications (Barresi & Campbell, 2006;
Winder, 2001). Its critical role is supported by the fact that alterations in its
synthesis, in its primary structure, and in its modifications lead to very dra-
matic effects in the organism, as first described by Williamson and colleagues.
In that study, in contrast to the heterozygous mice which had an apparently
normal phenotype, the ablation of the Dag1 gene led to peri-implantation
lethality, which were characterised by alteration of Reichert’s membrane and
in the localisation of laminin and collagen extracellular matrix components
(Williamson et al., 1997).
Dystroglycan was mapped to the short arms of human chromosome 3 in
a locus that spans the region 3p21.1-3p21.31. An early report suggested a
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potential role for dystroglycan as a tumour suppressor, because of its ability
to facilitate the communication between the surrounding extracellular matrix
and the cytoskeleton (Sgambato & Brancaccio, 2005). Interestingly, there are
reports indicating that the region 3p21.3 harbours many genes with tumour
suppressor properties (Hesson, Cooper, & Latif, 2007) and furthermore this
region seems to be susceptible to different chromosomal rearrangements in
epithelial tumours, such as breast, lung, cervical, ovarian and others (Angeloni,
2007; Ji, Minna, & Roth, 2005; Lerman & Minna, 2000). It is also reported
that the same locus is involved in Crohn’s disease (Morgan, Han, Lam, Fraser,
& Ferguson, 2010). These findings indicate a potential role of dystroglycan in
cancer and Crohn’s disease.
Over time, subsequent reports have further highlighted the detrimental ef-
fects of the alteration of dystroglycan at its genomic level, named primary
dystroglycanopathies; and that of the enzymes in charge of the glycosyla-
tion of alpha dystroglycan, termed secondary dystroglycanopathies (see sec-
tion 1.5.3.1). However, the role of dystroglycan seems not to be only limited to
dystroglycanopathies, as a new role in cancer has emerged, as described later
(see section 1.5.3.2).
1.5.3.1 Dystroglycan in muscular dystrophies
The disease field involving dystroglycan that is most studied is that concerning
the muscular dystrophies. As understanding the effects of dystroglycan’s alter-
ations in muscular diseases could provides us with clues about its alterations
in cancer and vice versa, the impact of beta-dystroglycan in the muscular
dystrophies will be briefly discussed.
Muscular dystrophies are a group of gradually progressive inherited dis-
eases. At the cellular level, some of the main characteristics of these diseases
are the alteration in proteins levels of members of the DAPC and their glyco-
sylases, proteins associated to the nuclear membrane, and others (Mercuri &
Muntoni, 2013).
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A few studies of primary dystroglycanopathies have shown how important
dystroglycan is. Following the description by Williamson about the severe
effects of dystroglycan loss (Williamson et al., 1997), another report relating
the deficiency of beta-dystroglycan to a mild form of muscular dystrophy phe-
notype, further highlighted the consequences of the alteration of dystroglycan
in humans (the other components of the DAPC were normal) (Salih et al.,
1996). Later, although not confirmed that the phenotype was due to DAG1’s
alteration, the heterozygous deletion of a locus comprising the DAG1 gene in a
young female, resulted in a phenotype that resembled that of Walker-Warbur
syndrome and muscle-eye-brain disease (Frost et al., 2010).
The breakthrough to the critical role of dystroglycan was provided by
Kevin Campbell’s group. His group described the first known primary dys-
troglycanopathy. This was caused by the mutation Thr192Met located in the
N-terminal side of alpha-dystroglycan. This mutation, which prevented the
O-glycosylation performed by LARGE, led to a reduction in the binding of
dystroglycan to laminin. Thus, the critical role of dystroglycan is highlighted
by the fact that a single mutation was able to cause limb-girdle muscular
dystrophy, despite the fact that alpha-dystroglycan has many potential O-
glycosylation sites, other than those described here (Hara et al., 2011).
Additional mutations in the DAG1 gene leading muscular dystrophy phe-
notypes have been identified (Dong et al., 2015; Geis et al., 2013) and recently,
the first mutation leading to a complete absence of dystroglycan has been re-
ported (Riemersma et al., 2015).
Compared to the mouse, the ablation of dystroglycan in zebrafish was
not lethal, although a dystrophic phenotype was observed (Parsons et al.,
2002). Interestingly, the mutation V567D in Patchytail fish was able to cause
a muscular dystrophy-like phenotype (Gupta et al., 2011).
Secondary dystroglycanopathies are characterised by defects in glycosyl-
transferases that attach sugar groups to alpha-dystroglycan, which in turn
prevent the interaction of alpha-dystroglycan with laminin, neurexin, agrin
and perlecan, leading to the disruption of the connection between cytoskeleton
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and the extracellular matrix (Michele & Campbell, 2003). There are different
genes (enzymes) whose disruption have been shown to affect dystroglycan’s gly-
cosylation: they include LARGE (like glycosyltransferase), FKTN (fukutin),
FKRP (fukutin related protein), POMGNT1 (protein-O-linked mannose beta
1,2-N-acetylglucosaminyltransferase), POMT2 (protein-omannosyltranferase 2),
POMT1 (protein-O-mannosyltransferase 1), DPM2 (dolichyl-phosphate man-
nosyltranferase polypeptide 2), DPM3 (dolichyl-phosphate mannosyltranferase
polypeptide 3), and many others which were recently reported by Jae and col-
leagues (Brown & Winder, 2012; Jae et al., 2013; Godfrey, Foley, Clement,
& Muntoni, 2011). The phenotypes associated with these alterations are di-
verse, but they usually involve the damage to the skeletal muscle, cardiac
problems, ocular problems and mental retardation. The differential combina-
tion of these defects leads to distinct forms of muscular dystrophies, such as
Fukuyama congenital muscular dystrophy (FCMD), muscle-eye-brain disease
(MEB), Walker-Warburg Syndrome (WWS) and limb girdle muscular dystro-
phy (LGMD) which can also be divided in various sub-types (Brown & Winder,
2012; Godfrey et al., 2011; Mercuri & Muntoni, 2013; Michele & Campbell,
2003).
Current research is aimed to gain a better understanding of dystroglycan
glycosylation. This PTM is so critical that there are numerous genetically
modified mouse models for many of the enzymes implicated in the glycosy-
lation of dystroglycan; in addition, other mouse models that are deficient for
constituent proteins of the DAPC other than dystroglycan have been gener-
ated (Whitmore & Morgan, 2014). Additional research aims to understand
the glycosylome of alpha-dystroglycan, which includes the way dystroglycan
is structurally modified, and additional players involved in its glycosylation
(Harrison et al., 2012; Jae et al., 2013; Nilsson, Larson, & Grahn, 2010; Stal-
naker et al., 2010, 2011)
Altogether, these findings demonstrate that dystroglycan is important and
that small changes in its primary structure or post-translational modifications
can lead to severe effects in humans. From the examples so far, the prevail-
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ing factor as a cause of disease is the hypo-glycosylation of alpha-dystroglycan.
Therefore, finding a way of producing normal, glycosylated alpha-dystroglycan
will be a breakthrough in muscular dystrophies. However, dystroglycan is a
protein not only expressed on the sarcolemma in skeletal muscle, but a protein
that is also expressed in nervous and epithelial tissues. In epithelial tissues,
dystroglycan maintains the cellular integrity and restricts the uncontrolled
growth of the cells by its interaction with components of the extracellular
matrix. This lead us to question, what do dystroglycan’s roles in cellular envi-
ronments other than those of skeletal muscle tell us about its role in disease?
1.5.3.2 Dystroglycan in cancer
In the previous section it was highlighted how important the role of dystro-
glycan is at the plasma membrane. In skeletal muscle, through its association
with other members of the DAPC, dystroglycan provides structural roles, and
functions as a kind of bridge, facilitating communication between the exterior
and interior environments of the cells. Interestingly, in epithelial cells these
same mechanisms seem to be governing dystroglycan and, importantly, the
disruption of those mechanisms are an important part in the development of
cancer (Sgambato & Brancaccio, 2005).
The cross-linked extracellular matrix, the basement membrane, surrounds
epithelial and endothelial tissues as a form of protection. The communication
of the cell with its extracellular environment is mediated by the interaction be-
tween components in the extracellular matrix, such as laminin, agrin, collagen,
perlecan and nidogens, and receptor proteins found on the plasma membrane of
the cells, which can include integrins, dystroglycan, sarcoglycan, the Lutheran
glycoprotein and sulfatides. This interaction is important in order to regu-
late the behaviour of the cell, and importantly, the disruption of the integrity
of the basement membrane favours the invasion and migration of metastatic
cells. Thus, a cell can be modulated from the outside, and vice versa, by
changing the activation of genes responsible for producing components of the
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extracellular matrix and the adhesion proteins that interact with it, the cell
can modulate its interaction with the surrounding tissue environment (Kelley,
Lohmer, Hagedorn, & Sherwood, 2014; Yurchenco, 2011).
In this regard, integrins are a group of proteins that confer adhesion to cells
during migration and invasion, as well as participating in signalling between the
interior and exterior environments. By adhering to the extracellular matrix,
integrins are able to trigger downstream signalling pathways involved in the
remodelling of the cytoskeleton which in turn lead to the formation of cellular
structures, like lamellipodia (outside-in signalling). The processes mediated
by integrins are important not only at the front of the cells but also at the
rear. Here, in order to migrate, the cell has to detach from the substrate, a
process that involves the degradation or internalization of integrins (Hood &
Cheresh, 2002). Hence, integrins can also respond to intracellular signals to
change their extracellular binding capabilities (inside-out signalling).
Dystroglycan, a topologically similar protein to the integrins, shares a sim-
ilar functionality. Glycosylated dystroglycan interacts with laminin (or other
components of the extracellular matrix) (Matsumura et al., 1997), which in
turn is able to trigger the assembly of the basement membrane (Yurchenco,
2011). In cancer, the interactions that dependend on the glycosylation state
of alpha-dystroglycan, are also implicated in cell migration and invasion. Bao
and colleagues observed that the formation of prostate tumours and metastasis
was dependent on the degree of glycosylation on alpha-dystroglycan; hyper-
glycosylation alpha-dystroglycan lead to the formation of small tumours and
fewer metastatic events compared with hypo-glycosylated alpha-dystroglycan.
They concluded that the glycosylation on alpha-dystroglycan mediated by
β3GnT1 allowed the interaction with laminin, in turn attenuating downstream
events of the integrin pathway such as the sequestering of ERK (Bao et al.,
2009).
Changes to the glycosylation of alpha-dystroglycan seem to be common
in the development of cancer, as a similar phenomenon was observed by an-
other group in metastatic prostate cancer. However, high rates of invasion
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and proliferation were only detected with reduced levels of LARGE2 (Esser et
al., 2013). This phenomenon of the interaction between glycosylated alpha-
dystroglycan and laminin in tumorigenicity is also reported for breast cancers
(Akhavan et al., 2012). Although the enzyme responsible for the altered gly-
cosylation of alpha-dystroglycan (which in turn leads to the interaction with
laminin) is not reported by the studies, it is clear that the altered glycosylation
of alpha-dsytroglycan is a triggering event in the development of malignancies
such as: oesophageal (Parberry-Clark, Bury, Cross, & Winder, 2011), prostate
(Shimojo et al., 2011), pediatric solid tumours (alveolar rhabdomyosarcoma,
embryonal rabdomyosarcoma, neuroblastoma and medulloblastoma) (Martin,
Glass, Dosunmu, & Martin, 2007), cervical and vulvar (Sgambato, Tarquini,
et al., 2006).
In addition, glycosylation appears to confer protection to alpha-dystroglycan
and the other members of the DAPC. In other words, not only alpha-dystroglycan
is affected by the absence of this PTM: beta-dystroglycan is affected as well.
Upon hypo-glycosylation of alpha-dystroglycan, beta-dystroglycan is suscepti-
ble to proteolysis by proteases found in the extracellular environment. Previous
studies have shown that the cleavage between residues His-715 and Leu-716
on the extracellular globular domain of beta-dystroglycan (Bozzi, Inzitari, et
al., 2009) by matrix metalloproteases-2 and -9, results in a 31 kDa plasma
membrane attached fragment (Jing et al., 2004; Michaluk et al., 2007; Shang,
Ethunandan, Go´recki, & Brennan, 2008; Yamada et al., 2001; Zhong et al.,
2006).
Importantly, the presence of this fragment seems to be associated with dis-
ease. In the case of muscular dystrophies, the 31 kDa transmembrane fragment
was observed to be increased in sarcoglycanopathies and DMD (Matsumura et
al., 2005). In cancer, increases in the 31 kDa fragment were observed in squa-
mous cell carcinoma (Jing et al., 2004; Shang et al., 2008), breast (Losasso
et al., 2000), colon (Losasso et al., 2000), cervical (Losasso et al., 2000) and
prostate tumour cells (Losasso et al., 2000). Furthermore, this small 31 kDa
fragment was also observed in stroke and heart attack (Armstrong, Latham,
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& Ganote, 2003).
Additionally, and although the causes of the reduction were not determined,
full-length dystroglycan was found to be greatly decreased or absent at the
plasma membrane in most types of cancer studied including: breast (Cross et
al., 2008; Henry, Cohen, & Campbell, 2001; Muschler et al., 2002; Sgambato
et al., 2003), prostate (Henry et al., 2001; Sgambato et al., 2007), colon (Cross
et al., 2008; Sgambato et al., 2003), oesophageal (Cross et al., 2008; Parberry-
Clark et al., 2011) and transitional cell carcinomas of the urothelium (Cross
et al., 2008).
Therefore, it seems that the mechanism by which dystroglycan is reduced
from the plasma membrane starts with problems in the glycosylation of alpha-
dystroglycan. This in turn renders an exposed beta-dystroglycan that is sus-
ceptible to cleavage by matrix metalloproteases, which confers an advantage
in the mestastatic process of cancerous cells.
1.5.4 The nuclear translocation of beta-dystroglycan
The initial characterization of dystroglycan clearly established its important
role within the DAPC in order to confer stability to muscle fibres during con-
traction and relaxation. Throughout the years, further discoveries correlated
the alteration of dystroglycan as an important cause of muscular dystrophies.
More recently, research into dystroglycan has extended to cancer, where many
studies have correlated the reduced expression of dystroglycan with cancer
progression. Although it was not completely understood, the general idea was
that dystroglycan was the anchor of the cell to the extracellular matrix, pro-
viding integrity to the sarcolemma or, in the case of cancer, restricting the
uncontrolled growth of cells.
The puzzle became more complicated with the description by the Cisneros
group of the dystrophin variant Dp71 in the nucleus of cervical (HeLa), mus-
cle (C2C12), neuroblast (N1E-115) (Gonza´lez et al., 2000) and pheochromo-
cytoma (PC12) cells (Marquez et al., 2003). The initial observation of the
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co-localization between beta-dystroglycan and Dp71 prompted the question as
to whether other members of the DAPC were also present in the nucleus of
the cell. Later research performed by the same group revealed the localisation
of beta-dystroglycan and other members of the DAPC such as Dp71, sarco-
glycan, dystrobrevin, syntrophin and nNOS in the nucleus of cervical cancer
cells. It was then thought that the functions of the new nuclear complex were
related to scaffolding-related activities (Fuentes-Mera et al., 2006).
A further logic step was to determine the way that this complex, in partic-
ular beta-dystroglycan, was travelling to the nucleus.
The nuclear membrane is an important structure that divides the interior
of the cell into two spatial compartments, the nucleoplasm and the cytosol.
This compartmentalisation separates the machinery involved in the synthesis
of mRNA (transcription) in the nucleoplasm, from that involved in the pro-
duction of proteins (translation) in the cytosol. The communication between
both compartments is enabled by the presence of macromolecular structures
embedded in the nuclear membrane called nuclear pore complexes (NPC).
These complexes allow the regulated transport of proteins between the cytosol
and the nucleoplasm through a mechanism known as the nuclear import path-
way, and involves the protein to be transported (cargo) and adaptor proteins
(carriers) known as importins (karyopherins) or exportins (Kau, Way, & Silver,
2004; Stewart, 2007; Wente & Rout, 2010).
For proteins with a molecular weight (MW) below 40 kDa it is believed
that the mechanism of nuclear import through the NPC is by protein diffusion
and does not require carriers. On the other hand, proteins with a MW equal
or higher than 40 kDa require the presence of the importin system in order
to be translocated to the nucleus. Furthermore, high MW cargoes require
signals within their primary sequence in order to be recognised by the importin
system. These signals, known as nuclear localisation sequences (NLS), can
consist of a single stretch of basic amino acids composed of ∼ 4−5 amino acids
(monopartite), or two stretches separated by ∼ 10−12 amino acids (bipartite).
The NLS of SV40 large-T antigen and nucleophosmin are examples of mono
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and bipartite NLS respectively (Kau et al., 2004; Stewart, 2007; Wente &
Rout, 2010).
The mechanism starts in the cytosol with the formation of the cargo-carrier
complex. The formation of the importin-alpha-importin-beta dimer through
an importin-beta binding domain exposes a domain in importin-alpha, which
is able to recognise the NLS in the protein cargo. The complex is directed
to the NPC, where importin-beta mediates the interaction with nucleoporins
via phenylalanine-glycine-nucleoporin (FG-nucleoporin) repeats, and is then
translocated to the nucleoplasm. Once in the nucleus, high concentrations
of RanGTP disassemble the complex. The protein cargo is released, and
importin-alpha in complex with RanGTP, and importin-beta combined with
RanGTP, and nuclear export factor CAS are recycled back to the cytoplasm.
In the cytoplasm RanGAP helps in the disassembly of the complex, render-
ing importins free for another round of transport. High concentrations of
RanGDP in the cytoplasm or RanGTP in the nucleoplasm are maintained
by RanGAP (Ran GTPase activating protein) and RanGEF (Ran guanine
nucleotide-exchange factor) respectively (Figure 1.7) (Kau et al., 2004; Stew-
art, 2007; Wente & Rout, 2010).
The nuclear export of proteins is mediated by the counterparts transportin,
CRM1, exportin-5 and exportin-t and the sequences that mediate the recog-
nition of the protein cargo to the exportin complex are named nuclear export
signals (NES), which are a cluster of leucine-rich amino acids. In the clas-
sic nuclear export pathway, importin-beta complexed with RanGTP is trans-
ported back to the cytoplasm. Importin-alpha on the other hand, forms a
complex with RanGTP and CAS. Both complexes containing importin-alpha
and importin-beta are transported to the cytoplasm through the NPC. Once
in the cytoplasm by the action of RanGAP, both importins are released, leav-
ing them free for another round of transport. By a similar mechanism, cargo
proteins to be transported back to the cytoplasm are recognised by exportins
through their NES (Kau et al., 2004; Stewart, 2007; Wente & Rout, 2010).
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The import of proteins through the nuclear import pathway seems to be
the preferred mechanism by proteins with functions other than cytosolic roles,
as is the case of dystroglycan and other DAPC components.
Oppizzi and colleagues determined that, in breast carcinoma cell lines, the
nuclear translocation of beta-dystroglycan was mediated by the presence of
a bipartite NLS located after the sequence that encodes the transmembrane
domain. The interesting observation of a dynamic beta-dystroglycan in the
nucleoplasm directly questioned the previous static model proposed by the
Cisneros group (Fuentes-Mera et al., 2006; Oppizzi et al., 2008). Further
studies confirmed that, in addition to the transport mediated by a nuclear
localisation signal, beta-dystroglycan travels to the nucleus in an importin-
alpha/beta regulated pathway. In that study, it was suggested that Y892,
a tyrosine that has been implicated in other signalling processes, could be
influencing the transport of beta-dystroglycan to the nucleus (Lara-Chaco´n
et al., 2010). Parallel studies showed that the assembly of the DAPC com-
plex could be regulated by the differentiated status of myoblasts (Gonza´lez-
Ramı´rez, Morales-La´zaro, Tapia-Ramı´rez, Mornet, & Cisneros, 2008) and that
in pheochromocytoma cells, Dp71 was important for the assembly of the DAPC
in the nucleus (Villarreal-Silva, Sua´rez-Sa´nchez, Rodr´ıguez-Mun˜oz, Mornet, &
Cisneros, 2010).
These previous studies clearly showed the presence of a new pool of DAPC
components in the nucleus of different cell lines. The debate about the static
(by its immersion in the nuclear membrane), or dynamic (by its unrestricted
movement in the nucleoplasm) functions of beta-dystroglycan persisted, but
new observations suggested that both hypothesis were plausible.
Two papers published almost simultaneously provided more important
clues. In muscle derived cells, the C2C12 cell line, in addition to its previ-
ously described association with lamin B, beta-dystroglycan was found asso-
ciated with nuclear organelles such as the nucleolus, splicing speckles, emerin
and cajal bodies. The interaction between beta-dystroglycan and these or-
ganelles (verified by immunoprecipitation, immunofluorescence and pull-down)
36
1.5. DYSTROGLYCAN
was slightly altered by the downregulation of beta-dystroglycan compared to
the dramatic effect observed with lamin B. Additional alterations observed
were the miss-localisation of the centrosomes, which raised the hypothesis of
beta-dystroglycan and its possible involvement in the cell cycle (Mart´ınez-
Vieyra et al., 2013).
The second work took a step forward in providing clues to the activities
of beta-dystroglycan in the nucleus. In healthy prostate human tissue, there
was a strong expression of beta-dystroglycan on the basal side and baso-lateral
junctions of the epithelial cells. However, the intensity of the staining pattern
was greatly reduced in prostate carcinoma tissue. After cell fractionation the
nuclear distribution of beta-dystroglycan was confirmed. The most striking
result to emerge from that work was that the overexpression of the cytoplasmic
fragment of beta-dystroglycan had a preferential nuclear accumulation, which
in turn led to the expression of transcription factors such as ETV1, which the
authors confirmed by microarray analysis (Mathew et al., 2013).
From this set of results it appears that beta-dystroglycan is an impor-
tant player in the organisation of the nuclear architecture (Tadayoni, Rendon,
Soria-Jasso, & Cisneros, 2012), but is also an important modulator of other
nuclear processes, such as gene-transcription. The interplay between both
mechanisms is still not completely understood, nor the mechanisms triggering
the nuclear translocation of cytosolic beta-dystroglycan, although ezrin is im-
plicated (Va´squez-Limeta et al., 2014). Importantly, it is still not known what
the role of nuclear beta-dystroglycan is, nor how this enigmatic protein me-
diates those new nuclear events, despite it being clear that beta-dystroglycan
does not bind to the nuclear DNA (Bozzi, Morlacchi, et al., 2009; Brancaccio,
2012; Moore & Winder, 2010; Tadayoni et al., 2012).
1.5.5 Dystroglycan and the cell cycle
The conservation of life can be achieved by one simple, yet complex, process. It
consists of the division of a ’mother’ cell to give raise to two identical ’daughter’
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cells. This mechanism can be divided into two main phases, the interphase (a
kind of ”resting” phase) and mitosis (the process wherein one cell generates
two cells). These two phases are separated by two main intervals named ’gaps’,
G1 and G2.
The interphase, the phase of apparent resting, is instead a period of intense
activity in the cell. This phase can be sub-divided into G1-phase, S-phase
and G2-phase. During G1-phase, the phase that separates mitosis from the
S-phase, the cell senses the surrounding environment and, under favourable
conditions, the cells proceeds into S-phase. If the conditions are not favourable,
the cell enters into a phase of resting for an undefined time. In S-phase, the
cell is able to synthesize (S) two identical copies of DNA (replication). The cell
progress into G2 phase once replication has concluded. In this phase, the cell
verifies the proper replication of DNA and prepares all the material required
in order for the cell to enter into mitosis.
Mitosis comprises two important events during cell division, the segregation
of the nucleus (mitosis) and the segregation of the cytoplasm (cytokinesis).
Mitosis is divided into different stages, all of them characterised by specific
episodes during the separation of chromosomes: prophase, pro-metaphase,
metaphase, anaphase and telophase. Once the chromosomes are completely
separated, the cell specifies a site of division, the cleavage furrow, as a mark
that dictates the place where the cell has to be separated. This leads to the
constriction of the cell and the formation of the midbody, which functions until
the cells are completely separated (Alberts et al., 2008).
The evidence gathered so far indicates that beta-dystroglycan may be im-
plicated in the cell cycle at different stages: as a regulator, but also as a subject
of regulation.
The different events that are apparently regulated by beta-dystroglycan
are evident from by the following observations.
During the cytokinesis of REF52 and Swiss 3T3 fibroblasts, and cervical
HeLa cells, beta-dystroglycan is targeted to the cleavage furrow and midbody.
The possibility of the requirement of its cytoplasmic fragment was confirmed
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because a truncated form of beta-dystroglycan lacking this region was not
able to localise to these structures (Higginson, Thompson, & Winder, 2008).
This observation was further supported by a later report indicating that, in
pheochromocytoma cells (PC12), beta-dystroglycan (in association with Dp71)
was co-localised to the same structures and additionally, was observed to be
co-localised with the mitotic spindle. By decreasing Dp71 expression, the role
of Dp71 in organising this complex was established; furthermore, the authors
observed defects in the structure of the nuclear membrane (Villarreal-Silva,
Centeno-Cruz, Sua´rez-Sa´nchez, Garrido, & Cisneros, 2011). This last observa-
tion led the authors to hypothesize that beta-dystroglycan, together with lamin
B and Dp71, are able to organise the mitotic spindle poles during cell division
(Tadayoni et al., 2012). From these findings it is clear that beta-dystroglycan
modulates events in the final stages of mitosis.
Other characteristics that have been associated with beta-dystroglycan
within the cell cycle are abnormalities during the transition of the S- and
M-phases.
Following down-regulation of beta-dystroglycan it was reported that mam-
mary epithelial cells accumulated in the S-phase of the cell cycle (Sgambato,
Di Salvatore, et al., 2006). On the other hand, reduced levels of dystroglycan
have also been reported to cause a lag in a G2/M transition of fibroblats cells,
a phenomenon presumably attributable to reduced levels of ERK (Higginson
et al., 2008). A different study reported similar findings, but in the transition
of G0 to G1 (Villarreal-Silva et al., 2011). Although the results from the last
group can not be compared to the other papers cited above, because the tar-
geted reduced protein was Dp71, it points out the fact that the alteration of
the DAPC members may lead to alterations in the transition of the cell cycle.
Dystroglycan is subject to regulation throughout the cell cycle. In bovine
aortic entothelial cells (BAE) increased levels of beta-dystroglycan in S-phase
were associated with angiogenesis (Hosokawa, Ninomiya, Kitamura, Fujiwara,
& Masaki, 2002). Later on, in synchronised HC11 murine mammary epithe-
lial cells, dystroglycan mRNA levels were observed up-regulated during S-
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phase, a mechanism mirrored at protein level (Sgambato, Di Salvatore, et
al., 2006). Current research indicates that the observed up-regulation of beta-
dystroglycan during the S-phase of the cell cycle is extended to prostate LNCaP
cancer cells (Laura A. Jacobs, personal communication).
Finally, the role of dystroglycan (and that of the other DAPC members)
in cell survival is highlighted once more by the fact that reduced expression
has been linked to apoptosis (Higginson et al., 2008; Sgambato, Di Salvatore,
et al., 2006; Villarreal-Silva et al., 2011).
1.6 Project outline
The presence of dystroglycan at the plasma membrane is important to control
the unrestricted growth of cells. In different carcinomas the reduced expression
of beta-dystroglycan has been frequently observed (Cross et al., 2008; Henry et
al., 2001). Previous evidence indicates that proteolytic events (Mitchell et al.,
2013) and post-translational modifications (Miller et al., 2012) may be involved
in this reduction. Additionally, the nuclear localisation of beta-dystroglycan
and its association with nuclear organelles (Mart´ınez-Vieyra et al., 2013), as
well as the regulation of transcription factors (Mathew et al., 2013), indicate
that both mechanisms may be linked. However, the mechanisms behind these
events are still unknown.
The main motivations of this project are to understand: i) how post-
translational modifications, such as phosphorylation and ubiquitination, affect
the integrity of beta-dystroglycan; ii) the mechanisms that trigger the prote-
olysis of beta-dystroglycan from the plasma membrane and its downstream
consequences; and iii) possible functions of beta-dystroglycan in the nucleus
of LNCaP cells by means of its interaction with nuclear proteins.
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1.7 Hypothesis
In LNCaP cells, beta-dystroglycan is subject to the proteolytic cleavage by
gamma-secretase in a Regulated Intramembrane Proteolysis dependent manner
to release a 26 kDa cytoplasmic fragment which is transported to the nucleus
where it regulates nuclear functions.
1.8 Aims
1. To identify post-translational modifications on beta-dystroglycan regu-
lating its stability and function.
2. To identify the mechanisms and proteases involved in the generation of
the 26 kDa cytoplasmic fragment of beta-dystroglycan.
3. To perform a mass spectrometry analysis to identify candidate proteins
interacting with beta-dystroglycan that could explain its functions in:
the nucleus, the cell cycle, the ubiquitin proteasome system and others.
4. To perform mass spectrometry analysis to identify post-translational
modifications on beta-dystroglycan.
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Materials & methods
2.1 Materials and methods
The formulation of the solutions and the gels, the sequences of the primers,
the characteristics of the plasmids and the antibodies referred in the text are
fully described in the corresponding appendixes.
2.1.1 Bacterial techniques
2.1.1.1 Preparation of calcium competent Escherichia coli DH5α
A colony of fresh plated E. coli DH5α bacteria were used to inoculate 10 ml
of 2x YT medium (starting culture) (see Appendix A) and then incubated
at 37◦C overnight in a shaking incubator. Next day, 0.5 ml of the starting
culture was used to inoculate 100 ml of 2x YT medium and left at 37◦C in a
shaking incubator until the optical density at 600 nm was 0.6 (OD600=0.6),
as determined by use of a 7315 spectrophotomer (Jenway). Cellular growth
was stopped by incubating the bacterial culture on ice for 10 minutes followed
by centrifugation at 5000 x g for 10 minutes at 4◦C. The supernatant was
discarded and the pellet was resuspended in 50 ml of chilled sterile 100 mM
CaCl2 solution and then incubated on ice for 4 hours. Following a second
centrifugation at 5000 x g for 10 minutes at 4◦C, the supernatant was discarded
and the pellet was resuspended in 5 ml of 100 mM CaCl2. To prepare stocks
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of competent cells, the resuspended pellet was mixed with sterile glycerol to a
final concentration of 15% (v/v), and then frozen and stored at -80◦C.
2.1.1.2 Transformation of competent bacteria
Frozen bacteria were thawed on ice before mixing with the required amount
of DNA (usually 500 ng), and subsequent incubation on ice for 30 minutes.
Bacteria were transformed by heat shock at 42◦C for 2 minutes in a water bath.
Thereafter, 1 ml of pre-warmed 2x YT medium without antibiotic was added
and the culture was incubated at 37◦C for 30 minutes in a water bath. 200 µl
of this recovering culture were spread on to plates of 2x YT agar containing
the appropriate selective antibiotic. Plates were incubated overnight at 37◦C.
2.1.1.3 Bacterial protein induction
E. coli BL21(DE3) transformed with the plasmids pGST (GST) or pGST-
MD (MultiDsk) (M. D. Wilson, Saponaro, Leidl, & Svejstrup, 2012) and
grown on 2x YT agar with Ampicillin (100 µg/ml) were used to inoculate
600 ml LB medium with ampicillin (100 µg/ml). Inoculated medium was in-
cubated in a rotating incubator at 37◦C until it reached an optical density of
0.6 (OD600=0.6). Once the OD was reached, protein expression was induced
by the addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final
concentration of 1 mM. A good protein expression was obtained by incubating
the culture for a further 4 hours at 37◦C in a rotating incubator after induction
(Figure 2.1). Following this, bacteria were pelleted by centrifugation at 6000
x g for 15 minutes, the supernatant was discarded and the pellet was washed
once with PBS pH 7.4. The bacterial pellet was used immediately or stored
at −20◦C.
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Figure 2.1: Transformed bacteria with the plasmid pGST-MD were inoculated
in 2x YT medium and the expression of GST-MD was induced by the addition
of IPTG. Samples of the induced culture were taken at the various time points
shown and boiled with an equal volume of 2x Laemmli loading buffer, prior
to gel electrophoresis and electroblotting. (a) Western blot analysis with an
anti-GST antibody shows an increase in the amount of GST-MD protein (60
kDa) expressed over the time. (b) The membrane stained with Ponceau S red
staining solution reveals total proteins in samples.
2.1.1.4 GST and MultiDsk protein purification
GST and GST-MD were purified according to the method described by Wil-
son and colleagues (M. D. Wilson et al., 2012). An induced bacterial pellet,
produced as described above, was resuspended in 20 ml of STE buffer (Sodium
Chloride-Tris-EDTA) supplemented with lysozyme to a final concentration of
100 µg/ml and incubated on ice for 15 minutes. Dithiothreitol (DTT) and
sarcosyl (N-lauryl sarcosine) were added to the resuspended pellet to final
concentrations of 5 mM and 1.5% (v/v) respectively (DTT was added before
sarcosyl). Samples were mixed, gently sonicated and then centrifuged at 10000
x g for 5 minutes at 4◦C. After filtration through a 0.45 µm filter to get rid
of viscous material, the filtrate was combined with Triton X-100 to a final
concentration of 3% (v/v) followed by a 5 minute incubation on ice.
500 µl of pre-equilibrated glutathione agarose beads in STE buffer were
incubated with the filtrate for 4 hours at 4◦C on a tube roller. Following
incubation and by sequential centrifugation, the beads were washed with 50
ml of chilled wash buffer 1 (450 mM NaCl, 10% glycerol (v/v), 0.1 mM EDTA,
0.1% Triton X-100 (v/v), 2 mM DTT and protease inhibitors in PBS), followed
45
CHAPTER 2. MATERIALS & METHODS
by washing with 25 ml of buffer 2 (50 mM NaCl, 10% glycerol (v/v), 1 mM
2-mercaptoethanol, 0.2% Triton X-100 (v/v) in 50 mM potassium phosphate
buffer (40.1 mM K2HPO4, 9.9 mM KH2PO4, pH 7.4)). Following washing,
beads were equilibrated with PBS pH 7.4, and then resuspended in PBS pH
7.4 supplemented with 1 mM sodium azide. Resuspended beads were stored
at 4◦C (M. D. Wilson et al., 2012) (Figure 2.2).
2.1.2 Molecular biology techniques
2.1.2.1 Agarose gel electrophoresis
All agarose gels used in this project were prepared at a final concentration of
1% (w/v). Agarose was melted in 1x TAE buffer (Tris-acetate-EDTA) (see
Appendix A) and combined with ethidium bromide to a final concentration
of 0.5 µg/ml. The solidified gel was placed in a tank containing 1x TAE and
then DNA, which had been mixed with DNA loading buffer (see Appendix A),
was loaded into the gel. Samples were separated at a constant voltage of 140
V for 40 minutes. DNA was visualized using the UV source in the ChemiDoc
XRS+ system from Bio-Rad.
2.1.2.2 Small (miniprep) and large (maxiprep) scale DNA purifica-
tion and DNA concentration determination
Purification of DNA was performed according to manufacturer’s guidelines.
For small and large scale DNA purification, the Plasmid Mini Kit (Bioline)
and the QIAGEN Plasmid Maxi Kit were used respectively. DNA pellets were
resuspended in sterile 10 mM Tris-Cl pH 8.5. The concentration of the DNA
was determined by measuring the absorbance at 260 nm using a quartz 1 cm
path-length cuvette (Unico) in a 7315 spectrophotometer (Jenway). DNA was
stored at 4oC for immediate use or at -20◦C for long-term storage.
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Figure 2.2: Purification of GST and GST-MD proteins. Proteins were puri-
fied as described in materials and methods. An aliquot of the input, the flow
through, the washes and the beads was mixed with 2x sample loading buffer
and resolved by SDS PAGE. Gels were stained with Coomassie blue safe stain-
ing. Shown are the bands corresponding to GST( 25 kDa) (a) and GST-MD
( 60 kDa) (b) recombinant proteins.
2.1.2.3 Generation of a Flag tag in the primary sequence of mouse-
αβDgFlag by site directed mutagenesis
A Flag tag was introduced into the coding sequence of mouse αβDg (plasmid
pcDNA2-αβDg, see Appendix C) through a complementary pair of primers
(see Appendix B) designed to insert and to mutate the amino acids shown in
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Figure 3.6. The design of the primers and the protocol followed were performed
according to the instructions provided by the QuikChange XL Site-Directed
Mutagenesis Kit (Agilent Technologies). The primers were designed to incor-
porate the desired changes with minimal modifications in the primary structure
of the protein.
XL10-Gold Ultracompetent cells (Agilent technologies) were transformed
with mutated construct and then incubated with NZY+ broth as indicated in
the manufacturer’s protocol. Transformed bacteria were plated on 2x YT agar
with ampicillin (100 µg/ml) and then incubated at 37◦C for >16 hours.
Candidate transformed colonies were used for purification of DNA using
the Plasmid Mini Kit (Bioline). Purified DNA was characterized by DNA
sequencing (Source BioScience). Working stocks of DNA containing αβDgFlag
were prepared by maxi-prep.
2.1.2.4 Cloning of coding sequences of mouse-αβDgFlag (full) and
mouse-cβDgFlag (cyto) into the plasmid pcDNA3.1(+)
A pair of oligonucleotides containing the restriction sites for the enzymes EcoRI
(5’) and XhoI (3’) were used to amplify the coding sequence of full-length
mouse αβ-dystroglycan by PCR. For the cytoplasmic domain, which corre-
sponds to residues 773 to 892 of the full-length sequence, the forward primer
was designed to contain an additional methionine after the restriction site for
EcoRI and before the tyrosine 773 (the reverse primer was the same used in
the amplification of full dystroglycan) (see Appendix B). The PCR was carried
out using the 2x Phusion Master mix according to manufacturer’s guidelines
(New England Biolabs Inc) (Table 2.1).
The amplicons were verified by agarose gel electrophoresis. The plasmid
pcDNA3.1(+) and the amplicons from the full-length and cyto-βdystroglycan
PCRs were digested with the restrictions enzymes EcoRI-HF and XhoI in Eco-
RI buffer (New England Bio-labs) for 2 hours at 37◦C.
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Cycle step Temp (◦C) Time (s) Cycles
Initial denaturation 98 30 1
Denaturation 98 10 30
Annealing 60 30 30
Extension 72 75 30
Final extension 72 600 1
4 ∞
Table 2.1: PCR conditions
The digested products were characterized by agarose gel electrophoresis and
then purified from the agarose gel using the QIAquick gel extraction kit (QI-
AGEN). The purified digested amplicons were ligated into the pcDNA3.1(+)
vector using the Quick Ligation kit (New England Bio labs). Ligated DNA
was used for transformation. Candidate colonies were expanded in 2x YT with
ampicillin (100 µg/ml) and DNA purified by mini-prep. Correct ligation of the
construct was validated by sequencing.
2.1.2.5 Generation of the mutations Y890F and K806R in the pri-
mary sequence of mouse αβDgFlag by site directed muta-
genesis
The mutations Y890F and K806R were introduced into the coding sequence
of mouse αβDgFlag (see Appendix C) by PCR using the primers listed in
Appendix B following the instructions provided in the QuikChange Lightning
Site-Directed Mutagenesis kit (Agilent Technologies). Transformed candidate
bacteria were used for small scale DNA purification. Purified DNA was charac-
terized by DNA sequencing, and DNA carrying either of the desired mutations
was used to prepare working stocks by maxi-prep.
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2.1.3 Tissue culture techniques
2.1.3.1 Growth and passaging of LNCaP cells
LNCaP cells were maintained in RPMI medium (Gibco, Life technologies) [+]-
L-glutamine supplemented with 10% (v/v) Fetal Bovine Serum (Gibco, Life
technologies). Cells were incubated at 37◦C in an incubator with a 5% CO2
atmosphere (Galaxy S, Biohit). Before each experiment, cells were allowed to
grow for a minimum of 24 hours. For cell passaging, cells were dissociated using
1% (v/v) Trypsin-EDTA (Sigma) and reseeded at a final cell density according
to the requirements of each experiment. Growth medium was replaced with
fresh medium every 2 days.
2.1.3.2 Preparation of LNCaP cell stocks
LNCaP cells were grown in RMPI medium [+]-L-glutamine supplemented with
10% (v/v) of Fetal Bovine Serum and allowed to reach a high cell density in
large flasks (175 cm2). Following trypsinization, cells were pelleted at 600 x
g for 3 minutes and gently resuspended in freezing medium (RPMI medium,
20% DMSO, 20% FBS). Resuspended cells were aliquoted into cryovials and
stored in a container with isopropanol at -80◦C for 24 hours.
Long-term storage was carried out by storing the tubes in liquid nitrogen.
Cells were thawed by placing the vial in a water bath at 37◦C for 3 minutes
and then resuspended in complete warm medium. Medium was replaced after
the complete attachment of the cells to the flask in order to minimize exposure
to DMSO.
2.1.3.3 Cell counting using a Neubauer chamber
10 µl of trypsinized pelleted cells resuspended in RPMI medium (usually 10
ml) were mixed with 90 µl of Trypan Blue Solution 0.4% (Sigma, T8154). An
aliquot of 10 µl was used to load the Neubauer chamber. Cells were counted
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according to the manufacturer’s instructions. The total number of cells was
calculated according to the following formula:
Total cells = ( cell counted
4 (to average for one square)
) x (dilution factor used) x104(to
convert the volume into ml)
2.1.3.4 Transfection of LNCaP cells using the Neon Transfection
System
LNCaP cells were grown for a minimum of 48 hours before transfection. On
the day of transfection cells were trypsinized as described above, before resus-
pension in growth medium. Cells were pelleted by centrifugation at 600 x g
for 3 minutes at RT. The pellets were resuspended in growth medium and an
aliquot was used to determine the cellular density with a Neubauer chamber.
The number of cells was adapted to the conditions of each individual experi-
ment according to the table 2.2.
Tip 10 µl 100 µl
Scale 6 well scale 6 well scale 60 mm or 100 mm disch scale
Well number 1 well/6 well 6 well/6 well 1 well/6 well 6 well/6 well 60 mm dish 100 mm dish
Cell number 0.6 x 106 4 x 106 1.2 x 106 8 x 106 3.6 x 106 7.2 x 106
DNA 2.4 µg 16 µg 2.4 µg 16 µg 7.2 µg 14.4 µg
Solution R 12 µl 64 µl 120 µl 784 µl 120 µl 120 µl
Table 2.2: Transfection conditions
The required number of cells were centrifuged at 600 x g for 3 minutes at
RT and the pellets were resuspended in the recommended amount of Solution
R (Life technologies). Resuspended cells were combined with the appropriate
amount of DNA as shown on the table above and then loaded into an appro-
priate Neon Pipette Tip (Life technologies). The pipette was assembled into a
Neon Pipette Station containing 3 ml of solution E2 (Life technologies). The
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cells were microporated according to the conditions in the table 2.3.
Pulse voltage (v) Pulse width (ms) Pulse number Tip type
1200 20 2 10 µl
1200 20 2 100 µl
Table 2.3: Microporation conditions
Once microporated, the cells were seeded onto poly-L-lysine pre-coated
petri dishes containing pre-warmed growth medium. Cells were grown for a
minimum of 24 hours before starting further experiments.
2.1.3.5 Stimulation of LNCaP cells with phorbol 12,13-dibutyrate
(PDBu)
Cells were grown at a low cell density for 24 hours on petri dishes coated
with poly-L-Lysine in RPMI growth medium. PKC activation was induced
with RPMI medium containing PDBu [2.5 µM] (Sigma, prod. no. P1269) or
DMSO (control) and incubated for different times protected from the light.
After the specified times, cells were rinsed gently with cold 1x PBS.
2.1.3.6 Treatment of LNCaP cells with DAPT or Furin Inhibitor I
Confluent LNCaP cells were seeded on petri dishes coated with poly-L-lysine.
Cells were allowed to attach and to grow for a minimum of 24 hours before
starting treatment. The inhibition of gamma-secretase or furin activities, was
performed by treating the cells with DAPT (N-[N-(3,5-Difluorophenacetyl-L-
alanyl)]-S-phenylglycine t-Butyl Ester) (Calbiochem, cat. no. 565770) or Furin
Inhibitor I (Decanoyl-RVKR-CMK) (Calbiochem Millipore, prod. no. 344930)
respectively. DAPT or Furin Inhibitor I prepared in DMSO, were dissolved
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in complete RPMI medium and then added to the cells. The treatment, per-
formed at different concentrations as shown on the respective figures, was
performed for 24 hours for both compounds. Cells were treated with the same
volume of DMSO alone as a control.
2.1.3.7 Treatment of LNCaP cells with resveratrol
Non-confluent LNCaP cells (15000 cells/cm2) were seeded on petri dishes
coated with poly-L-lysine. Cells were grown for 24 hours and then treated
with resveratrol (Enzo Life Sciences, prod. no. BML-FR104) to a final con-
centration of 100 µM for different times in order to induce the activation of
NOTCH. For each time point, the same volume of DMSO was used for control
treatments.
2.1.3.8 Treatment of LNCaP cells with MG132
Confluent LNCaP cells were grown on petri dishes coated with poly-L-lysine for
24 hours. The proteasome activity inhibition was performed by replacing the
medium with full medium supplemented with MG132 [15 µM] (Calbiochem,
cat. no. 474790) and then incubated for 4 hours at 37◦C. The experiment was
also performed using different concentrations of MG132 or using one concen-
tration of MG132 for different times as shown in the respective figures. Cells
treated with the same volume of DMSO were used as a control.
2.1.3.9 Treatment of LNCaP cells with cycloheximide
LNCaP cells, either WT or transfected, were grown for 24 hours and then
treated with the protein synthesis inhibitor cycloheximide (Sigma, C7698) to
a final concentration of 100 µg/ml for different times. Cells were washed with
1x PBS before further analysis.
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2.1.3.10 Treatment of LNCaP cells with calyculin A and sodium
peroxovanadate
24 hours post-transfection, LNCaP cells were washed with pre-warmed RPMI
medium without serum and phenol red. The inhibition of serine and threonine
phosphatases was performed by treating the cells with calyculin (Cell Signaling
Technology, prod no. 9902), and of tyrosine phosphatases by treatment with
sodium peroxovanadate.
Calyculin (prepared in DMSO) was used at a final concentration of 0.1 µM
dissolved in RMPI medium without serum.
For peroxovanadate treatment, hydrogen peroxide and sodium orthovana-
date were dissolved in RPMI medium without serum to final concentrations of
2 mM and 1 mM respectively.
These treatments were performed alone or together, and DMSO was used
as the control. Following the addition of treatment, cells were incubated for 15
minutes at 37◦C. Afterwards, LNCaP cells were washed with 1x PBS before
further analysis (Ruff, Chen, & Cohen, 1997; Resjo¨, Oknianska, Zolnierowicz,
Manganiello, & Degerman, 1999).
2.1.4 Microscopy techniques
2.1.4.1 Immunofluorescence staining
Cells were seeded on glass 13 mm coverslips pre-coated with poly-L-Lysine.
After each individual experiment, cells were washed twice with 1x PBS. Cells
were immediately fixed using paraformaldehyde 3.7% (v/v) in PBS for 10
minutes at RT, washed once with 1x PBS, and then permeabilized using 0.1%
(v/v) Triton X-100 in PBS for 5 minutes at RT. Cells were gently washed
twice with cold PBS. To block non-specific binding, coverslips were inverted
on to blocking buffer (see Appendix A) on parafilm. Blocking was carried
out at room temperature for 10 minutes in a humidified chamber in the dark.
After blocking, cells were incubated with the required concentration of primary
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antibodies (see Appendix E), dissolved in blocking buffer for 2 hours in the
same way as in the blocking step. Gentle washing of the coverslips in PBS
reduced low affinity primary antibody binding. Coverslips were incubated with
fluorophore-labelled secondary antibodies, dissolved in blocking buffer, in a
similar manner to the primary antibodies (see Appendix E). Multiple washes of
coverslips in PBS reduced the excess of secondary antibody binding. Coverslips
were allowed to dry and mounted on to a glass slide using a preservative
antifade mounting medium (see Appendix A) and stored overnight at 4◦C in
the dark, prior to microscopy analysis (Fincham, James, Frame, & Winder,
2000).
2.1.4.2 Epifluorescence microscopy
Epifluorescent images were taken using a Leica DMIRE2 inverted fluorescence
microscope powered by a Leica CTRMIC controller. Images were taken using
a Leica HCX PL 63x immersion oil objective lens and a Leica DC350F CCD
camera and acquired using Leica QFluoro software.
2.1.4.3 DeltaVision microscopy
Widefield deconvolution microscopy was performed using a DeltaVision RT
system (Applied Precision, Issaquah, WA, USA).
Samples were analyzed with an Olympus 60x/1.40, PlanApo oil objective.
The excitation bandwidths were 340-380 nm, 480-500 nm, and 541-569 nm
for the blue, green and red channels, respectively. The emission filters had
bandwidths of 432-482 nm, 541-569 nm and 581-654 nm for the blue, green
and red channels respectively. Images were captured using a Photometrics
COOLSNAPHQ CCD camera. Image data was deconvolved using the Soft-
Worx constrained iterative deconvolution algorithm.
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2.1.5 Protein biochemistry techniques
2.1.5.1 Protein extraction from mammalian cells
Cells on petri dishes were washed twice with cold 1x PBS, followed by direct
cell lysis with 1x RIPA or mild cell lysis buffer supplemented with protease
and phosphatase inhibitors (see Appendix A) at 4◦C for 15 minutes. Cell
extracts were collected using a cell scraper, and then transferred to a micro-
centrifuge tube. Lysates were briefly sonicated to shear the DNA and clarified
by centrifugation at 18000 x g for 15 minutes at 4◦C to pellet cell debris. The
supernatant was then transferred into a new tube and stored at -20◦C.
2.1.5.2 Cell fractionation
Cells were washed twice with cold 1x PBS and then scraped in a minimum vol-
ume of cold hypotonic Buffer I (see Appendix A). Plasma membrane was then
further disrupted using a cold glass Dounce homogenizer. The homogenate was
spun down at 600 x g for 10 minutes at 4◦C. Pellet (nuclei) and supernatant
(non-nuclear) were retained for further purification. Nuclear contaminants
were removed from the non-nuclear fraction by centrifuging the supernatant
twice at 9300 x g for 10 minutes at 4◦C. The pellet was discarded and the final
supernatant was saved as the purified non-nuclear fraction.
The nuclear fraction was further purified by resuspending the nuclear pellet
in equal volumes of Buffers II and I (see Appendix A). This mixture was
carefully overlayed on an equal volume of a 1.8 M sucrose cushion and then
spun down at 30000 x g for 1 hour at 4◦C. The supernatant was discarded
and the pellet was recovered as the purified nuclear fraction. The pellet was
resuspended in a small amount of either RIPA or lysis buffer according to the
requirements of each particular experiment and clarified as in section 2.1.5.1.
Non-nuclear and nuclear fractions were stored at -20◦C (Mathew et al., 2013).
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2.1.5.3 Protein quantification using the Micro BCA Protein Assay
Kit
The concentration of protein in cell lysates was determined following the rec-
ommendations of the manufacturer (Thermo scientific, product no. 23235).
Briefly, proteins were diluted 1/125 using RIPA buffer to a final volume of 500
µl and then mixed with 500 µl of working reagent. The mixture was incubated
at 60◦C for 1 hour and then allowed to cool to RT. The absorbance of the
samples was determined at 562 nm against a blank composed of a mixture of
RIPA and working reagent. The total amount of protein was determined by
interpolating the absorbance of the samples against a standard curve (0-200
µg/ml) prepared using dilutions of BSA as a standard.
2.1.5.4 Immunoprecipitation with protein A
30 µl of 50% protein A slurry (Amintra, expedeon) were transferred to a 1.5 ml
tube and washed three times with cold RIPA buffer. To pre-clear the sample,
beads were combined with protein lysates and incubated at 4◦C on a tube
roller for 1 hour at 4◦C. Beads were pelleted by centrifugation at 15000 x g for
30 seconds at 4◦C.
A small aliquot of pre-cleared lysate was saved as the input sample. The
remaining pre-cleared lysate was divided in two. One half was combined with
the desired antibody according to the dilutions shown in Appendix E and the
other half was left without antibody (control). Samples were incubated on a
tube roller for 2 hours at 4◦C. Thereafter, samples with and without antibody
were incubated for an additional hour with 30 µl of pre-equilibrated protein A
on a tube roller at 4◦C followed by centrifugation at 15000 x g for 30 seconds.
The supernatant was kept on ice and the beads were washed three times with
cold RIPA buffer. A small aliquot of input, supernatants and beads were
combined with the respective amount of 2x Laemmli loading buffer and boiled
at 100◦C for 5 minutes.
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2.1.5.5 Immunoprecipitation of Flag tagged proteins with anti-Flag
M2-agarose affinity gel
The protocol followed was that provided by the manufacturer (Sigma, cat.
no. A2220). Flag M2 resin was thoroughly resuspended and transferred to
a clean tube. The resin was washed five times with 1x TBS buffer (20x gel
volume) at 7000 x g for 30 seconds. After removing the supernatant, the resin
was combined with the required amount of lysate (total lysates, cell fraction
lysates, etc.) and adjusted to a final volume of 1000 µl with lysis buffer.
Samples were left incubating on a tube roller at 4◦C for 2 hours to overnight.
After the incubation period, the resin was recovered by centrifugation at 7000
x g for 30 seconds, and the supernatant was removed by pipetting using a
narrow-end pipette tip. Beads were then washed 3 times with chilled 1x TBS.
Protein elution was performed by competition with 100 µl of the 3x Flag
peptide (Sigma, cat. no. F4799) to a final concentration 300 ng/µl. Samples
were incubated on a tube roller for 30 minutes to 1 hour at 4◦C and centrifuged
at 7000 x g for 30 seconds. The supernatant was transferred to a new tube for
immediate use or stored at -20◦C.
2.1.5.6 Ubiquitin enrichment from LNCaP whole cell lysates
The total lysates used for this experimental approach were obtained as de-
scribed in the section 2.1.5.1 using RIPA buffer supplemented with 10 mM
NEM. 500 µg of clarified extracts were then diluted with RIPA buffer (with-
out any Triton X-100) to a final concentration of 0.25% Triton X-100 and
incubated with 40 µl or agarose-GST or agarose-MD beads on a tube roller
at 4◦C for 3 hours. Supernatants and beads were collected by centrifugation
at 700 x g for 2 minutes. Beads were subjected to two washes with high salt
buffer (RIPA buffer 0% Triton X-100 supplemented with 500 mM potassium
acetate), two washes with low salt buffer (RIPA buffer 0% Triton X-100 plus
50 mM potassium acetate) and one wash with RIPA buffer 0% Triton X-100.
Beads were finally resuspended in an equal amount of 2x Laemmli loading
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buffer and boiled at 100◦C for 5 minutes (M. D. Wilson et al., 2012).
2.1.5.7 Sodium orthovanadate activation
In order to achieve a maximal inhibition of protein phosphotyrosyl-phosphatases,
sodium orthovanadate 200 mM was adjusted to pH 10.0 using 1 N NaOH or 1
N HCl. The solution was boiled until turned colorless. The pH was readjusted
and stabilized to 10, through different rounds of boiling-cooling (Gordon,
1991).
2.1.5.8 In vitro protein dephosphorylation assay using Calf Intesti-
nal Phosphatase (CIP)
Dephosphorylation of proteins was carried out by combining a volume of lysate
containing 40 µg of protein with 40 U of CIP and NEBuffer 3 (New England
Biolabs, prod. no. M0290S). The mixture was adjusted to the desired final
volume using distilled water. The mixture was incubated at 37◦C for 1 hour
and then stopped by the addition of an equal volume of 2x Laemmli loading
buffer.
2.1.5.9 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophore-
sis (SDS-PAGE) (single concentration and gradient gels)
Pre-clarified protein samples were mixed with the required amount of 5x
Laemmli loading buffer, boiled at 100◦C for 5 minutes and then cooled to
RT. Mini-gels (10 cm x 10 cm x 1 mm) were run using the BioRad mini-gel
system. Resolving gels were prepared at 7.5%, 10% or 12.5% concentration
and the stacking gels at 5% concentration (see Table D.1). Samples were sep-
arated at 150 volts while running in the stacking gel and resolved at 200 volts
while running in the resolving gel.
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For gradient gels, the concentrations of resolving and stacking gels are given
in Appendix D (Laemmli, 1970).
2.1.5.10 Tricine-SDS-PAGE discontinuous gels
The preparation of these gels was performed employing the setup used for
multiple gradient gels and the protocol described by Scha¨gger and Von Jagow,
(1987) (Scha¨gger & von Jagow, 1987).
For the preparation of resolving 11%T, 0.67% gels (see Table D.3), the
amounts of acrylamide and bisacrylamide were calculated using the following
formulas (http://www.carlroth.com/media/ en-com/usage/3039.pdf).
Va = (T x (100-C) x Vt)/4000*
Vb = (T x C x Vt)/200
Where:
Vt=Total volume of gel casting solution (ml)
T = Gel concentration in % = % acrylamide + % bisacrylamide
C = % crosslinking =(% bisacrylamide x 100)/T
Va = volume gel A (acrylamide) in ml
Vb = volume gel B (bisacrylamide) in ml
* The concentration of acrylamide was 40%, hence the factor 4000.
2.1.5.11 Electrotransfer
Proteins were electroblotted to polyvinylidene fluoride (PVDF) membranes
activated in methanol (Immobilon-PSQ, 0.2 µm, Merck Millipore) using a Mini
Trans-Blot electrophoretic transfer cell (Bio-Rad). After electrophoresis, the
gel, together with the fiber pads and the filter papers, was soaked in Towbin
buffer supplemented with 20% (v/v) methanol and 0.02% (w/v) SDS for 10
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minutes (see Appendix A). Following this, all components were assembled in
a gel sandwich as required by the Mini Trans Blot electrophoretic transfer
system. The chamber was filled with Towbin transfer buffer supplemented
with 20% methanol and 0.02% SDS. An even buffer temperature (generated
by the Bio-Ice cooling unit) and ion distribution were maintained by stirring
(Towbin, Staehelin, & Gordon, 1979).
2.1.5.12 Western blotting
After electroblotting of proteins to PVDF membranes, membranes were soaked
in TBST to eliminate the excess SDS. Membranes were then incubated with
blocking buffer (5% skimmed milk (w/v) in TBST) for 30 minutes at RT. The
membrane was then incubated overnight at 4◦C with the primary antibody
diluted in blocking buffer according to the required dilution of each specific
antibody (see Appendix E). The following day, membranes were washed three
times with TBST for 10 minutes each at RT in order to eliminate the excess
primary antibody. Following this, membranes were incubated with a secondary
antibody (see Appendix E) diluted in blocking buffer for 1 hour at RT. Anti-
bodies not bound to the membrane were reduced by washing the membrane
3x with TBST for 10 minutes each. The presence of specific proteins on the
membrane was revealed by the chemiluminescent signal generated by the mix-
ture and addition of equal volumes of ECL I and II solutions to the membrane
(see Appendix A) (Miller et al., 2012). Chemiluminescent signal was recorded
using a BioRad Chemidoc XRS+ system.
2.1.5.13 Membrane stripping
The removal of primary and secondary antibodies from PVDF membranes
was achieved by incubating the membranes with mild stripping buffer (see
Appendix A). Membranes were incubated at RT twice with mild stripping
buffer for 15 minutes, then twice with 1x PBS pH 7.4 for 15 minutes and,
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finally twice with TBST for 10 minutes. After blocking with milk 5% (w/v) in
TBST, membranes were ready for incubation with another desired antibody.
2.1.5.14 Coomassie blue safe staining of SDS-PAGE gels
After SDS electrophoresis, gels were rinsed briefly with distilled water. Coomassie
blue safe stain (see Appendix A) was poured on the gels and microwaved
for 10 seconds. Following incubation on a moving platform at RT for 1
hour, staining solution was discarded. Further washing of the gel with dis-
tilled water, usually overnight, removed non-specific staining and revealed
protein bands (http://www.labtimes.org/labtimes/issues/lt2008/lt06/
lt 2008 06 53 53.pdf). Gels were imaged in the ChemiDoc XRS+ using the
image Lab software (BioRad).
2.1.6 Imaging techniques
2.1.6.1 Western blot band quantification and data analysis
Chemiluminescent signal was imaged using the ChemiDoc XRS+ (BioRad)
and the quantification of band intensity was performed using image Lab soft-
ware (BioRad). Images with saturated pixels were not considered for quantifi-
cation. The values obtained from the bands were then exported and analyzed
with GraphPad Prism 6. In all the cases the mean calculated was the average
of a minimum of three independent experiments. The average and standard
error of the mean (SEM) were plotted and used to distinguish changes between
controls and treatments.
2.1.7 Proteomic techniques
Solutions were prepared using MilliQ water at 18.2MΩcm−1 and the chemi-
cals/solvents used were LC-MS grade.
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2.1.7.1 Reduction and alkylation of proteins
To reduce proteins, DTT (dithiothreitol) prepared fresh to a final concentra-
tion of 1mM was mixed with sample loading buffer. The mixture was incubated
at 70◦ for 10 minutes and then allowed to cool down before alkylation. The
sample was alkylated with fresh prepared IAA (iodoacetamide) to a final con-
centration of 2 mM. The mixture was further incubated for 30 minutes at room
temperature in the dark.
2.1.7.2 In gel protein di-methyl labeling
Gel slices were completely destained with 50% ACN (acetonitrile) and shrunk
with 100% ACN. The excess of ACN was eliminated by evaporation and the gel
slices were incubated with labeling solution (0.4% formaldehyde (v/v) (Sigma,
prod. no. F1635), 60 mM cyanoborohydrade (Aldrich, prod. no. 156159) in
0.25 M MES buffer pH 5.5 (prepared fresh)) in a thermomixer at RT for 30
minutes. The labeling solution was removed and the gel pieces were washed
5 times with 50% ACN/100 mM ammonium bicarbonate. The gel slices were
shrunk once more with 100% ACN before proceeding with tryptic digestion.
2.1.7.3 Brilliant blue G-colloidal staining compatible with mass
spectrometry
After SDS electrophoresis, gels were rinsed with Milli-Q water. Proteins were
fixed in a solution containing 40% methanol / 2% acetic acid (v/v) for 1 hour.
Following this, gels were stained for 2 hours with brilliant blue G-colloidal
according to the instructions provided by the company (Sigma, prod. no. B-
2025).
Gels were destained with 25% methanol for 2 hours and then left in Milli-Q
water until further processed.
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2.1.7.4 Tryptic digestion and peptide extraction from gel slices
All the solutions used for tryptic digestion were prepared fresh before use.
Excised gel slices were placed in Protein LoBind tubes (Eppendorf, cat.
no. 0030108116) and fully destained by the addition of 50% ACN /50 mM
ammonium bicarbonate pH 8.5 followed by incubation at RT for 30 minutes.
The liquid was removed by centrifugation at 600 x g ; this step was repeated
until gel slices were colorless (from hours to overnight). To secure the complete
destaining, the gel slices were incubated once more with 100% ACN for 15
minutes at RT. Once the liquid was discarded the gel slices were stored at 4◦C
until tryptic digestion.
Before digestion, Sequencing Grade Trypsin from bovine pancreas (Roche,
cat. no. 11418475001) was prepared as follows:
Stock solution: Trypsin was prepared at a concentration of 0.1 µg/µl using
0.1% TFA.
Working solution: Trypsin was prepared at a final concentration of 1 ng/µl
using 50 mM Ambic.
To perform digestion, dried gel slices were incubated with trypsin (working
solution) in a thermomixer (600 rpm) for 1 hour at 37◦C. Samples were then
left incubating at 25◦C overnight.
Next day, after centrifugation at 600 x g for 1 minute, the supernatants
were collected into a new tube SCT (supernatant collection tube). Further
extraction of peptides was performed by incubating the gel slices with 100%
ACN at 37◦C for 20 minutes followed by collection of supernatants as before.
Gel slices were further incubated with 0.5% formic acid at 37◦C for 20
minutes and then 100% ACN for the same time and temperature followed
by the collection of supernatants into SCT as stated before. After a further
repetition of this step, gel slices were incubated with 100% ACN at 37◦C for
15 minutes followed by the collection of supernatants into the SCT.
Extracted peptides were dried down using a SpeedVac concentrator and
then stored at 4◦C.
Before the analysis by LC-MS the peptides were resuspended in 0.5% formic
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acid at RT for 10 minutes with gentle shaking.
2.1.7.5 HPLC-Mass spectrometry settings
100% of resuspended peptides was injected, using a Dionex Ultimate 3000
uHPLC, onto a PepMap100 C18 2 cm x 75 µm I.D. trap column (ThermoFisher
Scientific) at 5µl/min in 0.1% formic acid, 2% acetonitrile and 45◦C in the
column oven and 6◦C in the autosampler. The sample was separated, over a
60-minute gradient of increasing acetonitrile from 2.4% up to 72%, in 0.1%
formic acid, using a 15 cm PepMap100 C18 analytical column (2 µm particle
size, 100 A˚pore size 75 µm I.D.) (ThermoFisher Scientific) at 300 nl/min and
45◦C.
The mass spectrometer analyzer used was an ETD (electron transfer dis-
sociation) enabled ThermoFisher-Scientific Orbitrap Elite, equipped with a
Nanospray Flex Ion ESI source (ThermoFisher Scientific). Nanospray ioniza-
tion was carried out at 2.3 kV, with the ion transfer capillary at 250◦C, and
S-lens setting of 60%. MS1 spectra were acquired at a resolving power of
60,000 with an AGC (automatic gain control) target value of 1x106 ions by
the Orbitrap detector, with a range of 350-1850 m/z. Following MS1 anal-
ysis the top 15 most abundant precursors were selected for data dependant
activation (MS2 analysis) using CID (collision induced dissociation), with a 10
ms activation time, and an AGC setting of 10,000 ions in the dual cell linear
ion trap on normal scan rate resolution. Precursor ions of single charge were
rejected, and a 30 second dynamic exclusion window setting was used after a
single occurrence of an ion.
2.1.7.6 Data analysis
Data analysis from 4 biological replicates was performed using the MaxQuant
and Perseus v 1.4 databases. For protein identification, false discovery rates
(FDRs) at both the protein and peptide levels were set at 1% by decoy database
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searching. Proteins with 3 valid intensity values in the Flag-βDG immunopre-
cipitations were considered for quantification. Missing values for proteins with
2 or more missing values in the control IP were impute from a down shifted
normal distribution. The statistical analysis was then performed by t-testing
with correction for multiple hypothesis testing at two thresholds, 0.05 (5%
FDR) and 0.01 (1% FDR). A fold enrichment (S0) = 2 for both, non-nuclear
and nuclear fractions was included in the statistical analysis. Proteins required
a minimum of two peptides or above in order to be reported.
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Beta-dystroglycan protein modifications
3.1 Introduction
The human body can develop its activities thanks to the precise and coordi-
nated action of its organs and systems, which is dictated by the homeostatic
status of its cells. The vast collection of proteins within cells orchestrates most
of the cellular functions such as perception of the extracellular environment,
inter and intra cellular communication, cellular shape, internal organization,
structural integrity and several other functions.
The functional regulation of proteins, from integral membrane proteins
to metabolic enzymes and transcription factors, is achieved by an array of
post-translational modifications (PTM). The concerted regulation in space and
time of PTM such as acetylation, phosphorylation, glycosylation, sumoylation,
methylation, proteolysis, ubiquitination and others, dictate the functional ac-
tivity of the proteins. Under certain conditions, these PTM either individu-
ally or as combinatorial sequence of events, affect the stability, concentration,
conformational changes, interactions, cellular location and other functions, of
specific target proteins as shown in Figure 3.1 (Deribe, Pawson, & Dikic, 2010;
Filtz, Vogel, & Leid, 2014; Jensen, 2006).
Plasma membrane proteins have to be subject to dynamic and strict quality
control mechanisms through different post-translational modifications in order
to regulate a vast array of signalling pathways. Also, these mechanisms have
the function of detecting and removing proteins from this environment that
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Figure 3.1: Protein post-translational modifications. Proteins are subject to a
vast array of modifications affecting key cellular functions.
otherwise could damage the cellular integrity (Babst, 2014). In these instances,
PTM functions as a form of quality control.
The dystrophin glycoprotein complex spans the plasma membrane provid-
ing structural integrity to muscle cells during processes of contraction and
relaxation. Also, due to its ability to interact with signalling molecules, this
complex is thought to be an important modulator of signalling events from the
extra to the intracellular environment (Constantin, 2014; Moore & Winder,
2012).
Dystroglycan, an important core protein within this complex, performs
both mechanical and signalling functions. By interacting with the laminin,
agrin, perlecan and neurexin extracellular matrix components, and cytoskele-
tal linker proteins (e.g., dystrophin/utrophin) in the intracellular environment,
dystroglycan provides a structural link, which is important for the adhesion
and communication of the cell with the surrounding environment and vice
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versa (Barresi & Campbell, 2006; Henry & Campbell, 1999; Sgambato & Bran-
caccio, 2005).
Besides its structural activities, dystroglycan is an important modulator
of a multitude of signalling events. The presence of a structurally disordered
cytoplasmic domain seems to confer an advantage to beta-dystroglycan for
its interaction with a great variety of signalling molecules in specific cellular
situations. Importantly, the phosphorylation of a tyrosine in its C-terminal
motif PPXY seems to be an important master switch modulating these protein
interactions (Bozzi, Morlacchi, et al., 2009; Moore & Winder, 2010).
Given the important and dynamic functions of this type I transmembrane
protein, its quality control, turnover and remodelling, all have to be under
tight control in order to avoid the impairment of the plasma membrane. Such
impairments are linked to severe outcomes, such as defects during develop-
ment, muscular dystrophies and cancer (Godfrey et al., 2011; Sgambato &
Brancaccio, 2005; Williamson et al., 1997).
Phosphorylation, glycosylation, proteolysis and ubiquitination, are the PTM
most commonly studied with beta-dystroglycan. Regarding phosphorylation,
it has been shown that the presence of a phosphate group on Y892 (of human
dystroglycan) is able to regulate the structural interaction of beta-dystroglycan
with dystrophin or utrophin, and the stability of the other associated proteins,
rendering beta-dystroglycan, presumably, susceptible to targeting for protea-
somal degradation (Ilsley et al., 2001; James et al., 2000; Miller et al., 2012;
Sotgia et al., 2001). Additionally, the same Y892, is thought to be a potential
regulator of signalling events by virtue of its proposed interaction with sig-
nalling molecules (Sotgia et al., 2001). Recently, it was hypothesized that in
addition to Y892, other phosphorylated tyrosines in beta-dystroglycan could
have potential roles in key cellular events, such as the processes of arenavirus
infection (Moraz et al., 2013). In addition to tyrosines, the cytoplasmic domain
of beta-dystroglycan is particularly rich in serine/threonine residues, which
may also be the target of phosphorylation.
Ubiquitination seems to be another PTM modulating key events on dystro-
69
CHAPTER 3. BETA-DYSTROGLYCAN PROTEIN MODIFICATIONS
glycan. Indirect experimental evidence suggests that not only dystroglycan,
but also other members of the dystrophin associated protein complex (DAPC)
axis could be subject to ubiquitination. In laminin alpha2 chain deficient mice,
an up-regulation of components of the ubiquitin proteasome system was ob-
served (Carmignac, Que´re´, & Durbeej, 2011). Similarly, an up-regulation
of the E3 ubiquitin ligases Atrogin-1/MAFbf and MuRF1, was observed in
cancer induced mdx mice (these ligases were subsequently reduced upon the
restoration of the dystrophin glycoprotein complex (DGC)) (Acharyya et al.,
2005). Furthermore, although not directly investigated here, the restoration
of components of the DAPC upon treatment with MG132 in dystrophic mice
models suggest their modification by ubiquitination in proteolytic mediated
events (Assereto et al., 2006; Bonuccelli et al., 2003; Kumamoto et al., 2000).
Together, these studies provide important evidence that phosphorylation
events on dystroglycan, as well as ubiquitination, regulate dystroglycan and
may regulate cellular processes as a result. The studies presented thus far
support the hypothesis of additional phosphorylation events carried out on
phosphorylatable amino acids other than Y890 and the modification of dys-
troglycan by ubiquitination.
In this chapter, the characterisation of the LNCaP cell line for the local-
isation of endogenous dystroglycan will be described. The characterisation
of the recombinant dystroglycan proteins used to study the phosphorylation-
ubiquitination post-translational modifications will also be presented. Addi-
tionally, it will be shown that dystroglycan is modified with phosphates and
ubiquitin groups.
3.2 Cellular distribution
Beta-dystroglycan is a ubiquitous protein expressed in all vertebrate cells and
tissues (http://www.genecards.org). Its expression, post-translational mod-
ifications such as glycosylation and proteolysis, effects in epithelial to mes-
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enchymal transition (a process linked to development and cancer progression),
migration and metastasis and its nuclear translocation have been characterized
using the LNCaP cell line, a widely used model of prostate cancer (Mathew et
al., 2013; Mitchell et al., 2013; Sgambato et al., 2007).
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Figure 3.2: Binding epitopes of Mandag2 and 1709 antibodies. The
schematic shows the residues 871-893 on the carboxy-terminus domain of beta-
dystroglycan. In (a), Mandag2 antibody detects the non-phosphorylated form
of the PXYVP epitope (amino acids highlighted in red), while 1709 antibody
(b) binds a phosphorylated tyrosine within the same epitope (residues high-
lighted in red).
A basic cellular characterisation for the localisation of dystroglycan in
LNCaP cells was carried out. Lysates of wild type LNCaP cells were collected
and either used directly or processed by biochemical fractionation. Lysates and
fractions were then analysed by western blot using antibodies raised against
non-phospho- and phospho-βDg, herein referred to as βDg and pβDg respec-
tively. Given the critical role of the phosphorylated tyrosine 892, it was im-
portant to differentiate the cellular distribution of βDg and pβDg. In or-
der to achieve this, it was decided to use the Mandag2 and pYβDG (1709)
antibodies. These antibodies were produced in the Morris and Winder labs
respectively (Helliwell, Nguyen, & Morris, 1994; Ilsley et al., 2001). The sub-
sequent characterisation by peptide spot assays showed that, Mandag2 binds
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the PxYVP epitope located in the C-terminus of βDg, while pYβDG binds a
phosphorylated tyrosine within the same epitope (James et al., 2000; Miller et
al., 2012) (Figure 3.2).
By using both antibodies, it was possible to detect the full-length 43 kDa
beta-dystroglycan (Full) in total lysates and in non-nuclear and nuclear frac-
tions. Additionally, in total lysates, other smaller species with sizes of 36
(herein referred to as 31) and 26 kDa were observed (Figure 3.3). Previ-
ous reports have pointed out that these species belong to the transmem-
brane anchored domain (TM) and to the cytoplasmic fragment (Cyto) of beta-
dystroglycan respectively (Mitchell et al., 2013; Yamada et al., 2001). Impor-
tantly, the cytoplasmic fragment was distributed between the non-nuclear and
nuclear fractions (Figure 3.3).
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Figure 3.3: Cellular distribution of beta-dystroglycan in LNCaP cells. LNCaP
WT cells were collected for total lysates or for biochemical fractionation. West-
ern blot analysis of the lysates using Mandag2 and pYβDG antibodies shows
the non-nuclear and nuclear localisation the 43 (Full) and 26 (Cyto) kDa forms
of non-phospho-(βDg) and phospho-beta-dystroglycan (pβDg). Lamin A/C
and alpha-tubulin are shown as the loading controls of the nuclear and non-
nuclear fractions respectively.
The results obtained from the biochemical fractionation were corroborated
by immunocytochemistry analysis through the use of organelle-specific protein
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markers such as lamin A/C and Fibrillarin, and alpha-tubulin and GAPDH, for
nuclear and non-nuclear fractions respectively. The presence and quantification
of these protein markers provided an idea about the purity of the cellular frac-
tions (Lodish et al., 2008). With Mandag2 the signal is distributed through-
out the cell. Filopodia structures were well stained in addition to the plasma
membrane and parts of the cytoplasm. Interestingly, βDg also had a nuclear
distribution along the nuclear envelope-like structure (white arrowhead) and
nucleoplasm. The signal around the nuclear envelope is not an experimental
artefact (the signal generated by secondary antibodies was observed to be at
very low levels in control immunofluorescences) as most of the cells analysed
in middle stack sections of confocal microscopy images showed a similar pat-
tern (Figure 3.4, left). The phosphorylated form of beta-dystroglycan had a
more cytoplasmic and nucleoplasmic distribution (it was also found distributed
along the nuclear envelope-like structure, white arrowhead). It is interesting
to note that pβDg is found surrounding the DNA of metaphase cells (white
arrow) (Figure 3.4, bottom right). The potential nuclear functions of beta-
dystroglycan, such as in the cell cycle or nuclear regulation, are discussed later
in this work.
Taken together, these results show that in LNCaP WT cells both βDg and
pβDg are distributed throughout non-nuclear and nuclear fractions as shown
by biochemical and immunocytochemistry analysis. Importantly, the nuclear
distribution of beta-dystroglycan supports use of the LNCaP cell line as a good
model to study the hypothesis that this protein has nuclear functions.
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3.3 A C-ter tag affects the phosphorylation of
Y890
The insertion of tags such as myc/his or GFP, in the C-terminus of beta-
dystroglycan could be a good strategy for its isolation, purification and locali-
sation, but on the other hand, these tags could affect the PTM of neighbouring
amino acids and the interaction of beta-dystroglycan with other proteins.
Dystroglycan is an important cell adhesion molecule subject to PTM such
as phosphorylation and tags that alter PTM may have a profound effect on nor-
mal processing. For example, the phosphorylation of Y890 in the C-terminal of
mouse beta-dystroglycan, has been reported to be an important PTM regulat-
ing both stability (Miller et al., 2012) and the interaction with other proteins
such as dystrophin/utrophin and other proteins containing SH2 domains (Ilsley
et al., 2001; James et al., 2000; Sotgia et al., 2001).
To verify if the presence of a myc/his tag in the C-terminus of mouse βDg
affects its phosphorylation (Figure 3.5a), lysates of LNCaP cells transfected
with a plasmid encoding αβDg-myc/his were subjected to immunoprecipita-
tion with an anti-myc antibody. Figure 3.5b shows that the pYβDG antibody
is able to detect phosphorylated beta-dystroglycan in the supernatant fraction
but not in the pellet fraction of the immunoprecipitation performed with the
anti-myc antibodies. The presence of an additional faint band in the pellet
fraction is suggestive of beta-dystroglycan being phosphorylated on an amino-
acid other than Y890. The immunoblot of the same lysates with anti-myc
antibodies shows that there was a strong enrichment of βDg immunoprecipi-
tating with anti-myc antibodies, but this was not subject to phosphorylation
as it was not detected by the pYβDG antibody (at least the band that belongs
to the 43 kDa βDg) (Figure 3.5b). Overall, through immunoprecipitation
assay, it has been shown that the insertion of a myc tag in the C-terminus
of beta-dystroglycan affects its phosphorylation, making it a non-suitable re-
combinant protein for downstream analysis, such as those dependent on the
phosphorylation of Y890.
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Figure 3.5: The myc/his tag inhibits the phosphorylation of Y890 in beta-
dystroglycan. (a) Schematic showing the structure of dystroglycan and the
position of the myc/his tag in its C-terminus. (b) LNCaP cells were trans-
fected with the plasmid pcDNA3.1(+)-αβDg-myc/his and allowed to grow for
24 hours. Cells were collected with RIPA buffer and subjected to immunopre-
cipitation with anti-myc antibodies. Input, eluates and pellets were resolved
by SDS-PAGE. Immunoblot analysis with antibodies anti-pβDg shows the ab-
sence of immuno-reactivity.
3.4 The transgenic LNCaP-αβDgFlag cell line
Having shown that the insertion of a tag in the C-terminus of βDg affects an
important PTM, such as the phosphorylation of Y890, we were prompted to
generate a new plasmid encoding full-length dystroglycan (alpha and beta)
with the insertion of tag in a position with minimum deleterious effects. Flag
tags are hydrophilic 8 amino acid peptides proven to be detected by high
specific antibodies such as M1, M2 and M5. Due to its hydrophilic nature,
this tag has a high probability of being located on the surface of the proteins,
allowing a better detection by antibodies and having a minimum effect in the
functionality of the protein (reviewed in (Einhauer & Jungbauer, 2001)). By
using the ELM server (http://elm.eu.org) which predicts functional sites in
proteins, a region near amino acid 800 was identified with minimal interactions.
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Also, the alignment of the sequence of the Flag tag with the primary sequence
of βDg showed that there were some amino acids shared between the two
sequences, requiring minimal changes to generate the Flag tag (Figure 3.6a).
Taking into account these characteristics, the Flag tag was inserted around
residue 800, and downstream the proposed NLS of βDg (Lara-Chaco´n et al.,
2010) (Figure 3.6b).
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Figure 3.6: Insertion of the Flag tag in the coding sequence of mouse αβDg.
(a) To generate the Flag tag in the primary sequence of mαβDgFlag, a pair
of oligonucleotides was designed to insert the residues YKDD (blue) and to
change the amino acid S to D (red) (see Appendix B). These changes were
made in order to avoid major changes in the structure of βDg while inserting
the whole sequence of Flag (underlined). Also, according to the Eukaryotic
Linear Motif resource (http://elm.eu.org), the area used to insert the Flag
tag is an area with no predicted interactions in βDg. (b) The schematic shows
the final position of some key elements in the primary sequence of mαβDgFlag
such as its TM domain, its NLS (green) and its Flag tag (red).
The generation of the Flag tag in mouse dystroglycan was confirmed by
DNA sequencing and then subjected to DNA purification for the characterisa-
tion of the recombinant protein by western blot. LNCaP cells were transiently
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transfected with the plasmid αβDgFlag, allowed to grow for 24 hours and then
collected for total lysates. The immunoblot analysis using anti-Flag M2 an-
tibodies shows the presence of a strong band of approximately 43 kDa in the
total lysates. Additionally, the antibody was able to detect bands above and
below the 43 kDa form (Figure 3.7).
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Figure 3.7: Characterisation of the recombinant DgFlag. The plasmid
pcDNA3.1(+)-αβDgFlag was used for transient transfection of LNCaP cells.
Cells were collected for total lysates and subjected to immunoblot analysis
with antibodies anti-Flag. Western blot analysis of total lysates shows a band
of approximately 43 kDa and other bands in lysates of cells transfected. These
bands were absent in lysates of cells not transfected indicating a high specificity
of the antibody.
By immunoprecipitation it can be observed that, in addition to Flag anti-
bodies (Figure 3.8a), pYβDG and Mandag2 antibodies had immunoreactivity
with Flag-tagged βDg. There was a clear difference in the signal generated
by pYβDG (Figure 3.8b) and Mandag (Figure 3.8c) indicating that the most
abundant species of βDg is the phosphorylated form. Additionally, Flag an-
tibodies were able to immunoprecipitate species of βDg of high (HDGA and
HDGB) and low molecular weight (TM and Cyto). The origin of high molecu-
lar weight bands (HDGB) is due to, presumably, PTM such as ubiquitination
and phosphorylation (amongst others); and the band detected between 130-
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250 kDa (HDGA) could represent the propeptide of dystroglycan or perhaps,
oligomerization of beta-dystroglycan, all of them a matter of discussion in the
following sections.
By biochemical fractionation, there was a clear distribution of βDgFlag in
non-nuclear and nuclear fractions of LNCaP cells (Figure 3.13).
By immunofluorescence, the distribution of βDgFlag was throughout the
cell, presenting a clear signal on the plasma membrane, the cytoplasm and the
nucleus. The Flag antibodies clearly co-localized with pYβDG and Mandag2
antibodies. Transfected LNCaP cells had an increased number of longer filopodia-
like structures, microvilli and an increased number of branches compared with
the wild type cells, a similar phenotype to that previously observed in my-
oblast, fibroblat, HeLa and other cell types (Batchelor et al., 2007; Y. J. Chen
et al., 2003; Spence, Chen, et al., 2004; Thompson, 2007; Thompson et al.,
2008). Also, beta-dystroglycan was observed around the cell body, with ac-
cumulation at the leading edges of the new filopodia and growth cone-like
structures (Figure 3.9).
The branching and filopodia formation upon the overexpression of dys-
troglycan clearly resembled the observations previously reported by Eyer-
mann and colleagues, in differentiating oligodendroglia (Eyermann, Czaplinski,
& Colognato, 2012). Furthermore, some transfected LNCaP cells displayed
neuronal-like morphologies.
Taken together, the biochemical and immunocytochemical analysis show
that exogenous dystroglycan expressing the Flag tag has similar characteristics
to the endogenous counterpart, making it a better candidate for localisation
and interaction experiments than a carboxyl-terminal tag.
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Figure 3.8: Immunoprecipitation of the recombinant αβDgFlag. Total lysates
of LNCaP transfected with the plasmid αβDgFlag were used for a detailed
characterisation by immunoprecipitation. Immunoprecipitations were pre-
pared by combining the total lysates with anti-Flag M2 (raised in mouse)
(a and b), anti-rFlag (c) (raised in rabbit) antibodies or left without antibody.
Inputs, recovered supernatants after immunoprecipitation (SN) and the beads
(P) were resolved by SDS-PAGE. Lysates immunoprecipitated with antibodies
raised in mouse were used for immunoblotting with antibodies raised in rabbit
and vice versa in order to avoid the signal produced by the light and heavy
chains of the immunoglobulins. This immunoprecipitation permitted to con-
firm that αβDg with the Flag tag is recognized by antibodies against Flag and
against phospho- and non-phospho-βDg (1709 and Mandag2 respectively).
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3.5 Localisation of alpha-dystroglycan in LNCaP
cells
As pointed out in the previous section, the antibodies Flag, pYβDG and
Mandag2, were able to detect an additional band between 130 and 250 kDa.
So far, from previous studies and judging by electrophoretic mobility, one can
hypothesize that the slow migrating band belongs to the dystroglycan pro-
peptide. As reviewed by Barresi and Campbell in 2006, αDg can have a size
that ranges from 120-156 kDa, although the estimated size of the core protein
is approximately 70 kDa (Barresi & Campbell, 2006). It has been suggested
that the big changes in size are in part due to the tissue under study, although
other parameters such as glycosylation may also affect mobility.
In order to determine how the expression of alpha-dystroglycan in LNCaP
cells is and its possible relationship with the 130-250 kDa band, it was de-
cided to express exogenous αDg harbouring a myc/his tag (see appendix C.1).
LNCaP cells transfected with the plasmid αDg-myc/his were collected for total
lysates or cell fractionation.
Surprisingly, the band detected in whole cell lysates with anti-myc an-
tibodies, presumably alpha-dystroglycan, did not correspond in size to the
previously observed 130-250 kDa band (Figure 3.10).
The band of alpha-dystroglycan observed had a size of approximately 50
kDa with a smearing that extended far beyond the 70 kDa marker. More-
over, αDg had a non-nuclear and nuclear distribution. The smearing could be
indicative of some variable PTM such as glycosylation. These observations ob-
tained from at least three independent replicates and the fact that the nuclear
fractions were not contaminated with non-nuclear fractions give also a strong
support of a new pool of nuclear alpha-dystroglycan.
As will be discussed later, the lack of expression of enzymes in charge of
the glycosylation of αDg (like LARGE), could be a potential explanation of
the very reduced size of αDg in LNCaP cells. Interestingly, the identity of
the 130-250 kDa remains a mystery and more deep analysis will be required to
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Figure 3.10: Nuclear localisation of alpha-dystroglycan. LNCaP cells WT or
transfected with the plasmid αDg-myc/his were fractionated in non-nuclear
and nuclear fractions. Western blot analysis with anti-c-Myc and anti-his
(not shown) antibodies showed immunoreactivity in the non-nuclear and nu-
clear fraction of the cells transfected (shown is a representative image of three
independent experiments). Membranes were stripped and reprobed with anti-
calnexin (ER marker) and anti-fibrillarin (nuclear marker) antibodies as con-
trols of purity and protein loading.
discard the different running hypotheses. In conclusion, an alpha-dystroglycan-
like protein is expressed in non-nuclear and nuclear fractions of LNCaP cells
and based on the size, the band observed does not seem to correspond to the
previously seen 130-250 kDa band.
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3.6 Phosphorylation and ubiquitination of dys-
troglycan
3.6.1 The transgenic LNCaP-Y890F and K806R cell lines
The residues Y890 and K806 in beta-dystroglycan have been shown to be
subject to phosphorylation and ubiquitination respectively (Miller et al., 2012;
K. A. Lee et al., 2011). In order to determine their effects in the stability
of dystroglycan, it was decided to engineer coding sequences of dystroglycan
carrying the mutations Y890F and K806R and transfect them into LNCaP
cells. The absence of the hydroxyl group in phenylalanine keeps a structural
similar amino acid to tyrosine and prevents the addition of phosphate groups,
rendering a protein with minimal structural changes; similarly, the blocked
amino group in arginine, prevents the additional modification with ubiquitin
groups (Figures 3.11).
Western blot analysis with anti-Flag antibodies of total lysates of LNCaP
cells WT or transfected with the parental or mutated plasmids, show that the
mutants had a similar expression to the unmodified exogenous dystroglycan.
It is interesting to note that the mutant K806R had a slightly faster migration
when compared to the mutant Y890F and parental exogenous dystroglycan
(Figure 3.12).
Turning now to the cellular distribution of exogenous αβDgFlag and its
mutants, LNCaP cells transfected with the 3 plasmids were subjected to cell
fractionation followed by immunoblot analysis. Both plasmids, Y890F and
K806R, had a similar distribution in the nucleus compared to the unmodified
αβDgFlag. Apparently, both mutations neither affect the synthesis nor their
nuclear translocation (Figures 3.13a and 3.13b).
By immunofluorescence, the staining of cells expressing the mutant Y890F
with Mandag2 was distributed along the plasma membrane and mostly ex-
cluded from the cytoplasm and nucleus (Figure 3.14, left, green). Interest-
ingly, the signal generated by Flag (red) was distributed all along the cell
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Figure 3.11: Generation of the mutants Y890F- and K806R-αβDgFlag. The
schematics show the amino acids that were changed to introduce the mutations
Y890F (a) and K806R (b) by site directed mutagenesis. After corroborating
the proper introduction of the mutations by DNA sequencing, the plasmids
were purified and used for transient transfection of LNCaP cells.
(Figure 3.14, left, red). It is worth noting that both antibodies, Flag and
Mandag2, showed a clear localisation all around the cells, but the signal gen-
erated by Mandag2 was excluded from the cytoplasm (Figure 3.14, left, merge).
Regarding the co-localisation between pYβDG and Flag antibodies, both
antibodies were distributed throughout the cell. The signal generated by
pYβDG was more cytoplasmic (Figure 3.14, right, red). Flag, on the other
hand, had a strong signal at the plasma membrane and in the cytoplasm (Fig-
ure 3.14, right, green). Both antibodies showed some co-localisation but the
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Figure 3.12: Characterisation of the mutants Y890F- and K806R-αβDgFlag.
By western blot analysis, the anti-Flag M2 antibody is able to detect specific
bands in the lysates of the cells transfected with the plasmid αβDgFlag and
the ones harbouring the mutations Y890F and K806R. Lysates of LNCaP WT
were included as a control of specificity of the anti-Flag antibody. GAPDH is
shown as the loading control.
1.  WT 
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Figure 3.13: Cellular distribution of the mutants Y890F- and K806R-
αβDgFlag in LNCaP cells. LNCaP cells WT or transfected with the plasmids
αβDgFlag, αβDgFlag-Y890F (a) and αβDgFlag-K806R (b) were collected for
total lysates or cell fractionation. The analysis by western blot with anti-Flag
antibodies shows that both mutants have a cytoplasmic and nuclear distribu-
tion. Lamin A/C, GAPDH and Calnexin are shown as the loading controls.
co-localized signals were restricted to some areas of strong signal on the plasma
membrane and was reduced towards more central areas near the nucleus (Fig-
ure 3.14, right, merge).
Turning now to the mutant K806R, it was observed that there was a good
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co-localisation between Mandag2 and Flag (raised in rabbit), and pYβDG and
Flag (raised in mouse) antibodies compared with the mutant Y890F. The dis-
tribution of the protein was all along the plasma membrane to the cytoplasm.
There were some areas of non co-localisation that could be explained by the
fact that some species that harbour the mutation K806R could be either sub-
ject to phosphorylation or left unmodified (Figure 3.15).
Overall, these results show that dystroglycan harbouring the mutations
Y890F and K806R is expressed in LNCaP cells. They are distributed from the
plasma membrane to the nucleus and apparently, these two modifications do
not interfere in their nuclear transport.
3.6.2 Beta-dystroglycan is extensively phosphorylated
Beta-dystroglycan is a transmembrane protein with many serine (S), threonine
(T) and tyrosine (Y) amino acids predicted to be phosphorylated. Due to its
critical localisation, Y890 (in mouse) is the amino acid that has been most
deeply studied. As mentioned before, its phosphorylated state (maintained by
Src) is critical for interactions with other proteins, and to keep the stability of
other dystrophin associated proteins on the plasma membrane. By site directed
mutagenesis and mass spectrometry analysis, other amino acids in addition to
the Y890 have been identified as potential residues subject to phosphorylation
(http://www.phosphosite.org/homeAction.do).
So far, in the experiments performed with WT or overexpressed dystro-
glycan, there were some bands appearing above the 43 kDa species. The
shift in the migration of the bands could be due to the presence of post-
translational modifications on dystroglycan such as phosphorylation, ubiqui-
tination or sumoylation. In 2000, James and colleagues observed that upon
treatment of HeLa cells with peroxovanadate, beta-dystroglycan had a retar-
dation in its electrophoretic migration. Immunoprecipitation analysis with
anti-p-tyrosine antibodies confirmed that the slow migrating band was due to
dystroglycan phosphorylation (James et al., 2000).
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In order to test the hypothesis that the slower migrating bands observed
on immunoblots during the course of this project, are due to phosphoryla-
tion, it was decided to inhibit the activity of serine, threonine and tyrosine
phosphatases in LNCaP cells. Sodium peroxovanadate (Ruff et al., 1997)
and calyculin (Resjo¨ et al., 1999) have been shown to be potent inhibitors
of tyrosine, and serine/threonine phosphatases respectively. To determine the
effects of both compounds on the phosphorylated status of beta-dystroglycan,
LNCaP cells transfected with the plasmid αβDgFlag were treated with ca-
lyculin A, sodium peroxovanadate, a combination of both, or DMSO. Total
lysates resolved in a Tricine-SDS-PAGE gels (see section 2.1.5.10) followed by
western blot analysis with anti-Flag antibodies showed no apparent changes
in the electrophoretic migration in lysates of cells exposed to individual treat-
ments compared with the control (DMSO). However, the combination of both
treatments led to a dramatic increase in the abundance of the 26, 35, 43 kDa
forms of beta-dystroglycan and, most importantly, in slow migrating bands of
a higher molecular weight (HDGB) (Figure 3.16).
Blotting of the same lysates with antibodies anti-p-MAPK revealed the
protective effects against protein phosphatases provided by both inhibitors
(Figure 3.16, top figure on the right).
Another approach to test the phosphorylated status of proteins is by in vitro
analysis, such as dephosphorylation with Calf Intestinal Phosphatase (CIP),
which has the ability to remove phosphate groups from S, T and Y amino
acids. Changes in electrophoretic mobility upon treatment with CIP could
indicate the presence of phosphorylated amino acids. Therefore, lysates of cells
transfected with the plasmid αβDgFlag were treated with CIP. Additionally,
lysates of cells transfected with the αβDgFlag-Y890F mutant were included
in the analysis in order to highlight some changes not associated with the
phosphorylation of the Y890.
The transfection of the mutant αβDgFlag-Y890F in LNCaP cells followed
by immunoblot analysis with anti-Flag antibodies revealed two exciting re-
sults. First, the banding pattern of the mutant Y890F was not the same
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Figure 3.16: Calyculin and peroxovanadate lead to increased levels of phospho-
rylation of beta-dystroglycan. LNCaP transiently transfected with the plasmid
αβDgFlag were grown for 24 hours. Cells were then treated with DMSO, ca-
lyculin, peroxovanadate or a combination of calyculin/peroxovanadate for 15
minutes. Lysates were immunoblotted with anti-Flag antibodies. The treat-
ment of the cells with peroxovanadate and calyculin led to the appearance of
slower migrating bands (HDGB) when using a 11%T, 0.67% Tricine-SDS PAGE
gels. Membranes were incubated with an anti-p-MAPK antibody to show the
efficacy of calyculin and peroxovanadate treatments. Reprobed membranes
with anti-MAPK and anti-GAPDH are shown as the loading controls.
compared with the non-mutated form of exogenous beta-dystroglycan. There
was a slight delay in the migration of the Y890F mutant which was more evi-
dent in non-nuclear fractions of transfected cells (dashed line in Figure 3.17a).
This resembled a similar pattern in the mobility of the recombinant protein
beta-dystroglycan fused to an alkaline phosphatase tag harbouring the same
mutation (Sotgia et al., 2003). Second, the western blot analysis of total
lysates showed that some migrating bands above (-HDG) and below (-LDG)
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full-length beta-dystroglycan (43 kDa) were absent compared to the parental
protein αβDgFlag (Figure 3.17b).
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Figure 3.17: The mutation Y890F affects other PTM on beta-dystroglycan.
(a) Western blot analysis of non-nuclear fractions of cells transfected with the
plasmids αβDgFlag and αβDgFlag-Y890F reveals a retardation in the migra-
tion of the mutant Y890F compared with normal αβDgFlag (dashed line).
(b) The mutation Y890F affects other PTM on βDg. Lysates of LNCaP cells
transfected with the plasmids αβDgFlag and αβDgFlag-Y890F were subjected
to immunoblot analysis with antibodies anti-Flag. The introduction of the mu-
tation in Y890 abolished other PTM on beta-dystroglycan (-HDG and -LDG)
Following this, the treatment with CIP revealed interesting findings. Lysates
containing αβDgFlag had a multiple banding pattern above the main band of
βDg in the absence of CIP treatment. However, upon treatment with CIP,
there was a reduction in band intensity generated by anti-Flag antibody around
bands 100-130 (-HpDGa) and the signal was at very reduced levels on bands
near 60 kDa (-HpDGb). If we now turn to mutant Y890F, it is possible to
see that lysates not treated with CIP still lack some slower migrating bands
and the ones present were at a lower abundance (-HpDGa). When the same
lysates were subjected to treatment with CIP, the remnant doublet observed
at approximately 60 kDa (-HpDGb) was completely abolished (Figure 3.18a).
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The resolution of the same lysates in a 10%T, 3%C tricine-SDS-PAGE
system (see Table D.3), followed by immunoblotting with Mandag2 antibod-
ies gave unexpected outcomes. Lysates of cells transfected with the parental
plasmid αβDgFlag and left untreated, showed many slower migrating bands.
Some of those bands disappeared when the same lysates were subjected to
treatment with CIP. On the other hand, in lysates with mutant Y890F the
presence of bands above 43 kDa were considerably reduced under the two
conditions (HpDG in Figure 3.18b).
The disappearance of bands in lysates treated with CIP suggests the pres-
ence of additional phosphorylatable amino acids, and importantly, the phos-
phorylation of Y890 seems to be a triggering factor for additional post-translational
modifications in beta-dystroglycan. The use of anti-phosphotyrosine antibod-
ies in order to further show the presence of additional phosphorylatable amino
acids in beta-dystroglycan will be required.
3.6.3 Beta-dystroglycan is ubiquitinated
Immunoblotting of beta-dystroglycan, either endogenous or exogenous, with
the antibodies anti-pYβDG, Mandag2 or Flag, usually revealed some bands
of high molecular weight in addition to the unmodified 43 kDa species. The
experiments performed with the inhibitors of phosphatases calyculin A and
sodium peroxovanadate, and the treatment of total lysates with CIP, suggested
that the retardation in the migration of some bands was due to phosphoryla-
tion. These changes occurred mainly between the range of the 43 and 80 kDa,
which does not explain the presence of other bands usually observed above
80 kDa. The speed of their migration was suggestive of two important PTM,
ubiquitination or sumoylation.
Ubiquitination could be a potential candidate to explain the presence of
high molecular weight migrating bands. This dynamic PTM can control many
cellular processes depending on very specific situations. The classic pathway
is the labelling with ubiquitin groups of proteins targeted for degradation,
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Figure 3.18: Beta-dystroglycan is extensively phosphorylated. (a) Total lysates
of LNCaP transfected with the plasmid αβDgFlag or αβDgFlag-Y890F were
subject to dephosphorylation with CIP (+). The analysis by western blot using
anti-M2 Flag antibodies shows the absence of some slow migrating bands in
samples treated with CIP (-HpDGa and -HpDGb). GAPDH is shown as the
loading control. (b) The electrophoretic separation of the same samples using a
10%T, 3%C tricine-SDS PAGE gels gave a better resolution of phosphorylated
beta-dystroglycan (HpDG).
although other non-proteolytic activities have been attributed to ubiquiti-
nation, such as the modification of specific proteins for a better interaction
with other proteins or for protection against their degradation by the protea-
some (K. P. Bhat & Greer, 2011).
The inhibition of proteasome activity usually leads to an electrophoretic
retardation in the migration of proteins subject to ubiquitination. To probe
whether the bands above 80 kDa were ubiquitinated beta-dystroglycan, LNCaP
cells expressing exogenous αβDgFlag were subjected to treatment with MG132,
a proteasomal inhibitor. Total lysates obtained in the presence of N-ethylmaleimide
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(NEM), a deubiquitinase inhibitor, were then resolved by SDS-PAGE gradient
gels and western blotted with anti-Flag antibodies. When cells were treated
with DMSO and then lysed in the absence or presence of NEM, no significant
changes were observed in the migration of the bands above 43 kDa. How-
ever, treatment with MG132 still produced the bands between 55 and 70 kDa
(HuDGc), but reduced the density of the approximately 80 kDa band (HuDGb)
and led to the appearance of bands between the 90-120 kDa (HuDGa). The
band above 130 kDa was also altered. Upon treatment with MG132 this band
was reduced but present as a doublet (HuDGp) (Figure 3.19a).
It is well known that the concentration of acrylamide affects the good trans-
fer of proteins. The higher the concentration, the more difficult is to transfer
high molecular weight proteins. To determine if the reduced amount of the 130
kDa band was due to the generation of other slower migrating species above
200 kDa, the same lysates of Figure 3.19a, were resolved in a 11%T 0.67%C
Tricine-SDS-PAGE gel (see section 2.1.5.10). The most impressive result to
emerge from this second immunoblot analysis with anti-Flag antibodies is the
presence of other species of an even high molecular weight but only in the
presence of NEM (Figure 3.19b).
Taken together, these results support the hypothesis of beta-dystroglycan
being modified by ubiquitin groups. Although the high molecular weight
species of beta-dystroglycan were only present when cells were treated with
MG132, or collected in lysis buffer containing NEM, this does not completely
confirm that the shifts were due to ubiquitination.
The development of technologies for the isolation and protection of ubiq-
uitinated proteins has been of great advantage in the study of functional and
degradative processes in which ubiquitination is implicated. MultiDsk (MD),
a high affinity ubiquitin binding protein developed by Wilson and colleagues
in 2012, has been shown to be an important approach for the enrichment
and protection of mono- and poly-ubiquitinated proteins (M. D. Wilson et
al., 2012). This construct cloned into a GST expression vector consists of a
tandem of 5 repeats of the yeast Dsk2 ubiquitin binding domain flanked by
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Figure 3.19: Potential ubiquitination of beta-dystroglycan. (a) LNCaP cells
transiently transfected with the plasmid αβDgFlag were subjected to treat-
ment with MG132 for 4 hours. Cells lysed with RIPA buffer (supplemented
with NEM) were resolved by gradient SDS-PAGE gels (7.5-15%) and im-
munoblotted with primary antibodies anti-Flag. The treatment with MG132
leads to the appearance of slower migrating bands around 100 kDa (HuDGa).
(b) The loading of the same lysates in a 11%T 0.67%C Tricine SDS PAGE
gel, allowed a better resolution of bands migrating above 150 kDa. Lysates
of LNCaP WT were loaded as a control for specificity of Flag antibodies.
Stripped membranes were reprobed with anti-GAPDH antibody as a loading
control. The difference in the banding patter between the blots (a) and (b)
may be due to the different species of antibodies used.
two 6x His tags (Figure 3.20a). In order to determine the specificity of this
novel protein, LNCaP cells transfected with the plasmid αβDgFlag were lysed
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in the presence of NEM. Lysates were then incubated with agarose, agarose-
GST or agarose-MD beads. The separation of supernatant and pellets on a
SDS-PAGE gel followed by immunoblot analysis with anti-ubiquitin antibodies
showed that a great amount of ubiquitinated protein was recovered interacting
with MultiDsk (pellet). As no protein was observed in the pellet of agarose
or agarose-GST it can be concluded that MultiDsk is highly specific to bind
ubiquitinated proteins (Figures 3.20b and 3.20c).
Having corroborated the specificity of the resin, the next step was to de-
termine the profile of ubiquitinated beta-dystroglycan. For that, LNCaP cells
overexpressing αβDgFlag were treated with DMSO or MG132 and then lysed
in the presence of NEM. Untreated and treated lysates were incubated with
agarose-GST or MultiDsk, resolved by SDS-PAGE and immunoblotted using
anti-Flag antibodies.
As expected, many high molecular weight proteins in the range of 60-
300 kDa precipitated with MultiDsk and were absent in pellets of GST alone
(HuDG). Interestingly, the recovery of ubiquitinated proteins with MultiDsk
was the same for cells treated or not treated with MG132 indicating that
MultiDsk is sufficient to protect ubiquitinated substrates from degradation
(Figure 3.21b) (M. D. Wilson et al., 2012). Another interesting observation is
that the 55 and 60 kDa species, although present, were not precipitated with
the MultiDsk resin (HpDG). Despite the fact that this experiment suggests
that beta-dystroglycan is ubiquitinated, there is still the question of whether
βDg is being mono-ubiquitinated on multiple residues, modified in one critical
residue with a poly-ubiquitin chain, or a combination of both.
The next obvious question was to determine if beta-dystroglycan sub-
jected to ubiquitination was also subject to phosphorylation on Y890. As
stated before, pYβDG and Mandag2 are two antibodies that detect phospho-
rylated and non-phosphorylated tyrosines in a stretch of amino acids located
in the C-terminus of beta-dystroglycan respectively. The immunoblot anal-
ysis with these two antibodies detected the presence of two bands above 70
kDa (HuDG∗), suggesting that ubiquitination of beta-dystroglycan in LNCaP
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Figure 3.20: Purification of ubiquitinated proteins with MultiDsk affinity resin.
(a) Schematic structure of GST-MultiDsk (reproduced and modified with per-
mission of Jesper Q. Svejstrup.) (b) LNCaP cells were transfected with the
plasmid αβDgFlag and lysed with RIPA buffer supplemented with 10 mM
NEM. Lysates were incubated with agarose, agarose-GST or agarose-GST-
MD beads. After washing the beads as indicated in material and methods,
pulled down proteins were resolved by SDS PAGE. Western blot analysis with
an anti-ubiquitin antibody shows that most of the ubiquitinated proteins were
recovered in the MultiDsk pellet compared with the controls (agarose and
agarose-GST beads). (c) The membrane was stained with Ponceau S red
staining solution to show the equal loading of the recombinant proteins GST
and GST-MD.
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cells is not dependent of the phosphorylated tyrosine Y890 in its C-terminus
(Figures 3.21c and 3.21d).
To have a deeper insight into ubiquitinated dystroglycan, LNCaP cells
transfected with the plasmid αβDgFlag were used for imunocytochemical anal-
ysis. Co-immunostaining of the transfected cells with antibodies anti-Flag and
anti-ubiquitin shows some areas of clear co-localisation of ubiquitin and Flag
(Figure 3.22).
As shown in the section related to phosphorylation of βDg, the introduction
of the mutation Y890F led to a dramatic reduction of high molecular weight
migrating bands. Additionally, as stated in the introduction, the K806 seems
to be a critical residue in the ubiquitination for beta-dystroglycan. To deter-
mine if both mutants are affecting the generation of slow migrating species
in the range of 70-300 kDa, LNCaP cells transfected with the parental plas-
mid αβDgFlag and those harbouring the mutations Y890F and K806R were
treated with MG132 or DMSO. Lysates of cells treated with MG132 or left
untreated (DMSO) were obtained with RIPA buffer supplemented with NEM
or normal RIPA buffer respectively. As revealed by the anti-Flag antibodies
in Figure 3.23, the pattern of bands between the 70-300 kDa (HuDG) resem-
bled those generated by the parental plasmid (Figure 3.23). These all together
support the idea that the phosphorylation of Y890 in beta-dystroglycan does
not affect its ubiquitination. Additionally, the mutation K806R, although a
potential amino acid predicted to be modified by ubiquitin groups (K. A. Lee
et al., 2011), seems to not affect the overall pattern of higher molecular weight
bands of beta-dystroglycan.
Ubiquitination is a post-translational modification that can take place ei-
ther in the cytoplasm or in the nucleus. In an attempt to differentiate if
ubiquitination of beta-dystroglycan takes place in both, or is restricted to one
specific cellular compartment, LNCaP cells transiently expressing αβDgFlag
were treated with MG132. Cells were then collected for cell fractionation in the
presence of NEM for those under the treatment with MG132. The analysis of
non-nuclear and nuclear fractions with Flag, Mandag2, pYβDG and ubiquitin
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Figure 3.21: Beta-dystroglycan is multiply ubiquitinated. LNCaP cells trans-
fected with the plasmid αβDgFlag were treated with the proteasomal inhibitor
MG132(+) or DMSO (-). After 4 hours treatment, cells were lysed with RIPA
buffer supplemented with 10 mM NEM. Lysates were incubated with agarose-
GST (control) or agarose-GST-MD beads and resolved by gradient SDS-PAGE
gels (7.5-12.5%). (a) The schematic shows the molecular interactions of dys-
troglycan with MultiDsk and the Flag M2 Ab. (b) Immunoblot analysis using
an anti-Flag antibody shows the presence of slower electrophoretic migrat-
ing bands in the pellets of lysates incubated with the MultiDsk affinity resin
(HuDG). (c and d) The same lysates were immunoblotted on separate mem-
branes with antibodies anti-βDg (Mandag2) and anti-p-βDG (pYβDG) anti-
bodies.
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Figure 3.22: LNCaP cells transiently transfected with the plasmid αβDgFlag
were co-immunostained anti-Flag (red) and anti-ubiquitin (green) antibodies.
A middle stack section of deconvolved confocal microscopy images shows vari-
able co-localisation of ubiquitin and beta-dystroglycan in the cytoplasmic and
nuclear fractions of the cells. Nuclei were counterstained with DAPI. Scale bar
= 10 µm.
antibodies showed the classic banding pattern in the non-nuclear fraction of
cells under treatment with MG132. Contrary to the expected, the abundance
of ubiquitinated proteins in the nucleus was very low as was the amount of
overexpressed beta-dystroglycan (Figure 3.24).
The addition of ubiquitin groups to the proteins can target them for degra-
dation by the proteasome or other regulatory processes, as mentioned in the
introduction. As shown before, beta-dystroglycan is modified by phosphory-
lation and ubiquitination. In addition to this, it was already shown that the
mutation Y890F confers stability to beta-dystroglycan and other components
of the dystrophin associated protein complex (Miller et al., 2012). Regarding
the residue K806, there have been some mass spectrometry reports indicating
its potential ubiquitination (K. A. Lee et al., 2011), but there is not evi-
dence indicating how this potential ubiquitination affects the stability of beta-
dystroglycan. In order to have a better idea about the way in which these two
mutations, Y890F and K806R, affect the stability of beta-dystroglycan, cells
transiently transfected with the corresponding plasmids were treated with the
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Figure 3.23: The mutations Y890F and K806R have little effects in the slower
migrating bands of beta-dystroglycan. Transfected LNCaP cells with the plas-
mids αβDgFlag and the ones with the mutants Y890F and K806R were treated
with MG132 for 4 hours. Cells were washed with PBS before being collected
with RIPA buffer supplemented with NEM [20 mM]. Blotted lysates with an-
tibodies anti-Flag do not show big differences in the slow electrophoretic mi-
grating bands (HuDG). Stripped membrane was reprobed with anti-GAPDH
antibody to show the loading of the proteins.
protein synthesis inhibitor cycloheximide. After 24 h post-transfection, cells
were collected for total lysates or were left growing for 12 hours more in the
presence of cycloheximide and then collected for total lysates. Although it can
not be completely concluded and further analyses are required, at 12 hours
after stopping the synthesis of the proteins, the mutations Y890F and K806R
had not any apparent changes in the amount of protein indicating the same
ratio of degradation for both mutants (Figure 3.25).
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Figure 3.24: Differential ubiquitination of non-nuclear and nuclear beta-
dystroglycan. LNCaP cells were transfected with the plasmid αβDgFlag. Af-
ter 24 hours growth, cells were further treated with MG132 [15 µM] for 4
hours. Cells were collected with buffer I for cell fractionation supplemented
with NEM [10 mM]. Immunoblot analysis of both fractions shows the pres-
ence of the slower migrating bands in the non-nuclear fractions of cells treated
with MG132. Membranes were stripped and reprobed with anti-βDg and anti-
pβDg, anti-ubiquitin, anti-calnexin and anti-fibrillarin antibodies.
3.7 Discussion.
3.7.1 Distribution of dystroglycan in LNCaP cells
The cellular communication between the intracellular environment with neigh-
bouring cells or the surrounding extracellular matrix is enabled by the presence
of cell adhesion proteins immersed in the plasma membrane. The signal gener-
ated in the extracellular matrix is sensed by these plasma membrane proteins
which in turn transmit the signal into the cell taking advantage of adaptor
proteins found in the intracellular space (Alberts et al., 2008).
In addition to integrins, dystroglycan has been suggested to perform both
functions. The DG complex spans the plasma membrane of many different cell
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Figure 3.25: Comparison of the rate of degradation between the Flag-tagged
beta-dystroglycan and the mutants Y890F and K806R. LNCaP cells trans-
fected with the plasmid αβDgFlag, αβDgFlag-Y890F and αβDgFlag-K806R
were grown for 24 hours. Total lysates were obtained at 0 h (0 h) or after fur-
ther incubation with cycloheximide [100 µg/ml] for 12 hours (12 h). Shown are
the lysates of three independent experiments blotted with anti-Flag antibod-
ies. Bands intensities of the Flag signal were normalized to GAPDH (means
± SEM, n=3).
types and tissues, performing structural and signalling activities. In prostate
tissue, dystroglycan is expressed in the epithelium of basal and secretory cells
but is reduced in prostate adenocarcinoma (Henry et al., 2001; Mathew et
al., 2013; Sgambato et al., 2007). This prompted research to unravel the
mechanisms leading to the loss of dystroglycan in prostate cancer, using the
LNCaP cell line as a model system.
In this work, the biochemical fractionation and immunocytochemistry anal-
ysis of LNCaP cells showed the distribution of βDg and pβDg in the nucleus
of LNCaP cells, which is in agreement with previous observations in prostate
tissue and in LNCaP cells (Mathew et al., 2013). Additionally, immunofluores-
cence analysis showed a clear distribution of both forms of beta-dystroglycan
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all along the cellular body. It is also worth noting the fact that Mandag2
showed a signal around the nuclear periphery (green channel in Figure 3.4).
Although analysis of the co-localisation of beta-dystroglycan with members
of the nuclear envelope were not performed, the immunocytochemistry and
biochemical fractionation (Figures 3.3 and 3.4, on pages 72 and 74), are in
agreement with previous reports showing the presence of dystrophin and mem-
bers of the dystrophin associated protein complex, such as dystroglycan in
the nucleus of different cell lines and their association with nuclear compo-
nents (Fuentes-Mera et al., 2006; Gonza´lez et al., 2000; Gonza´lez-Ramı´rez et
al., 2008; Lara-Chaco´n et al., 2010; Marquez et al., 2003; Mart´ınez-Vieyra
et al., 2013; Mathew et al., 2013; Oppizzi et al., 2008; Va´squez-Limeta et
al., 2014; Villarreal-Silva et al., 2010). Further analyses are required to show
the specific location of dystroglycan within the nucleus, and in other cellular
compartments such as the Golgi apparatus or endoplasmic reticulum.
3.7.2 The myc/his tag affects the phosphorylation of
Y890 in beta-dystroglycan
The critical position in the plasma membrane, the localisation in the nucleus,
the diverse array of its interactions and multiple PTM, lead to the hypothesis
that there are other interactions and cellular events in which dystroglycan plays
a critical role that have not been unravelled. The integrity of the alpha subunit
is important for linkage with extracellular components. On the other hand, its
cytoplasmic domain regulates important cellular processes in the cytoplasm. In
this regard, a phosphorylated tyrosine in the very C-terminus of βDg appears
to be regulating a great variety of important protein interactions, such as
those with dystrophin/utrophin, in addition to regulating the activation of
other signalling pathways, as will be discussed later. Also, this region harbours
many putative protein binding motifs such as SH2 and SH3 domains, and WW
domain ligands and many additional phosphorylatable amino acids (Moore &
Winder, 2010), all of which are located downstream of its nuclear localisation
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signal. So, small modifications could be disadvantageous to the structure and
potential interactions of the C-terminus.
The immunoprecipitation of endogenous dystroglycan for the characterisa-
tion of additional unknown interacting proteins with the antibodies Mandag2
and pYβDG has the main disadvantage that these antibodies bind the PPPY
motif, the main interaction site for cytoskeletal proteins such as dystrophin/utrophin
among others. Therefore, an alternative strategy could be the insertion of tags
downstream the PPPY motif, however, the size and folding of such tags could
alter important cellular events such as PTM and protein interactions medi-
ated by this PPXY motif. Indeed, Figure 3.5b shows that the introduction
of a myc/his tag in the carboxy-terminus affected the phosphorylation of the
Y890 in mouse beta-dystroglycan.
3.7.3 The recombinant αβDgFlag
Beta-dystroglycan cannot easily be expressed in the absence of alpha-dystroglycan
due to the complicated co-translational modification, proteolysis and inser-
tion in the plasma membrane. Furthermore, the extracellular domain of beta-
dystroglycan is susceptible to cleavage by matrix metalloproteinases (Yamada
et al., 2001). Therefore, because insertion of a tag at the C-terminus of dystro-
glycan prevented phosphorylation, it was necessary to look for another region
in the cytoplasmic domain. An area around amino acid 800 was identified
as being away from most of the putative binding motifs and suitable for the
insertion of a Flag tag with minimum changes. The insertion of this Flag tag,
however, does overlap with the K806 reported by Lee and colleagues to be
subject to ubiquitination (K. A. Lee et al., 2011). Because of its hydrophilic
characteristics, this tag seems to be always structurally exposed, which is ad-
vantageous for its detection (Figure 3.6).
The characterisation of LNCaP cells transfected with the recombinant
αβDgFlag showed that the Flag tag did not interfere in the detection by
Mandag2 and pYβDG antibodies (Figure 3.8). Importantly, species other than
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the 43 kDa beta-dystroglycan were observed on western blots and the anal-
ysis by immunofluorescence clearly resembled the visual staining phenotype
observed with endogenous dystroglycan (Figure 3.9). Through cell fractiona-
tion, the nuclear distribution of recombinant beta-dystroglycan and associated
species was confirmed. Therefore, through western blot and immunofluores-
cence analyses, the cellular localisation of αβDgFlag resembles that of endoge-
nous dystroglycan. However, it will be important to keep in mind that the
solely insertion of Flag into the primary structure of dystroglycan may still
affect its function, folding and some protein interactions, even the fact that it
was inserted in a region with minimal interactions.
During the course of the characterisation of LNCaP WT cells and cells
transfected with exogenous αβDgFlag, a band between 130 and 250 kDa
was commonly observed on immunoblots of total lysates, non-nuclear, or nu-
clear fractions (Figures 3.7, 3.8). This band usually immunoreacted with the
Flag, Mandag2 and pYβDG antibodies and, intriguingly, was sometimes ob-
served as a doublet. From the original characterisation of the dystrophin as-
sociated protein complex, the sizes ascribed to alpha- and beta-dystroglycan
were 156- and 43-kDa respectively, although for core alpha dystroglycan it is
much lower (Ervasti & Campbell, 1991; Ibraghimov-Beskrovnaya et al., 1992).
Therefore, it was hypothesized that the band observed between 130-250 kDa
could correspond to alpha-dystroglycan with some modifications.
3.7.4 Nuclear alpha-dystroglycan
The transfection of LNCaP cells with a plasmid encoding alpha-dystroglycan
gave unexpected results. In total lysates, the protein detected by anti-myc
and anti-6xHis antibodies had a size in the range of 50-70 kDa. What is more,
it was surprising to find alpha-dystroglycan in the nucleus of LNCaP cells.
The results presented in Figure 3.10 clearly show that alpha-dystroglycan was
distributed in non-nuclear and nuclear fractions.
As mentioned above, one unanticipated finding was the low molecular
107
CHAPTER 3. BETA-DYSTROGLYCAN PROTEIN MODIFICATIONS
weight of alpha-dystroglycan. In accordance with the present results, pre-
vious studies have demonstrated that defects in the glycosylation of alpha-
dystroglycan could be an explanation for its reduced size. Previous reports
demonstrated that LARGE was able to recognize and modify alpha-dystroglycan
but only when found in its functional form (alpha dystroglycan harbouring
its N-terminal, mucin-like and C-terminal domains) (Kanagawa et al., 2004).
Experiments performed in models of prostate cancer, such as the aggressive
metastatic LNCaP cell line, have found that, although alpha-dystroglycan is
expressed, its glycosylation is reduced. The defects in glycosylation were at-
tributed to the reduced expression of LARGE2 in this cell line and to its
concomitant reduction during prostate cancer progression (Esser et al., 2013).
This phenomenon was not restricted to prostate cancer as the same defect in
glycosylation was observed in cell lines derived from breast, lung and cervical
cancers, presumably attributed to the silencing of LARGE (de Bernabe´ et al.,
2009).
Thus, the defects in glycosylation could be an explanation for the reduced
size of alpha-dystroglycan indicating that the species detected in this work
corresponds to the core peptide. Another explanation for the reduced size of
the alpha-dystroglycan species observed in this work, is the fact that other
PTM, such as proteolysis could be affecting its integrity. In this regard, it has
been previously reported that alpha-dystroglycan is subject to the cleavage by
Furin on its N-terminal domain, liberating a ∼30kDa fragment (Kanagawa et
al., 2004; Singh et al., 2004).
Together, these data lead to conclusion and future hypothesis that alpha-
dystroglycan has a non-nuclear and nuclear distribution in LNCaP cells and
that the great variability in its size from its counterpart in muscle could be
attributed to the defects in glycosylation caused by the down-regulation of
LARGE2 and to the proteolytic action of Furin in LNCaP cells. In support
of this hypothesis, and although it was not clearly concluded, White and col-
leagues reported the nuclear localisation of alpha-dystroglycan in airway ep-
ithelial cells during wound repair using wheat germ agglutinin (WGA) (White,
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Wojcik, Gruenert, Sun, & Dorscheid, 2001).
All this evidence, however, still does not explain the origins of the 130-
250 kDa band. In 1996, Mummery and colleagues reported the presence of a
164 kDa and a 25 kDa species of beta-dystroglycan in post-synaptic density
fractions of an adult rat forebrain. The additional in vitro treatment with en-
doglycosidase F did not show changes in the electrophoretic migration of these
species of beta-dystroglycan (Mummery, Sessay, Lai, & Beesley, 1996). The
observed size could be in agreement with the bands observed here in this chap-
ter, however, in this thesis the treatment with PNGaseF did lead to a slight
reduction in the size of the 130-250 kDa species of beta-dystroglycan (possibly
because of the differential activities between endoglycosidase F and PNGaseF).
A similar high molecular species was observed in rat retina (Ueda, Gohdo, &
Ohno, 1998). Thus, if this band has immunoreactivity with antibodies used to
detect the 43 kDa species, one can hypothesize that beta-dystroglycan is sub-
ject to oligomerization. In this regard, through chemical cross-linking it was
shown that beta- and alpha-dystroglycan have the tendency of oligomerization
in tissues such as diaphragm, skeletal muscle and heart (Finn & Ohlendieck,
1998).
A later report, however, described that the similar band of approximately
160 kDa corresponded to the precursor peptide of dystroglycan (Holt et al.,
2000). This could be the explanation for the observed band in this thesis,
but the reduced size of alpha-dystroglycan plus the size of beta-dystroglycan
observed in these experiments do not match to the size of the high molecular
weight band observed in this chapter, leading to the previous hypothesis of dys-
troglycan being subject to oligomerization. In support of this, a recent study
reported big differences in the molarity of laminin:dystroglycan:dystrophin in
a ratio of 1:41:1 in skeletal muscle (Johnson et al., 2013). Although it was
concluded that the differences observed were due to the existence of complexes
of dystroglycan associating with different proteins, it could be tempting to
speculate that the big differences in the ratio observed are due to the forma-
tion of beta-dystroglycan multimers in the plasma membrane. This in some
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way would help to explain the strong interaction with alpha-dystroglycan, as
it is well know that these two subunits have a non-covalent interaction. On
the other hand, the formation of multimers could help prevent the proteolysis
of beta-dystroglycan. It is worth noting that cell lysates were separated in a
reducing SDS-PAGE gel, which should be enough to disrupt the formation of
multimers, however it has been shown that the opposite effect may happen
as was observed for presenilins (De Strooper et al., 1997). Further evidence
will be required to support the formation of beta-dystroglycan multimers in
the plasma and nuclear membranes, and the significance of those hypothetical
oligomers in cellular homeostasis.
3.7.5 Ubiquitination and phosphorylation of dystrogly-
can
3.7.5.1 Generation of the mutants Y890F and K806R
Given the multiple functions ascribed to dystroglycan, one would expect it
to be subjected to tight regulation. From Figure 3.8 and other experiments
presented in this thesis, it can be seen that beta-dystroglycan usually presents
some slow migrating bands above the main 43 kDa form. Previous reports and
assumptions point towards dystroglycan modification by sumoylation, ubiqui-
tination and phosphorylation. These could be plausible hypotheses as the
sequence of dystroglycan, specially the cytoplasmic domain, is rich in amino
acids with a high probability of being modified by ubiquitination or phospho-
rylation. Growing evidence through mass spectrometry analysis confirm the
previous assumption. The high sensitivity of this technique has shown that the
N-terminal as well as the C-terminal domains in alpha- and beta-dystroglycan
respectively, are domains subject to a broad number of modifications (most of
these modifications were indirectly discovered in meta-analysis that were not
aimed at dystroglycan) ( http://www.phosphosite.org/homeAction.do).
Given the fact that Y890 is critical for protein interactions (Sotgia et al.,
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2001) and for the stability of dystroglycan at the plasma membrane (Miller
et al., 2012) it was decided to investigate the role of this phosphorylation
in the stability of dystroglycan. Also, a lysine at position 806, K806, was
identified at the peptide level as a substrate of the E3 ubiquitin ligase HDR1
by using quantitative proteomics (K. A. Lee et al., 2011). Thus, the role of
this ubiquitination in the integrity of dystroglycan was investigated.
By biochemical and cytochemical analysis of LNCaP cells, similar pheno-
types (expression and cellular distribution) of the mutants Y890F and K806R
to the parental protein were recognized (Figures 3.11 - 3.15). Slight differences
in the electrophoretic migration of the mutants compared to the parental pro-
tein were observed. The mutant K806R migrated a bit faster than the unmod-
ified protein, however, the mutant Y890F had a retardation in its migration
which will be discussed in the next section.
3.7.5.2 Dystroglycan is highly phosphorylated and ubiquitinated
The impact of phosphorylation on the regulation of beta-dystroglycan is highly
debated. This PTM modifies a number of important protein-protein interac-
tions (Ilsley et al., 2001; James et al., 2000; Sotgia et al., 2001), its protein
stability (Miller et al., 2012), its vesicular transport (Sotgia et al., 2003), its
virus permissibility (Moraz et al., 2013) or its adapter properties of the ERK-
MAPK cascade components (Spence, Dhillon, et al., 2004). Previous research
has focused the attention on tyrosine 890 located in the C-terminus of dystro-
glycan. This is based in the premise that the presence of pY890 is the main
factor leading to the disruption of its interaction with dystrophin/utrophin,
which in turn leads to the instability of the other members of the DGC lead-
ing to muscular dystrophy.
The experiments performed by Moraz and colleagues in 2013, clearly showed
the existence of unknown tyrosines other than Y890 that could be subject to
phosphorylation, which could be in agreement with our previous observations
in Figure 3.8 (Moraz et al., 2013). Here the presence of multiple slow migrating
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bands are indicative of dystroglycan being subject to either phosphorylation
or ubiquitination.
Indeed, the combined effect of calyculin and peroxovanadate led to an en-
richment of phosphorylated species of beta-dystroglycan, more interestingly,
the appearance of slow migrating bands was suggestive of beta-dystroglycan
being phosphorylated on multiple amino acids (Figure 3.16).
By immunoblot analysis the most abundant species detected were the
43 kDa species. The others were absent or at undetectable levels indicat-
ing that this mutation could be regulating other PTM like phosphorylation-
ubiquitination (bands above the 43 kDa dystroglycan) or proteolysis (bands
below the 43 kDa form) (Figure 3.17). Interestingly, the treatment with CIP
of the parental protein and the mutant Y890F (Figure 3.18) confirmed the
observations obtained with calyculin and peroxovanadate. A detailed map of
amino acids subject to phosphorylation on dystroglycan will be important to
determine the role of these amino acids in cellular processes such as the cell
cycle and protein interactions.
In spite of the changes attributed to phosphorylation, there are still some
questions about if all the observed bands above 43 kDa correspond to phos-
phorylated dystroglycan or other PTM such as ubiquitination. Interestingly,
the treatment with MG132 and/or NEM led to the generation of bands of high
molecular weight, particularly above 130 kDa. Through the use of a highly
specific ubiquitin-binding resin with protective properties (M. D. Wilson et
al., 2012), it was possible to see the presence of some slow migrating bands,
suggestive of dystroglycan being subject to ubiquitination. Interestingly, the
antibodies Mandag2 and pYβDG were able to detect some bands that were
precipitated with MultiDsk indicating that dystroglycan phosphorylated or
non-phosphorylated in tyrosine 890 is subject to ubiquitination (Figure 3.21).
The introduction of the mutations Y890F and K806R seems to have (if
any) little effects in the ubiquitination of dystroglycan (Figure 3.23) although
further characterisation with MultiDsk will be required. These small changes
are not surprising since there are amino acids other than K806 that could be
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modified by ubiquitination. Also, this does not discard the idea of K806 being
ubiquitinated, but supports the fact that once restricted to ubiquitination
other lysines are ubiquitinated instead.
The existence of the nuclear ubiquitin-proteasome system and the function-
ality to degrade substrates such as the transcription factor MyoD is very well
established (Floyd, Trausch-Azar, Reinstein, Ciechanover, & Schwartz, 2001;
Rockel, Stuhlmann, & von Mikecz, 2005; von Mikecz, 2006). So, the nuclear
degradation of dystroglycan is a feasible hypothesis that has to be probed
by combining inhibitors of the nuclear export/import together with MG132
and MultiDsk or by using isolated nuclei/cytoplasm cellular extracts. This
could support the idea that, once translocated to the nucleus, dystroglycan
exerts its structural/regulatory function before being degraded by the nuclear
ubiquitin-proteasome system.
The inhibition of protein synthesis confirmed that the mutations Y890F and
K806R are not enough to stop the ubiquitination and hence, the degradation
of dystroglycan. This indicates that there are other underlying mechanisms
playing an important role in the degradation of dystroglycan. Further research
will be required to show if in addition to degradation, ubiquitinated dystro-
glycan has other roles in protein interactions or cell signalling regulation. It
will also be important to have a complete map of the ubiquitinated amino
acids in order to determine the role of these modifications in the stability of
dystroglycan with therapy purposes.
The multiple ubiquitination of dystroglycan could be part of the explana-
tion of its reduced levels in muscular dystrophies and cancer, and the reason
by which its levels are restored following the inhibition of proteasomal ac-
tivity (Acharyya et al., 2005; Assereto et al., 2006; Bonuccelli et al., 2003,
2007; Kumamoto et al., 2000). It will be important to determine if previously
identified members of the ubiquitin-proteasome system in muscle, or their cor-
responding homologues in prostate cancer, are responsible for the multiple
ubiquitination observed in this work (Acharyya et al., 2005; Bodine et al.,
2001; Matsumoto et al., 2008). Additionally, it will be interesting to deter-
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mine if other mechanisms such as proteolysis are dependent on ubiquitinated
dystroglycan for its removal from the plasma membrane.
3.7.6 Summary
The results of the research presented in this chapter show that:
1. Alpha- and beta-dystroglycan are present in the nucleus of LNCaP cells.
2. The insertion of tags in the C-terminal of beta-dystroglycan affects the
phosphorylation of its Y890.
3. Beta-dystroglycan may be subject to oligomerization.
4. Beta-dystroglycan is multiply phosphorylated.
5. Beta-dystroglycan is multiply ubiquitinated.
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Regulated intramembrane proteolysis of
beta-dystroglycan
4.1 Introduction
Dystroglycan is a member of the Dystrophin Associated Protein Complex
(DAPC) (Ervasti & Campbell, 1991). It is a glycoprotein that mediates inter-
actions between cytoskeletal proteins and the extracellular matrix through
its alpha and beta subunits. These subunits are generated after a post-
translational cleavage of a 97 kDa precursor peptide derived from a 5.8 kb
mRNA transcript. The 56 kDa core alpha-dystroglycan polypeptide is sub-
ject to a high degree of O- and N-linked glycosylation, which is very variable
in different tissues, rendering a mature protein with a molecular weight up to
160 kDa. On the other hand, the transmembrane beta subunit of dystroglycan
has a more constant molecular mass of 43 kDa, and contrary to its counter-
part alpha, it is glycosylated to a much lesser extent, although it is subject to
other post-translational modifications as described in chapter 3 (Ibraghimov-
Beskrovnaya et al., 1992).
The high degree of glycosylation on alpha-dystroglycan is important for its
interaction with components of the basal lamina (Ervasti & Campbell, 1993;
Michele et al., 2002; Saito et al., 2005) and is believed to confer protection
against proteolytic activities of extracellular matrix proteases (Singh et al.,
2004), the alteration of which could lead to an uncontrolled growth, as observed
in cancer (Martin et al., 2007).
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In muscular dystrophies and in a myriad of cancers (among them prostate
cancer), the cellular levels of beta-dystroglycan are frequently observed to be
reduced (Cross et al., 2008; Henry et al., 2001; Losasso et al., 2000; Muschler et
al., 2002; Parberry-Clark et al., 2011; Sgambato et al., 2007). The reduction of
beta-dystroglycan in these pathologies is due to proteolytic events. In this re-
gard, a 31 kDa species separate from the 43 kDa full-length beta-dystroglycan
has been frequently described in both muscular dystrophies (Matsumura et
al., 2005) and cancer (Jing et al., 2004). This 31 kDa fragment is thought to
comprise the transmembrane and cytoplasmic fragments of beta-dystroglycan
(Losasso et al., 2000; Yamada et al., 2001), and is generated by the prote-
olytic action of matrix metalloproteases-2 and -9 (MMP-2 and MMP-9) in
the extracellular environment (Yamada et al., 2001; Zhong et al., 2006). This
cleavage is thought to be prevented by the glycosylation of alpha-dystroglycan,
and so enzymes that participate in the glycosylation process can be linked to
the degree of proteolysis. For example, in prostate cancer, the reduction in
the expression of LARGE2 could cause hypo-glycosylated alpha-dystroglycan,
leading to increased proteolysis of beta-dystroglycan, and the generation of
the 31 kDa fragment (Esser et al., 2013).
Work performed in the Winder lab has demonstrated the presence of an
additional cleavage product of beta-dystroglycan of approximately 26 kDa that
was generated when myoblasts cells were exposed to the PKC activator, PDBu
(Thompson, 2007). The same band was observed in studies of different human
carcinomas, including prostate cancer(Cross et al., 2008; Mathew et al., 2013;
Parberry-Clark et al., 2011). This lead us to hypothesize that MMPs have the
ability to cleave beta-dystroglycan on its extracellular domain, but generate a
fragment that is still anchored to the plasma membrane. This transmembrane
fragment (TM), when exposed to a second cleavage by an unknown protease,
releases a 26 kDa fragment to the cytoplasm to exert unknown cellular func-
tions.
Beta-dystroglycan is a type I protein embedded in the hydrophobic environ-
ment of the plasma and nuclear membranes, and these characteristics resem-
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ble other type I transmembrane proteins subject to regulated intramembrane
proteolysis (RIP). RIP is mediated by intracellular proteases, and for type
I membrane proteins like beta-dystroglycan, such as EpCAM, Notch, APP,
Neogenin, CD44, and others (De Strooper et al., 1998, 1999; Goldschneider,
Rama, Guix, & Mehlen, 2008; Lal & Caplan, 2011; H. J. Lee et al., 2002;
Maetzel et al., 2009), gamma-secretase is the responsible protease. Hence, one
could hypothesize that this enzyme also regulates RIP of beta-dystroglycan.
In this chapter the mechanisms triggering the cleavage of beta-dystroglycan
and leading to the generation of the 26 kDa cytoplasmic fragment will be in-
vestigated. Also, some mechanisms leading to the nuclear translocation of
beta-dystroglycan will be described. Additionally, an insight into the mecha-
nisms regulating the turnover of beta-dystroglycan will be assessed. All of this
is also in support of the hypothesis that, once beta-dystroglycan has performed
its structural/signalling processes on the plasma and nuclear membranes, it is
prone to RIP by gamma-secretase and then subjected to degradation by the
nuclear proteasome system (Figure 4.1).
4.2 Triggering factors
The proteolysis of plasma membrane proteins can have several underlying ef-
fects, such as the activation of dormant domains within a protein. These prote-
olytic events can also generate cytoplasmic domains that exert nuclear regula-
tory effects, as is the case of Notch, EpCAM, Neogenin and others (De Strooper
et al., 1998, 1999; Goldschneider et al., 2008; Lal & Caplan, 2011; H. J. Lee
et al., 2002; Maetzel et al., 2009). Stimulation with phorbol esters and in
vitro culturing of cells at a high density are two experimental techniques used
to trigger and study these regulatory events mediated by cleaved cytoplasmic
domains (Goldschneider et al., 2008; Lal & Caplan, 2011).
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Figure 4.1: Beta-dystroglycan is subject to different proteolytic events. Beta-
dystroglycan has been observed to be reduced in different pathologies includ-
ing muscular dystrophies and cancer. The current hypothesis points towards
proteolytic events mediated by proteases in the extracellular and intracellu-
lar environments capable of generating a 31 kDa transmembrane fragment.
However, the processes governing the generation of an additional 26 kDa cy-
toplasmic fragment and its biological relevance remain still to be investigated.
4.2.1 PDBu stimulates the proteolysis of beta-dystroglycan
Phorbol esters, such as phorbol-12-myristate-13-acetate (PMA) and phorbol-
12,13-dibutyrate (PDBu), are potent activators of the PKC pathway. In cel-
lular models, such as the human umbilical vein endothelial cells (HUVECs),
activated PKC stimulates Src, which in turn activates Cdc42, inducing the for-
mation of podosome-like structures (Tatin, Varon, Ge´not, & Moreau, 2006).
A similar process is observed in myoblasts where, following PDBu stimulation,
Src is able to phosphorylate dystroglycan, which in turn binds the adaptor pro-
tein Tks5 leading to the formation of podosomes-like structures (Thompson
et al., 2008). Podosomes are actin-rich cellular structures that degrade the
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surrounding extracellular matrix components through the activation of matrix
metalloproteinases such as MMP-2 (Murphy & Courtneidge, 2011; Tatin et
al., 2006).
Given the reported interactions of PKC, Src, MMP-2 and dystroglycan, the
activation of MMP-2 by PKC, and their recruitment to podosome-like struc-
tures upon PDBu stimulation, it was therefore decided to investigate the ef-
fects of PDBu in the proteolysis of beta-dystroglycan in LNCaP cells. Western
blot analysis of phosphorylated beta-dystroglycan showed an increase in the
amount of levels of phosphorylated cytoplasmic fragment (black arrowhead)
compared with the full-length protein (arrow) in cells exposed to PDBu treat-
ment. However, the levels of transmembrane fragment of beta-dystroglycan
did not appear to change over the course of the treatment (empty arrowhead)
(Figure 4.2). It is important to note that, cells were maintained at a low den-
sity for the PDBu experiments in order to differentiate the effects mediated by
PDBu from those mediated by a high cell confluency, as will be shown later.
PDBu has been shown to stimulate the formation of podosomes-like struc-
tures in myoblasts (Thompson et al., 2008) and in LNCaP cells (unpub-
lished Winder lab observations). To determine any possible changes pro-
duced by PDBu stimulation, including the potential nuclear translocation
of beta-dystroglycan, LNCaP cells transfected with the plasmid αβDgFlag
were treated with PBDu and then co-immunostained with pYβDG, Mandag2
and Flag antibodies. Interestingly, upon PDBu stimulation, there is a re-
localisation of beta-dystroglycan, both native and phosphorylated, to the peri-
nuclear area. Most of the signal was lost from the plasma membrane and cells
lost the classical fillopodial structures observed in cells over-expressing beta-
dystroglycan, and exhibited rounded and flat lamellipodia (Figure 4.3 and
4.4).
In order to have a better idea if the visual accumulation of beta-dystroglycan
observed around the nucleus represented increased levels in the nucleus, frac-
tionation of cells treated with PDBu or without PDBu was performed. Al-
though there was an evident increase in the amount of the 26 kDa cytoplas-
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Figure 4.2: PDBu stimulates the proteolysis of phospho-beta-dystroglycan.
(a) Wild type LNCaP cells seeded at a low confluency (40000 cells/cm2) were
grown for 24 hours. After the stated time, the medium was replaced with
medium supplemented with PDBu [2.5 µM] and further treated for different
times as shown above. Cells were collected with RIPA buffer and lysates
were subjected to immunoblot analysis with antibodies to p-beta-dystroglycan.
Beta-tubulin is shown as the loading control. There is a clear increase in the
amount of phosphorylated cytoplasmic fragment of beta-dystroglycan over the
time (black arrowhead). (b) The graph shows the ratio of the signal of the 26
kDa cytoplasmic fragment (black arrowhead) against the 43 kDa full-length
(arrow) beta-dystroglycan (means ± SEM, n=3, *p=<0.05).
mic fragment of beta-dystroglycan (CD) following PDBu stimulation in the
non-nuclear fraction, this increase was not observed in the nuclear fraction
(Figure 4.5).
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Overall, these results suggest that beta-dystroglycan is subject to prote-
olytic events downstream of PDBu stimulation with the consequent release of
a 26 kDa cytoplasmic fragment. These events decrease the amount of beta-
dystroglycan present at the plasma membrane and increase cytosolic, but not
nuclear, accumulation.
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Figure 4.5: PDBu stimulates the proteolysis of beta-dystroglycan but not its
nuclear translocation. LNCaP cells treated with PDBu [2.5 µM] for 2 hours
were fractionated in non-nuclear and nuclear fractions. Immunoblot analysis of
both fractions with antibodies anti-p-βDg and anti-βDg shows a clear increase
in the amount of the 26 kDa fragment in the non-nuclear compared to the
nuclear fraction. Membranes were reprobed with anti-Lamin A/C and anti-
αTubulin as controls of fraction and equal loading. The images shown are
representative images of three independent experiments.
4.2.2 Cellular density triggers the proteolysis and nu-
clear translocation of beta-dystroglycan
The partial loss of beta-dystroglycan from the basal and basolateral sides of
epithelial cells has been demonstrated in cases of high grade prostate cancer
(Mathew et al., 2013). Given the limitations of obtaining pure prostate tu-
mor tissue samples, a good in vitro assay to mimic tumour growth is growth
or culturing of cells at high densities. Through these assays, Mitchell and
colleagues were able to demonstrate the cell density-dependent proteolysis of
beta-dystroglycan (Mitchell et al., 2013).
In this regard, LNCaP cells were plated at different densities (20, 50, 80
and 110 x 106/cm2) representing the range from low to high cell density (Fig-
ure 4.6a) and then the total lysates were analysed by western blotting using
the antibodies Mandag2 and pYβDG. With successive increases in cell density
an increase in the amount of the cytoplasmic fragment of beta-dystroglycan
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(CD) was observed. Interestingly, the increase in the cellular density led to an
increase in the synthesis of full-length beta-dystroglycan (Full). Apparently,
non-phospho and phospho-beta-dystroglycan were subject to the same rate of
proteolytic events (Figure 4.6b).
After corroborating that cell density is a mechanism triggering the proteol-
ysis of beta-dystroglycan it was decided to investigate if changes in cell density
where linked to an alteration in the levels of proteolysed beta-dystroglycan in
the nucleus. LNCaP cells under the same conditions as those described above
(see Figure 4.6) were subjected to cell fractionation. Surprisingly, through cell
fractionation it was possible to differentiate mechanisms regulating the fate
of beta-dystroglycan. First, increases in the cell density led to an increase in
the proteolysis of beta-dystroglycan observed by the reduction of full-length
protein (FULL) and an increase of the 26 kDa fragment (CD) in the non-
nuclear fraction. Second, increasing the cellular density led to an increase in
the amount of full (FULL) and cytoplasmic (CD) forms of beta-dystroglycan
in the nucleus (Figure 4.7).
Together these results provide important insights into the proteolysis of
beta-dystroglycan: upon PDBu stimulation and in high cell density conditions,
beta-dystroglycan is cleaved generating a 26 kDa fragment. Both, the full-
length and cytoplasmic forms of beta-dystroglycan are translocated to the
nucleus when cells reach a high cell density, but not upon PDBu stimulation,
suggesting an overlap of both mechanisms in proteolysis but not in nuclear
transport. The next section, therefore, reports on the proteases involved in the
cleavage of beta-dystroglycan that generates the 26 kDa cytoplasmic fragment.
4.3 Dystroglycan-cleaving proteases
Beta-dystroglycan is a type I transmembrane protein. From previous reports it
is known that matrix-metalloproteases are able to exert a proteolytic cleavage
on the extracellular domain of beta-dystroglycan (Yamada et al., 2001). This
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Figure 4.6: Cell density dependent proteolysis of beta-dystroglycan. (a)
LNCaP cells were seeded at different densities (20, 50, 80, 111 x 106 cells/cm2
representing the ranges from low to high cell density) (bright field microscopy,
objective 10X, scale bar = 100 µm) and lysed after 48 hours growth. (b)
Lysates were immunoblotted with antibodies anti β-dystroglycan (Mandag2)
and anti p-β-dystroglycan (pYβDG) antibodies. The increase in the cell den-
sity leads to an increase in the proteolysis of beta-dystroglycan. Alpha-tubulin
is shown as the loading control.
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Figure 4.7: Full-length and cd-βDg are translocated to the nucleus in a cell
density dependent manner. LNCaP cells were seeded as in Figure 4.6. After
48 hours, cells were collected for cell fractionation. Non-nuclear and nuclear
fractions were incubated with primary antibodies Mandag2 and pYβDG. Rep-
resentative images of three independent experiments show the nuclear accu-
mulation of the 43 kDa and 26 kDa forms of non-phospho- and phospho-beta-
dystroglycan. Fibrillarin and alpha-tubulin are shown as the loading controls.
cleavage generates a 31 kDa fragment of beta-dystroglycan that is still an-
chored to the plasma membrane. So, there may be other proteases responsible
for additional cleavages and generation of the 26 kDa cytoplasmic fragment.
The plasma membrane is a hydrophobic environment wherein most cellular
enzymes have a restricted function, because of their main requirement for wa-
ter. Of the proteases known to exert proteolytic functions in hydrophobic
environments, gamma-secretase is the best candidate enzyme for the cleavage
of beta-dystroglycan and the generation of the cytoplasmic fragment.
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4.3.1 Gamma-secretase and furin
It was observed previously that at high LNCaP cell density the amount of the
26 kDa fragment of beta-dystroglycan increased. To replicate this, LNCaP
cells were plated at a high confluency. Following growth for a further 24
hours, cells were treated with DAPT (N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-
S-phenylglycine t-Butyl Ester), which has been shown to be an inhibitor of
gamma-secretase (Dovey et al., 2001). Cells that were treated with different
concentrations of DAPT (although not significant) showed a tendency to re-
duction in the ratio of cytoplasmic fragment to full-length beta-dystroglycan
compared with the control, however this reduction was not significant. Al-
though this was expected to be partnered with an increase in the levels of
the transmembrane fragment of beta-dystroglycan, this did not happen (Fig-
ure 4.8). It could be that, if increased, the transmembrane fragment is not
detected because it is subjected to a rapid turnover by mechanisms such as
the proteasomal activity, as will be shown later.
From experiments involving cell fractionation under high cell density con-
ditions, a large amount of cleaved beta-dystroglycan was observed and also
an increase in the amount of full and cytoplasmic forms of beta-dystroglycan
within the nucleus (Figure 4.7). To determine if the same effects observed in
whole cell lysates of cells treated with DAPT were also observed in nuclear
beta-dystroglycan it was decided to fractionate cells under DAPT treatment
and compare non-nuclear and nuclear beta-dystroglycan with untreated con-
trols. This time the reduction in the amount of the cytoplasmic fragment
(CD) was not very evident, however, an increase in the amount of the trans-
membrane (TM) fragment of beta-dystroglycan in cells under pharmacological
treatment in total cell lysates was observed (Figure 4.9). Although faint, the
same effect was observed in non-nuclear and nuclear fractions. The increase
in the amount of the transmembrane fragment of beta-dystroglycan was ac-
companied by an increase in the amount of the full-length form (FULL) in the
nucleus (Figure 4.9).
Beta-dystroglycan harbours a nuclear localisation signal immediately down-
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Figure 4.8: The generation of the 26 kDa fragment of beta-dystroglycan is
gamma-secretase dependent. (a) LNCaP WT were grown for 24 hours before
being treated with different concentrations of DAPT or DMSO (control) for
further 24 hours. Cells were washed with PBS and then lysed with RIPA buffer.
Lysates were immunoblotted with anti-p-βDg and anti-βDg antibodies. The
increase in the concentration of DAPT leads to a reduction in the amount
of the cytoplasmic fragment of beta-dystroglycan. Alpha-tubulin is shown as
the loading control. (b) The graphs show the normalization of the 26 kDa
fragment to the full-length 43 kDa beta-dystroglycan (means ± SEM, n=3).
stream of the transmembrane domain (see Figure 3.6b). This domain is a motif
rich in basic R and K amino acids. An in-depth analysis of this motif using the
Eukaryotic Linear Motif resource (http://elm.eu.org), highlighted its sus-
ceptibility to further proteolytic events mediated by furin. In order to exclude
the possibility of furin cleaving beta-dystroglycan, LNCaP cells were treated
with increasing concentrations of the peptidyl chloromethylketone, furin in-
hibitor I. Increasing concentrations of the inhibitor reduced the level of the
26 kDa fragment of beta-dystroglycan (Figure 4.10). Although there were re-
duced levels of the cytoplasmic fragment of beta-dystroglycan as a consequence
of the treatment with furin inhibitor I, additional experiments are required to
further show the role of furin in the cleavage of dystroglycan downstream its
transmembrane domain.
In summary, the experiments shown in this section provide evidence of
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Figure 4.9: Gamma-secretase has a potential role in the proteolysis of nuclear
beta-dystroglycan. LNCaP cells treated under the same conditions as for whole
cell lysates were collected for cell fractionation. Immunoblot analysis with anti-
p-βDg and anti-βDg of total lysates, non-nuclear and nuclear fractions show an
increase in the amount of the transmembrane fragment of beta-dystroglycan in
the cells treated. Membranes were stripped and reprobed with anti-GAPDH
and anti-Lamin A/C antibodies to show the loading controls for the non-
nuclear and nuclear fractions respectively.
gamma-secretase and furin as the enzymes involved in the generation of the
cytoplasmic fragment of beta-dystroglycan. Regulated intramembrane proteol-
ysis is a process that usually involves the generation of a cytoplasmic fragment
that is then translocated to the nucleus to exert regulatory functions. The
next section will therefore examine some of the cellular processes regulating
the fate of the cytoplasmic fragment of beta-dystroglycan.
4.4 Nuclear translocation of the cytoplasmic
fragment of beta-dystroglycan
4.4.1 The cdβDgFlag is degraded by the proteasome
From DAPT treatment experiments (Figure 4.8) a reduction in the levels of
the cytoplasmic fragment of beta-dystroglycan was observed, but there were
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Figure 4.10: Potential role of furin in the cleavage of beta-dystroglycan. (a)
LNCaP cells grown for 24 hours and then treated with Furin inhibitor I at
different concentrations. After 24 hours post-treatment, cells were lysed with
RIPA buffer and immunoblotted with antibodies anti-βDg and anti-p-βDg.
There is a reduction in the amount of the cytoplasmic fragment of beta-
dystroglycan upon the increase in the amount of furin inhibitor. Alpha-tubulin
is shown as the loading control. (b) The graphs show the normalization of the
26 kDa fragment against the 43 kDa form of phospho- and non-phospho-beta-
dystroglycan (means ± SEM, n=3, *p=<0.05).
not any apparent changes in the levels of the transmembrane fragment. This
was suggestive of other mechanisms involved in the rapid turnover of these
small fragments. From experiments with multiDsk it was observed that beta-
dystroglycan is subject to multiple ubiquitination events (see Figure 3.21),
indicating a possible involvement of the ubiquitin-proteasomal system.
Inhibition of proteasomal activity with MG132 allowed a great recovery of
the transmembrane (TM) and cytoplasmic fragment (CD) of beta-dystroglycan
compared with control treatments. Interestingly, the band usually observed be-
tween 130 and 250 kDa (HDG) was not detected on cells treated with MG132.
The loss was more prominent in immunoblots for non-phosphorylated beta-
dystroglycan compared to its phosphorylated counterpart (Figure 4.11).
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This leads to the conclusion that, once beta-dystroglycan is subject to pro-
teolytic events mediated by gamma-secretase and furin, both the transmem-
brane and cytoplasmic fragments are rapidly degraded by the proteasome.
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Figure 4.11: Beta-dystroglycan is degraded by the proteasome. After 24 hours
growth, LNCaP cells were further treated with MG132 [15 µM] or DMSO (con-
trol) for 15, 18 and 21 hours. Cells were collected with RIPA buffer and im-
munoblotted with anti-βDg and anti-p-βDg antibodies. Treatment of LNCaP
cells with MG132 leads to a great recovery of the 31 and 26 kDa forms of
beta-dystroglycan compared with the control. The experiment was also per-
formed using different concentrations of MG132 (10, 20 and 30 µM) for 24
hours with the same effect observed with both antibodies (data not shown).
Alpha-tubulin is shown as the loading control.
4.4.2 The cdβDgFlag is translocated to the nucleus
If beta-dystroglycan is frequently reduced in cases of muscular dystrophies and
cancer then it means that the rate of proteolysis is very high, hence the amount
of the cytoplasmic fragment of beta-dystroglycan should be increased. In order
to have a better idea about some of the cellular events involved in this situa-
tion, it was decided to take advantage of the plasmid expressing recombinant
αβDgFlag and perform some modifications in order to over-express the amino
acids encoding the cytoplasmic portion of beta-dystroglycan only (cdβDgFlag)
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(Figure 4.12). Besides the Flag tag, it was decided not to introduce any other
tags in order to mimic similar conditions to those of the endogenous cleaved
cytoplasmic fragment.
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Figure 4.12: Generation of the plasmid pcDNA3.1(+)-cd4βDgFlag. In the
schematic is shown the coding sequence of the cytoplasmic fragment of mβDg
that was amplified by PCR from the plasmid pcDNA3.1(+)-αβDgFlag. The
forward primer was designed to introduce the starting codon methionine
(black) in the 5’ end before the codon of Y773 that marks the start of the cyto-
plasmic fragment of beta-dystroglycan (see material and methods). Following
the characterisation by sequencing, the plasmid was purified and transfected
in LNCaP cells.
The transfection of LNCaP cells with the plasmid encoding cdβDgFlag
followed by co-immunostaining with Mandag2, pyβDG and Flag antibod-
ies showed a clear co-localisation between phospho and non-phospho beta-
dystroglycan with Flag-tagged beta-dystroglycan. Importantly, the cytoplas-
mic fragment was distributed all along the cell but was more concentrated
in the nucleus (Figures 4.13a and 4.14a). Additionally, and although it was
not quantitatively determined, it was observed that the overexpression of the
cytoplasmic fragment of beta-dystroglycan had profound effects in different
cellular processes such as (Figures 4.13b and 4.14b):
1. Nucleoli were reduced in number and had an apparent increase in size
(may be due to a process of nucleolar fusion)
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2. There was an increased number of multinucleated cells.
3. There was an increased number of vesicle-like structures throughout the
cytoplasm.
4. Cells were increased in size.
5. There was an increased number of apoptotic-like cells.
All these observations were gathered by comparing the phenotype of trans-
fected cells with their neighbour untransfected counterparts. However more
in-depth analysis will be required to further show the implication of the cy-
toplasmic fragment of beta-dystroglycan in each one of the cellular processes
described above.
During the process of characterisation of this recombinant cytoplasmic frag-
ment it was not possible to see its expression by western blotting supporting
the idea of a rapid degradation by the proteasome. However, inhibition of
proteasomal activity, followed by immunoprecipitation with Flag M2 resin, al-
lowed a substantial recovery of this fragment (Figure 4.15). The detection of
a single band is suggestive of a mono-ubiquitinated cytoplasmic fragment and
has to be confirmed by other in-depth analysis such as mass spectrometry.
As stated before, full-length beta-dystroglycan co-localized with ubiquitin.
In this regard, it was decided to get a better idea about the ubiquitinated
status of cdβDgFlag. The immunostaining of cells expressing this fragment
revealed its co-localisation with ubiquitin and most importantly, most of the
co-localisation was concentrated in the nucleus (Figure 4.16).
The series of experiments shown in this section suggest that the cytoplasmic
fragment of beta-dystroglycan is ubiquitinated, translocated to the nucleus and
rapidly degraded by the proteasome. The over-expression of the cytoplasmic
fragment apparently affected some stages of cell division (abnormal nuclear
separation), increased the number of vesicle-like structures in the cell and the
number of apoptotic cells (author’s own observation) which will require further
in-depth analyses to fully understand.
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Figure 4.13: The cdβDgFlag has a preferential nuclear localisation. Trans-
fected LNCaP cells with the plasmid encoding the cytoplasmic fragment of
βDgFlag were co-immunostained with anti-βDg (green) and anti-rFlag (red)
antibodies. A middle stack section of deconvolved confocal microscopy images
shows that a high amount of the exogenous expressed cytoplasmic fragment of
βDg is concentrated in the nucleus in addition to some cellular abnormalities
(CD’). DAPI is used to counterstain the nucleus. Scale bar = 10 µM.
135
CHAPTER 4. REGULATED INTRAMEMBRANE PROTEOLYSIS OF
BETA-DYSTROGLYCAN
Flag M2 p-β-dystroglycan 
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Figure 4.14: The cdβDgFlag has a preferential nuclear localisation. Trans-
fected LNCaP cells with the plasmid encoding the cytoplasmic fragment of
βDgFlag were co-immunostained with anti-p-βDg (red) and anti-Flag M2
(green) antibodies. A middle stack section of deconvolved confocal microscopy
images shows that a high amount of the exogenous expressed cytoplasmic
fragment of βDg is concentrated in the nucleus in addition to some cellular
abnormalities (CD’). DAPI is used to counterstain the nucleus. Scale bar =
10 µM.
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Figure 4.15: The cdβDgFlag is degraded by the proteasome. LNCaP cells
were transfected with the cytoplasmic fragment of βDgFlag. 24 hours post-
transfection, cells were treated with the proteasomal inhibitor MG132 followed
by further immunoprecipitation with the Flag M2 resin. The signal specific
to the 26 kDa form of βDg was only detected in cells treated with MG132
followed by immunoprecipitation. Lysates of cells transfected with full-length
βDg were included as a reference of the electrophoretic mobility of the exoge-
nous cdβDgFlag. WT lysates helped to discriminate any possible non speci-
ficity of the antibody.
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4.4.3 Cleavage site for the generation of cdβDgFlag
The cleavage of beta-dystroglycan, followed by its degradation by the protea-
some is a potential pathway for the turnover of this type I transmembrane
protein. Importantly, in some muscular dystrophies and forms of cancer these
processes are up-regulated. This could be due to an abnormal activity of the
proteasome, an increased activity of gamma-secretase and furin, or due to other
additional factors, such as glycosylation or the abnormal activity of matrix-
metalloproteases. A clear consequence of these abnormal activities could be
the increased cleavage of plasma membrane proteins important for the restric-
tion of the abnormal growth of cancerous cells. Additionally, although the
cleavage site by MMP-9 has been suggested, there is no knowledge of the func-
tional consequences of the secreted extracellular domains of beta-dystroglycan
(Bozzi, Inzitari, et al., 2009).
To distinguish naturally generated cytoplasmic fragments from that origi-
nated by trypsin, lysates were subjected to dimethyl labelling. By using this
protocol, it is possible to add methyl groups to the free N-terminal sides of
proteins by the chemical action of formaldehyde and cyanoborohydride (Shen,
Hsu, & Chen, 2007). Therefore, an immunoprecipitation assay was performed
using Flag M2 resin from lysates of LNCaP cells transiently transfected with
the plasmid αβDgFlag. Immunoprecipitated material with the Flag M2 resin
was separated by SDS-PAGE and then stained with brilliant blue G colloidal
dye (Figure 4.17a). Bands corresponding to cytoplasmic fragment and full-
length beta-dystroglycan were excised and di-methyl labelled with formalde-
hyde/cyanoborohydrade or left without any chemical labelling (Figure 4.17b).
Following this, the peptides were digested with trypsin and then analysed by
tandem mass spectrometry. From this attempt there was a good coverage
of beta-dystroglycan (78%), but it was not possible to identify both the se-
quence corresponding to the extracellular or transmembrane cleavage products
of full-length beta-dystroglycan (Figures 4.17c and 4.18).
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Figure 4.18: Analysis of the cleavage site of beta-dystroglycan. Procedure as
in Figure 4.17. Shown are the peptides identified by mass spectrometry in the
eluate and bead fractions of the gel slices corresponding to the full-length and
cytoplasmic fragment of beta-dystroglycan subject to chemical labelling or left
without any treatment.
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4.5 The relationship Notch-dystroglycan
During the course of our cell density experiments an apparent increase in the
synthesis of beta-dystroglycan was observed. The higher the cell density, the
greater the protein levels of full-length beta-dystroglycan (see Figure 4.6).
This indicated that cell density could be stimulating the synthesis (or reduc-
ing degradation) of beta-dystroglycan through unknown signalling pathways.
First, it could be that beta-dystroglycan stimulates its own synthesis through
an auto-regulatory mechanism: subsequent increases in the proteolysis of beta-
dystroglycan then increases levels of cytoplasmic fragment, its nuclear translo-
cation and its association with nuclear co-factors in order to stimulate its own
synthesis. During the course of this project it was observed (in some ex-
periments) that the mutant alpha/beta-dystroglycan-Flag-Y890F, which had
reduced levels of the 26 kDa cytoplasmic fragment, had also a reduced ex-
pression of full-length beta-dystroglycan compared with wild type alpha/beta-
dystroglycan-Flag. This partly supports the hypothesis of beta-dystroglycan
auto-regulation, although further, in-depth analysis will be required to show
that the cytoplasmic fragment is involved in this auto-regulatory process, as
will be discussed later in this chapter.
Second, the increased number of cell contacts generated during high cel-
lular density could be increasing the activation and nuclear translocation of
unknown proteins which in turn stimulate the synthesis of beta-dystroglycan.
Notch is a protein that is subject to RIP and translocated to the nucleus upon
cell-cell contact (Kopan, 2012). In this regard, a previous study has shown the
interaction of the DAP complex in Drosophila with genes involved in Notch
signalling pathway (Kucherenko et al., 2008). More recently, Sirour and col-
leagues demonstrated that, during skin morphogenesis in Xenopus laevis, the
transcription of dystroglycan is stimulated upon Notch activation (Sirour et al.,
2011). Together, these data support the hypothesis of beta-dystroglycan being
subject to transcriptional regulation upon Notch activation during increased
cell density.
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In order to test this second hypothesis, LNCaP cells were subjected to
treatment with the Notch signalling pathway activator resveratrol (Pinchot
et al., 2011). The treatment with resveratrol revealed several interesting ob-
servations. First, the growth of LNCaP cells was restricted over a period of
72 and 96 hours. Second, cells left untreated confirmed previous findings ob-
served in cell density experiments: that increases in cell confluency led to an
up-regulation in beta-dystroglycan protein synthesis. Third, the up-regulation
of beta-dystroglycan protein synthesis, was observed at very reduced levels in
cells exposed to resveratrol although it is worth noting that even with the very
low number of cells at 72 and 96 hours treatment (Figures 4.19a and 4.20a),
the levels of full-length and 26 kDa cytoplasmic fragment of beta-dystroglycan
had a tendency to increase (Figures 4.19b and 4.20b) and (Figures 4.19c and
4.20c).
Whether dystroglycan protein synthesis is up-regulated as a consequence
of its own auto-regulation, or Notch activation, is something that clearly needs
further research. It will necessary to link the effects of the over-expression of
beta-dystroglycan observed in high cell density experiments, with physiological
and disease processes, such as in prostate cancer.
4.6 Discussion
4.6.1 Regulated intramembrane proteolysis of beta-dystroglycan
Regulated intramembrane proteolysis is a mechanism that allows the activation
of specific domains within a protein. The mechanism starts with the shedding
of the extracellular domain of transmembrane proteins stimulated by different
factors such as cell density, phorbol esters, calcium, ligand binding and other
unknown stimulants (Jung et al., 2003; Kopan & Ilagan, 2004; Lal & Caplan,
2011), followed by a second cleavage generated by gamma-secretase in the
transmembrane domain.
A small 26 kDa cytoplasmic fragment of beta-dystroglycan in addition to
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Figure 4.19: Investigating the role of the Notch pathway in the regulation
of the synthesis of beta-dystroglycan. (a) LNCaP cells were seeded at a low
density and growth for 24 hours before being treated with Resveratrol [100
µM] or the corresponding amount of DMSO for 0, 24, 48 and 72 hours. At
every time point, bright-field microscopy images were taken to show the rate of
growth of the cells treated against the cells control. (b) Cells collected at the
stated times were lysed and the lysates were immunoblotted with antibodies
anti-βDg and anti-p-βDg. (c) The band intensity of controls and treatments
was quantified and normalized against the loading control GAPDH (means ±
SEM, n = 3). The treatment with resveratrol seems to keep the levels of βDg
throughout the 72 hours treatment regardless of the low number of cells as
shown in the bright-field microscopy images.
the 43 and 31 kDa forms observed in this and other studies (Mathew et al.,
2013; Mitchell et al., 2013; Thompson, 2007), suggests that beta-dystroglycan
is subject to a second proteolytic cleavage by gamma-secretase. From the
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Figure 4.20: Investigating the role of the Notch pathway in the regulation of
the proteolysis of beta-dystroglycan. Experiments were performed as in Figure
4.19. In (c), The band intensity of 43 kDa full (FULL), 31 kDa transmembrane
(TM), 26 kDa cytoplasmic (CD) and additional 38 kDa (38 kDa) band were
quantified and the percentages of each band from two independent experiments
are shown. GAPDH is shown as the loading control. The treatment with
resveratrol seems to keep increased levels of FULL and CD of βDg throughout
the 96 hours treatment regardless of the low number of cells as shown in bright-
field microscopy images (scale bar = 100 µm, objective = 10 X).
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mechanisms stimulating the proteolysis of plasma membrane proteins, there
is evidence that PDBu and cell density are triggering factors for the initial
shedding of beta-dystroglycan to the extracellular environment.
The stimulation of LNCaP cells with the PKC activator PDBu, led to an
increase in the amount of the 26 kDa cytoplasmic fragment in a time dependent
manner, indicating that not only in myoblasts (Thompson, 2007) but also in
LNCaP cells, the proteolysis of beta-dystroglycan is stimulated by phorbol
esters such as PDBu.
Following phorbol ester stimulation, the cleaved cytoplasmic domains of
the p75 neurotrophin receptor and megalin are translocated to the nucleus to
perform transcriptional regulatory activities (Jung et al., 2003; Y. Li, Cong,
& Biemesderfer, 2008). Stimulation with PDBu increased the levels of the
cytoplasmic fragment of beta-dystroglycan in non-nuclear extracts, but not in
nuclear extracts as was observed with p75 neurotrophin receptor and megalin.
PDBu stimulation produced some phenotypic cellular changes in LNCaP cells
such as the formation of ruffles like structures and the re-localisation of beta-
dystroglycan to an area surrounding the nucleus. This indicates that, although
beta-dystroglycan is prone to proteolysis stimulated by PDBu, the transloca-
tion of its cytoplasmic fragment is not triggered by PDBu stimulation.
A previous report has shown that the nuclear translocation of beta-dystroglycan
is mediated by the activated F-actin binding protein ezrin in C2C12 muscle
derived cells (Va´squez-Limeta et al., 2014). As ezrin is a downstream target of
PKC after stimulation with phorbol esters (Ng et al., 2001), it was expected
to see increased levels of beta-dystroglycan (either full-length or cytoplasmic
fragment) in the nucleus, however this did not happen. As the cytoplasmic
fragment of beta-dystroglycan is a sequence that harbours multiple motifs in
charge of regulating its interaction with a multitude of proteins (Moore &
Winder, 2010), then it is not surprising that the stimulation with PDBu may
be promoting its cytoplasmic retention and not its nuclear translocation as
might be predicted. In this regard it has been shown that after phorbol es-
ter stimulation, the generated cytoplasmic domain of the ErbB4 receptor is
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translocated to the nucleus alone or associated with the transcriptional coacti-
vator YAP, but retained in the cytoplasm as a consequence of its interactions
with the tumour suppressor WWOX, associations mainly dictated by the in-
teraction of WW domains with SH2 motifs (Aqeilan et al., 2005). Thus, it
may be that the generated cytoplasmic fragment of beta-dystroglycan inter-
acts with proteins containing WW domains through its activated SH2 domains
or vice versa, blocking the nuclear translocation regulated by activated ezrin.
Further research will be required to determine the protein(s) and cellular con-
ditions modulating the nuclear transport of beta-dystroglycan (or its generated
transmembrane and cytoplasmic fragments).
The stimulation with PDBu leads to the shedding of the extracellular do-
main of beta-dystroglycan leaving a truncated form containing the transmem-
brane domain (Bozzi, Inzitari, et al., 2009; Yamada et al., 2001). It is possible
that this transmembrane fragment is anchored to the nuclear membrane, ex-
plaining the strong beta-dystroglycan signal observed around the nucleus. It
may be that after the stimulation with PDBu, cleaved beta-dystroglycan is re-
tained at the nuclear envelope in a similar way as the Heparin-binding EGF-like
growth factor (HB-EGF) (Hieda et al., 2008) where it exerts its nuclear activ-
ities. The detection of full-length and cytoplasmic forms of beta-dystroglycan
in the nucleus suggests that if the transmembrane fragment is present in the
nucleus it may be in a transitional state, because of its rapid conversion to the
26 kDa cytoplasmic fragment.
So, if PDBu treatment did not result in an apparent increase in the amount
of full and cytoplasmic forms of beta-dystroglycan being translocated to the
nucleus, what could be another potential mechanism triggering this event? As
mentioned above, cell density is another factor that may be able to trigger
the proteolysis of plasma membrane proteins and the nuclear translocation
of the generated cytoplasmic domains. The growth of LNCaP cells at dif-
ferent densities permitted us to corroborate that beta-dystroglycan is subject
to proteolysis in a cell density dependent manner, confirming previous results
obtained by Mitchell and colleagues (Mitchell et al., 2013). From cell frac-
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tionation assays the nuclear translocation of full-length and cytoplasmic forms
of beta-dystroglycan were observed in a cell density dependent manner. One
unanticipated finding was the up-regulation of the synthesis of full-length beta-
dystroglycan with increasing cell density, a finding that will be discussed later
in this section.
From previous reports it is known that cell density could be a triggering
factor for the proteolysis and nuclear translocation of activated cytoplasmic
domains, as is the case of some protein tyrosine phosphatases (Anders et al.,
2006). However the same process can have opposite effects, as has been re-
ported for alpha- adducin (C. L. Chen, Lin, Lai, & Chen, 2011). Increasing
cell density leads to an increase in the number of cell-cell contacts suggest-
ing that these are the triggering factor for the cleavage of beta-dystroglycan.
However, how these proteolytic events on beta-dystroglycan and its nuclear
translocation regulate tumour growth, invasiveness and metastasis, is a ques-
tion that has to be addressed in order to ascribe a biological role to nuclear
beta-dystroglycan under these cellular events.
Different evidence provided by different labs (Cisneros, Muschler and Winder),
and cell fractionation experiments performed in this thesis, confirm the nuclear
localisation of beta-dystroglycan. In the course of finding an explanation to
the nuclear function of beta-dystroglycan the question arose as to whether it
provides a structural role to the nuclear lamina, due to an association with
components of the nuclear matrix (Fuentes-Mera et al., 2006; Villarreal-Silva
et al., 2010), or whether it performs a more dynamic role through the modu-
lation of transcriptional regulatory activities (Mathew et al., 2013; Oppizzi et
al., 2008; Sgambato & Brancaccio, 2005). The structural role can be supported
by the fact that beta-dystroglycan has a transmembrane domain and its re-
ported association with components of the nuclear lamina (Mart´ınez-Vieyra
et al., 2013). On the other hand, the localisation of beta-dystroglycan in the
nucleoplasm, detached from the nuclear membrane could be another plausible
option as has been observed for some cell surface transmembrane receptors
(reviewed in (Carpenter & Liao, 2009)).
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From experiments performed in normal and human prostate cancer tissues,
and in normal and prostate cancer derived cell lines (Mathew et al., 2013) in
addition to experiments performed in this thesis, it is clear that not only the
43 kDa full-length beta-dystroglycan is present in the nucleus as reported by
the Cisneros and Muschler labs (Fuentes-Mera et al., 2006; Oppizzi et al.,
2008), but also its 31 kDa transmembrane and 26 kDa cytoplasmic fragments.
The presence of these three species of beta-dystroglycan in the nucleus could
then provide an alternative explanation to the static-dynamic nuclear beta-
dystroglycan based on the following analysis.
Oppizzi and colleagues supported the idea of a dynamic 43 kDa beta-
dystroglycan that was not restricted to the nuclear envelope based on im-
munostaining and fluorescence recovery after bleaching (FRAP) experiments.
Although these techniques showed the mobility of beta-dystroglycan, they
were not sensitive enough to show if the species detected corresponded to its
full-length or cytoplasmic forms. Additionally, the biochemical method em-
ployed for cell fractionation did not allow them to discriminate if the detected
full-length beta-dystroglycan had a nuclear membrane or nucleoplasmic origin
(Oppizzi et al., 2008). Then, it may be that the 43 kDa beta-dystroglycan
species detected corresponded to the nuclear matrix associated form, whereas
the highly dynamic form corresponded to its 26 kDa cytoplasmic species.
If this is the case, are both the 43 and 26 kDa forms of beta-dystroglycan
translocated from the cytoplasm to the nucleus? or is full-length beta-dystroglycan
translocated from the cytoplasm to the nuclear envelope, and then further pro-
cessed to generate its 26 kDa species?
Treatment of LNCaP cells with a gamma-secretase inhibitor reduced the
levels of the 26 kDa cytoplasmic fragment of beta-dystroglycan in total lysates
indicating that the plasma membrane 43 kDa beta-dystroglycan is subject to
proteolysis mediated by gamma-secretase. Although the fractionation of cells
exposed to the same treatment conditions did not show a reduction in the
amount of the 26 kDa cytoplasmic fragment, it did show an increase in the
amount of the 31 kDa transmembrane fragment of beta-dystroglycan in non-
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nuclear and nuclear fractions. This is suggestive of plasma and nuclear mem-
brane anchored beta-dystroglycan being subject to RIP mediated by gamma-
secretase in order to generate a 26 kDa cytoplasmic fragment. The regulation
of beta-dystroglycan by proteolysis mediated by gamma-secretase is a mecha-
nism that is present in different cellular models as similar results obtained in
this thesis have been reported by mass spectrometry in other cellular models
such as HEK and HeLa cells (Hemming et al., 2008).
These findings can be summarised as the following hypothesis: nuclear
membrane anchored full-length beta-dystroglycan is subject to a first cleavage
on its extracellular domain mediated by MMP-9; the remaining transmem-
brane fragment is then cleaved by a second proteolytic event performed by
gamma-secretase, all this in a similar way to its homologue in the plasma
membrane.
As mentioned in the introduction to this chapter, RIP is a process that has
been demonstrated for transmembrane proteins found on the plasma mem-
brane, though there is not much evidence of the same process happening for
nuclear lamin anchored proteins. If nuclear beta-dystroglycan is subject to
RIP, the same elements (or homologues) found on the plasma membrane have
to be present in this environment. In this regard, although not direct evidence
was gathered in this project, the following elements can be provided in support
of the RIP of nuclear beta-dystroglycan:
1. LARGE2, the enzyme responsible for glycosylation of alpha-dystroglycan
is not expressed in LNCaP cells. This renders a hypoglycosylated nuclear
alpha-dystroglycan susceptible to the cleavage by MMPs (see section 3.5
for more details).
2. In various studies, it has been shown that MMPs, among them MMP-2
and -9, are not only present in the extracellular matrix environment and
at the plasma membrane, but also in the nucleus of different cells. Im-
portantly, the nuclear expression of active MMP-9 was correlated with its
expression during the S-phase of the cell cycle (Zimowska, Swierczynska,
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& Ciemerych, 2013). This could explain the mechanism by which full-
length nuclear beta-dystroglycan is being cleaved with the consequent
generation of its transmembrane fragment.
3. Presenilin, the core catalytic subunit of the gamma-secretase complex
was reported to be associated with components of the nuclear lamina
(J. Li, Xu, Zhou, Ma, & Potter, 1997). However, there has not been
any complementary reports indicating if this catalytic subunit is func-
tional and, more importantly, if the other components of the complex
are present in this nuclear environment.
4. In Arabidopsis it has been shown that the transcription factor NTM1 is
subject to RIP in the nuclear membrane mediated by calpains, support-
ing the possibility of the same process happening in mammalian cells
(Y. S. Kim et al., 2006).
In-depth research will be required to show that the proteolysis mediated by
gamma-secretase is performed in the nuclear boundaries. The employment of
strategies such as presenilin-deficient cells or site-directed mutagenesis will be
useful to determine the site(s) in where gamma-secretase performs its catalytic
activity. Subsequently it would be possible to determine the biological rele-
vance of reduced small cytoplasmic fragments of beta-dystroglycan in cancer
and muscular dystrophies.
In an attempt to determine the site where gamma-secretase performs the
transmembrane shedding of beta-dystroglycan, mass spectrometry analysis
and dimethyl labelling were employed. However, the approach was not success-
ful because the sequence corresponding to the transmembrane domain was not
recovered. The sequences retrieved from the mass spectrometer corresponded
to the amino-terminus of beta-dystroglycan and the other corresponded to
most of its carboxyl terminal half. Interestingly, the sequence reported by the
mass spectrometer started on the amino acid lysine 778 (K778), a sequence
predicted by in silico analysis as potential furin cleavage site. The inhibition
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of the proteolytic activity of furin showed moderate, but consistently reduced
levels of the cytoplasmic fragment of beta-dystroglycan.
Additionally, these results need to be interpreted with caution because the
stretch of basic amino acids corresponding to the nuclear localisation signal
of beta-dystroglycan is susceptible to proteolysis by trypsin, the enzyme used
to digest the peptides before mass spectrometry analysis. Also, an analysis
in either furin-null or furin-deficient cells will be required to show the specific
involvement of furin in the cleavage of beta-dystroglycan.
If gamma-secretase cleaves beta-dystroglycan in its transmembrane do-
main, how is this domain still susceptible to an extra-cleavage performed by
furin a few amino acids downstream of the remnant transmembrane domain?
The answer could be a cysteine amino acid located at the interphase between
the transmembrane domain of beta-dystroglycan and its nuclear localisation
sequence. Palmitoylated cysteines are frequently located in the cytoplasmic
side of regions next to transmembrane domains or located inside the hydropho-
bic environment of the plasma membrane, usually surrounded by hydrophobic
and basic amino acids of transmembrane proteins (Aicart-Ramos et al., 2011).
A cysteine 772 located within the cytoplasmic fragment of beta-dystroglycan
has these characteristics. Indeed, by mass spectrometry analysis it was shown
that beta-dystroglycan is subject to palmitoylation in rat embryonic cortical
neurons. However, it was not completely reported if the cysteine in the bound-
aries of the plasma membrane facing the cytosol is the one subject to this PTM
(Kang et al., 2008). Further research is necessary to determine if the cysteine
immediately below the transmembrane domain of beta-dystroglycan is subject
to palmitoylation and facilitates the putative cleavage by furin.
Although the experiments performed in this thesis support the proteolysis
of beta-dystroglycan mediated by gamma-secretase and the nuclear localisa-
tion of its full and cytoplasmic forms, why did the Cisneros and Muschler
groups not detect this small 26 kDa fragment in the nucleus and also, why
did they observe a great variability in the levels of full-length nuclear beta-
dystroglycan? The answer may be that, although the three species are present
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in the nucleus, the 31 kDa transmembrane and 26 kDa cytoplasmic fragments
are subject to a rapid turnover in the nucleus as has been reported for other cy-
toplasmic domains, such as those generated from Notch, EpCAM, Neogenin,
APP, among others (Cupers, Orlans, Craessaerts, Annaert, & De Strooper,
2001; Goldschneider et al., 2008; Maetzel et al., 2009).
The first clue was provided by treating LNCaP cells with MG132. Cells
in which the proteasomal activity was inhibited had a substantial recovery of
the transmembrane and cytoplasmic fragments of beta-dystroglycan indicating
that they are subject to a rapid turnover mediated by the proteasome.
To better understand the effects of the cytoplasmic fragment and its cellular
localisation, it was decided to transfect LNCaP cells with the DNA coding se-
quence corresponding to the cytoplasmic fragment of beta-dystroglycan. After
many attempts, this cytoplasmic fragment was only recovered when cells were
treated with the proteasome inhibitor MG132 followed by further immunopre-
cipitation. The signal corresponding to this small cytoplasmic fragment was
broadly distributed in the cell, but mainly localised to the nucleus. Additional
analyses are required to show if the signal detected in the nucleus corresponds
to the entire or the degraded cytoplasmic fragment of beta-dystroglycan. Im-
portantly, cells overexpressing this small 26 kDa cytoplasmic fragment pre-
sented different phenotypic changes compared with the non-transfected cells,
such as an increase in size of the nucleolus, defects in cellular division (nuclear
division), and a susceptibility to apoptosis. However, these results require of
an in-depth analysis to further show the broad implications of the cytoplasmic
fragment of beta-dystroglycan in different cellular processes.
From the the results gathered by the treatment with MG132 it can be
suggested that, after the proteolytic events mediated by MMPs and gamma-
secretase either on the plasma or nuclear membranes, the cytoplasmic fragment
of beta-dystroglycan is rapidly translocated to the nucleus to exert unknown
regulatory functions before being degraded by the nuclear proteasome. The
degradation of proteins by the nuclear proteasome system has been well estab-
lished (Rockel et al., 2005; von Mikecz, 2006) and has been demonstrated for
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transcription factors such as MyoD (Floyd et al., 2001). Then, it is tempting
to speculate that the nucleus is a cellular compartment for the degradation
of beta-dystroglycan by the ubiquitin proteasome system. However more evi-
dence will be required to further support this hypothesis or to show that beta-
dystroglycan is degraded in other cellular compartments. This will be very
important in order to support other therapies aided in restoring the members
of DAPC in diseases where the proteolytic activity of the ubiquitin-proteasome
system has been shown to be altered.
The proteolysis regulated by gamma-secretase and the degradation medi-
ated by the ubiquitin-proteasome system, could potentially explain the high
variability of non-nuclear and nuclear full-length beta dystroglycan observed
in tumour tissues (Jing et al., 2004; Sgambato et al., 2007). In these instances,
the abnormal function of MMPs and the proteasome, and the presence of a
hypo-glycosylated beta-dystroglycan could be the main factors modulating the
stability of this important transmembrane protein.
The cytoplasmic fragment of beta-dystroglycan performs most of its inter-
actions with cytoplasmic proteins. Hence, the susceptibility of the full-length
protein to frequent proteolytic events mediated by MMPs in cases of muscu-
lar dystrophies and cancer could be translated into high levels of the cyto-
plasmic fragment being secreted into the cytoplasm (or nucleoplasm), leading
to the disruption of ”normal” interactions, or to the activation/inhibition of
signalling pathways involving the cytoplasmic fragment of beta-dystroglycan.
Such a scenario has been described where overexpression of a myristoyl-tagged
CDβDg construct induced the formation of filopodia at the cell membrane
due to recruitment of RhoGEF (Batchelor et al., 2007). Detailed analyses are
required to further investigate the consequences of the over-expression of this
small fragment.
Cell density regulates not only the proteolysis and nuclear translocation of
full and cytoplasmic species of beta-dystroglycan in LNCaP cells, but also the
synthesis of full-length protein. It may be that the synthesis of dystroglycan
could be subject to cis- or trans-regulation. In a cis-regulation scenario, the
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high levels of proteolytic activity during invasion and metastasis of cancer-
ous cells would lead to increased levels of the cytoplasmic fragment of beta-
dystroglycan, which would then translocate to the nucleus to regulate its own
transcription, a phenomenon similar to that observed for the protein tyrosine
phosphatase µ (Gebbink et al., 1995).
The overexpression of beta-dystroglycan may help restrict cell growth through
contact inhibition, but in cancerous cells, such as LNCaP cells, this overex-
pression may be counterbalanced by high levels of MMP activity (Brehmer,
Biesterfeld, & Jakse, 2003), which in turn down-regulate the inhibitory activ-
ity of beta-dystroglycan. Further experiments involving overexpression of the
cytoplasmic fragment of beta-dystroglycan will be required to test this new
hypothesis.
With regard to trans-regulation, Notch has been shown to interact with
dystroglycan in a drosophila model (Kucherenko et al., 2008) and also to reg-
ulate the synthesis of dystroglycan during skin morphogenesis (Sirour et al.,
2011). Then the hypothesis of Notch playing a role in the synthesis of beta-
dystroglycan as a trans-regulator during cell density experiments could be a
reasonable idea. The treatment of LNCaP cells with resveratrol, led to a subtle
up-regulation in the expression of beta-dystroglycan in spite of the low number
of cells. This may be indicative of NOTCH regulating the transcription and
synthesis of beta-dystroglycan, as has been suggested by Sirour and colleagues
(Sirour et al., 2011). Further, in-depth analysis will be required to show that
cell density is a triggering factor stimulating the activation of Notch, which
in turn regulates the transcription and synthesis of beta-dystroglycan. In this
model, up-regulated beta-dystroglycan is modulated on the plasma membrane
by the proteolytic action of MMPs and gamma-secretase, leading to the gener-
ation of a cytoplasmic fragment that is capable of regulating other transcrip-
tional processes. Importantly, future experiments will need to differentiate
if the overexpression of beta-dystroglycan is due to a post-transcriptional or
post-translational regulation.
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4.6.2 Summary
Through the evidence provided in this chapter it can be concluded that:
1. PDBu and cell density are triggering factors for the generation of the 26
kDa cytoplasmic fragment of beta-dystroglycan.
2. The cytoplasmic fragment of beta-dystroglycan is translocated to the
nucleus in a cell density dependent manner.
3. Beta-dystroglycan is subject to proteolysis mediated by gamma-secretase
and furin.
4. Beta-dystroglycan is transported to the nucleus for its degradation through
the ubiquitin proteasome system after performing structural and dy-
namic nuclear roles.
5. The synthesis of beta-dystroglycan may be regulated by Notch signalling
in response to cell-cell contacts.
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Interactome of beta-dystroglycan
5.1 Introduction
The intricate network of proteins within a cell is indeed complex and exciting,
but the understanding of each one of these protein interactions is pivotal in or-
der to unravel the mechanisms that lead to disease. Cancer, the uncontrolled
growth of cells, is a clear example wherein most of the signalling pathways
are modified in favour of cell survival, invasion and metastasis, some of the
hallmarks of cancer (Hanahan & Weinberg, 2011). In this regard, by poten-
tiating cellular interactions with the extracellular matrix and restricting the
uncontrolled growth of cells, dystroglycan has been envisaged as a tumour
suppressor (Sgambato & Brancaccio, 2005). The role of dystroglycan seems to
not to be restricted to cellular interactions with the extracellular matrix, and
the following findings support this idea:
• Dystroglycan is ubiquitously expressed in different cellular compartments
like the plasma membrane, the cytosol, the nucleus; in a multitude of cells
of different systems such as the nervous system, the muscle, the breast,
the blood, the prostate, etc.
• Dystroglycan is able to form different complexes (Johnson et al., 2013).
• Dystroglycan is cleaved by gamma-secretase rendering a free fragment
with novel unknown functions.
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• Different amino acids in the cytoplasmic domain of beta-dystroglycan
may be susceptible to different PTMs, such as phosphorylation and ubiq-
uitination. Thus, depending on the triggering signal, different pathways
will be switched on, leading to specific cellular events.
• The cytoplasmic fragment of beta-dystroglycan is structurally, highly
disordered (Figure 5.1), granting a flexible region that can be shaped
according to the type of protein interaction required, possibly with an-
other protein harbouring a highly disordered domain as well, as has been
observed for the phosphatase and tensin homologue (PTEN) (Malaney,
Pathak, Xue, Uversky, & Dave´, 2013).
Alpha Beta 
Figure 5.1: The cytoplasmic domain of beta-dystroglycan is highly disordered.
ELM (http://elm.eu.org) in silico analysis of dystroglycan shows that the
cytoplasmic domain of beta-dystroglycan (stripped square) is highly disordered
with no predicted elements of secondary structure.
The combination of all these characteristics of beta-dystroglycan highlights
once more ”the complexities of dystroglycan” (Winder, 2001). With the recent
discoveries of its nuclear localisation, we asked if there were other proteins
interacting with beta-dystroglycan that could explain its functionality beyond
the plasma membrane.
Genomic sequence analysis provides us with information about the coding
sequence of a protein. However, it does not tell us about other characteristics
at the protein level, such as PTMs, protein interactions and subcellular lo-
calisation. Therefore, mass spectrometry analysis is an important and highly
sensitive tool to investigate and to understand the multitude of protein in-
teractions and post-translational modifications under certain circumstances
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(Ahmad & Lamond, 2014; Choudhary & Mann, 2010).
Thus, the objective of this chapter is to determine, by mass spectrome-
try analysis, other unknown interacting proteins that could provide us with
clues about the regulation of beta-dystroglycan throughout the cell cycle, its
functions in the nucleus and its regulation by the ubiquitin-proteasome sys-
tem. Through the set of results presented here, the exquisite multitude of
proteins interacting with beta-dystroglycan and the most representative path-
ways wherein beta-dystroglycan is involved will be shown. Finally, through
evidence already provided by other research groups and the results gathered
from the mass spectrometry screen analysis, the potential roles that beta-
dystroglycan can perform far beyond of those of a simple plasma membrane
protein will be highlighted.
5.2 Preparative analysis
The detection of beta-dystroglycan in the nucleus of different cell lines raised
the question of its role in this highly regulated compartment. The results
obtained in chapter 4, suggest that beta-dystroglycan provides structural in-
tegrity to members of the nuclear envelope and is then subjected to proteolytic
events, which signal the start of other cellular events, such as a possible co-
transcriptional regulation followed by its degradation by the nuclear protea-
some.
If dystroglycan (beta or the combination of alpha and beta) is present
in the nucleus, it has to perform a function. The possibility of its nuclear
translocation solely for degradation is controverted by the great expenditure
of energy that the cell has to invest in order to translocate a protein that can
be easily degraded in the cytosol (Stewart, 2007). Thus, the main objective of
this chapter is to determine if, in addition to the already reported non-nuclear
and nuclear components, beta-dystroglycan interacts with proteins that could
give an insight about its nuclear function(s) and the way it is further processed.
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With this in mind, it was decided to perform fractionation of LNCaP cells
in to non-nuclear and nuclear fractions. Because of the relative small size of
the nucleus compared with that of the remaining cellular components together
(cytosol, mitochondria, endoplasmic reticulum, Golgi apparatus and others),
it was therefore required to concentrate this cellular organelle in order to en-
rich nuclear proteins that could be expressed at relatively low levels, and hence
present a low number of interactions with beta-dystroglycan. Consequently,
LNCaP cells transiently transfected with the plasmid αβDgFlag were sub-
jected to cell fractionation by using a sucrose gradient protocol (see appendix
A). The reliability of the protocol was tested by immunoblotting the cellular
fractions with non-nuclear and nuclear markers such as calnexin and GAPDH,
and lamin A/C respectively. Additionally, in order to highlight non-specific
signal generated by unspecific binding of Flag antibodies, the same fractions
of non-transfected cells were included.
In Figure 5.2, it can be observed that full-length 43 kDa beta-dystroglycan
was well distributed between both fractions and importantly, it was accom-
panied by the 130-250 kDa high molecular weight form, the 31 kDa trans-
membrane fragment and the 26 kDa cytoplasmic domain (described in chap-
ter 3). Using the conditions mentioned above, it was possible to determine
that the protocol used for cell fractionation rendered fractions with minimum
cross-contamination between non-nuclear and nuclear fractions and that the
antibody Flag M2 had a high level of specificity for Flag-tagged proteins such
as beta-dystroglycan (Figure 5.2).
Using these conditions, it was decided to perform mass spectrometry analy-
sis on non-nuclear and nuclear fractions of LNCaP cells transiently transfected
with the plasmid αβDgFlag. The fractions of 4 replicate experiments were
subjected to a second screening for cross contamination between non-nuclear
and nuclear fractions by using the non-nuclear (GAPDH and calnexin) and
nuclear (lamin A/C and fibrillarin) markers. The absence of cross contamina-
tion was indicative of fractions suitable for mass spectrometry analysis (Figure
5.3).
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Figure 5.2: Standardization of a protocol for cell fractionation of LNCaP cells.
LNCaP cells WT and transiently transfected with the plasmid αβDgFlag were
growth for 36 hours and then collected for total lysates or cell fractionation.
Samples were immunoblotted with antibodies anti-Flag. This characterization
permitted to evidence the expression of beta-dystroglycan (full length, trans-
membrane and cytoplasmic) in non-nuclear and nuclear fractions. Calnexin
and GAPDH, and Lamin A/C are included as markers and loading controls of
non-nuclear and nuclear fractions respectively.
Although the antibody Flag M2 can be highly specific for Flag-tagged pro-
teins, there is the possibility of some proteins binding non specifically with this
antibody. Moreover, a high number of proteins can interact non-specifically
with agarose beads, the support of the Flag M2 resin (Mellacheruvu et al.,
2013). Thus, similar fractions of LNCaP WT cells were included and pro-
cessed along with the fractions of transfected cells.
Both non-nuclear and nuclear fractions of LNCaP WT and transiently
transfected cells with the plasmid αβDgFlag from 4 biological replicates were
immunoprecipitated using the Flag M2 resin following the workflow described
in Figure 5.4, and the protocol described in the material and methods chap-
ter (see section 2.1.5.5). Thereafter, eluates after immunoprecipitation were
reduced and alkylated, and separated by SDS-PAGE. Subsequently, the gels
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Figure 5.3: Characterization of cellular fractions used for mass spectrometry
analysis. Before performing each immunoprecipitation step with the Flag M2
resin, non nuclear and nuclear fractions of LNCaP cells WT or transfected
with the plasmid αβDgFlag were characterized with the controls GAPDH and
Calnexin, and Lamin A/C and Fibrillarin, as markers of non nuclear and
nuclear fractions respectively. The absence of signal generated by non-nuclear
and nuclear markers in the opposite fractions is indicative that if present,
the cross contamination between cellular fractions is minimum. Shown is a
representative image of 4 independent replicates.
were stained with colloidal Brilliant Blue G followed by further destaining.
Destained gels of each corresponding sample were cut in 5 gel slices and then
subjected to tryptic digestion. Extracted peptides were subjected to tandem
mass spectrometry analysis according to the conditions described in the pro-
teomics techniques in material and methods chapter (see section 2.1.7) (Figure
5.4).
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Figure 5.4: Workflow of the interactome of beta-dystroglycan. The schematic
shows the strategy used for the identification of proteins interacting with beta-
dystroglycan. Briefly, non-nuclear and nuclear fractions of LNCaP cells trans-
fected with the plasmid αβDgFlag were immunoprecipitated with the Flag M2
resin. Non-specific binding proteins (unhappy faces cartoons) were eliminated
by washing the beads under mild conditions with TBS buffer (see appendix A).
Following this, beta-dystroglycan Flag and interacting proteins (happy faces
cartoons) were eluted from the beads using the 3X Flag peptide. Eluted pro-
teins were reduced, alkylated and separated by SDS-PAGE. Stained gel slices
with colloidal Brilliant Blue G were destained and then subjected to tryptic
digestion. Extracted peptides were analysed by tandem mass spectrometry to
identify proteins interacting with beta-dystroglycan and some possible PTM.
The same procedure was followed for cellular fractions of LNCaP WT which
were included as a control of non specific interactions with the Flag M2 resin.
5.3 Mass spectrometry results
The results retrieved from the mass spectrometry analysis revealed many pro-
teins, from both non-nuclear and nuclear fractions, that were identified as
interacting with Flag M2 resin alone (control) and with Flag tagged beta-
dystroglycan (see attached excel file: 1.Interactome beta-dystroglycan,
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”protein groups tab” and Figure 5.5). Overall, non-nuclear fractions had a
good protein enrichment in Flag IPs, in contrast to the nuclear fraction where
the enrichment was sub-optimal. Therefore, proteins significantly enriched in
both non-nuclear and nuclear fractions, and with a peptide count number above
2, were considered for interactome analysis (see section 2.1.7.6 in material and
methods chapter, attached excel file (1.Interactome beta-dystroglycan,
”NN stats and Nuclear stats tabs (proteins highlighted in red)”) and Figure
5.5).
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Figure 5.5: Normalisation of proteins detected by mass spectrometry analysis.
Volcano plot for proteins identified in control and Flag immunoprecipitations.
The x-axis is the log2 fold change value (IP Flag intensity / IP control intensity)
and the y-axis is the corresponding adjusted log P value. The vertical lines
represent protein enriched 2 fold changes for control (left side) and Flag (right
side) immunoprecipitations, and the horizontal line the P-value cut-off (0.05).
a) and c) represent non-normalised data from non-nuclear and nuclear fractions
respectively, and b) and c), the normalised counterparts.
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5.4 Interactome analysis
Proteins found enriched in Flag IP in both non-nuclear and nuclear fractions
are shown in Figure 5.6. Importantly, in both fractions there were proteins
found enriched in Flag IPs, but not in control IPs. However, some proteins
presented signal in only two replicate experiments and for this reason they were
not considered in the list of enriched proteins (Figure 5.7). An important result
to highlight is that beta-dystroglycan was highly enriched in both fractions.
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Gene names of proteins found in 2 replicate experiments in Flag IPs
Figure 5.7: Proteins found enriched in Flag IPs in 2 replicate experiments.
The list shows the gene names of proteins from non-nuclear and nuclear frac-
tions enriched in two Flag IPs only without any signal in control IPs (for
a detailed description of each protein, please refer to the attached excel file
1.Interactome beta-dystroglycan).
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The amount of non-nuclear proteins found enriched in Flag IPs was very
high but, contrary to the expected, this was not the case for nuclear proteins. A
first analysis performed on nuclear proteins using the GeneMANIA prediction
server for biological network integration (http://www.genemania.org) and
the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt http://bioinfo
.vanderbilt.edu/webgestalt/) revealed that a large proportion of the en-
riched proteins in Flag IPs were related to ribosomal-related processes (Figure
5.8). It may be that these proteins represent true interactions with flagged
beta-dystroglycan; however non-specific interactions may also be possible.
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Figure 5.8: Interactome analysis of nuclear proteins found enriched in Flag
IPs. A first interactome analysis using GeneMANIA shows that dystroglycan,
DAG1, does not have any physical reported interaction with the proteins found
in Flag IPs. Additionally, the clustering using the WebGestalt server, shows
a random distribution of the proteins in different pathways and none of the
pathways retrieved had a particular enrichment of two or more proteins.
168
5.4. INTERACTOME ANALYSIS
The conception of this thesis comes from the idea that, in addition to
its function in the plasma membrane, beta-dystroglycan has also a nuclear
function. In this regard the type of proteins typically found in the pulldown
from the nuclear fraction are not suitable for ascribing a nuclear role to beta-
dystroglycan. However, in non-nuclear IPs there were many candidate proteins
involved in an immense number of cellular pathways, including some critical
nuclear processes (Figure 5.6). Additionally, in both cellular fractions there
were proteins significantly enriched but with a peptide count number below
two (attached excel file (1.Interactome beta-dystroglycan, ”NN stats and
Nuclear stats tabs (proteins with a ”+” sign)”). Furthermore, other interesting
candidates in Flag IPs were identified; but they were found in only two replicate
experiments (Figure 5.7).
The purpose of this chapter is to find proteins interacting with beta-
dystroglycan that could provide us with clues in order to understand the sig-
nalling pathways wherein dystroglycan (alpha and beta) has been found to be
involved, such as those related to: its interaction with cytoskeletal and extra-
cellular matrix components, its cytoplasmic and nuclear transport, its nuclear
function, its degradation, its involvement in the cell cycle, cell division, and
other cellular processes. Therefore, when taking into account the identity of
proteins significantly enriched but with a low peptide count (attached excel
file (1.Interactome beta-dystroglycan, ”NN stats and Nuclear stats tabs
(proteins with a ”+” sign)”), proteins found in only two replicate Flag IPs
(Figure 5.7) and the purposes pursued in this chapter, it was decided to take
into account all these proteins and merge them with the highly enriched pro-
teins of both fractions (Figure 5.6). In this way, through the interaction with
intermediate proteins it is expected to find a possible relationship between
beta-dystroglycan and cellular processes, such as those related to the nucleus,
the cell cycle or the ubiquitin proteasome system.
It is important to emphasize that combining all these proteins could lead
to an increase in the background and the number of non-specific interactions,
thus caution has to be taken before assuming a direct interaction of beta-
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dystroglycan with any reported protein. Importantly, future analyses may be
required, such as the corresponding co- and reverse immunoprecipitations to
further prove the interactions described here.
The combination of all candidate proteins, as described above, resulted
in a total of approximately 721 proteins, which could include some back-
ground (attached file 3. Mixed proteins). Fortunately, a meta-data anal-
ysis investigating the identity of contaminant proteins interacting with the
Flag M2 immunoprecipitation system has been reported (Mellacheruvu et
al., 2013). Hence, all the 721 proteins were subjected to CRAPome analysis
(http://www.crapome.org). Proteins such as tubulins, histones and GAPDH
were the hits with the highest scores, in addition to others, indicating that they
are potential background (attached file 2. CRAPome mixed proteins).
Protein analysis using the WebGestalt database allowed the clustering of
proteins by their biological, cellular and molecular characteristics (Figure 5.10).
Overall, there was a good distribution of proteins along a great variety of cellu-
lar processes from vesicular transport, cancer signalling, cell cycle, DNA repli-
cation, actin cytoskeleton regulation to apoptosis and many other processes
(Figure 5.11). Dystroglycan is ubiquitously expressed, so it is not surprising
to find that it has broad cellular implications. Due to the focus of this thesis on
the nuclear function of beta-dystroglycan, the pathways described below will
be those related to nuclear functions, cell cycle and the ubiquitin-proteasome
system. However, proteins highly enriched in other pathways, will be discussed
in the last chapter of this thesis (Chapter 6).
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(a)
(b)
Figure 5.9: KEGG pathway protein enrichment. Proteins considered for inter-
actome analysis were subject to a KEGG pathway enrichment analysis. Pro-
teins were grouped by their a) biological and b) cellular functions. Proteins
have a vast distribution throughout different cellular processes.
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Figure 5.10: KEGG pathway protein enrichment. Proteins considered for
interactome analysis were subject to a KEGG pathway enrichment analysis.
Proteins were grouped by their molecular functions. Proteins have a vast
distribution throughout different cellular processes.
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In the following figures the pathways of proteins recovered by immunopre-
cipitation with Flag are shown. The sequence of these images is based on
mechanisms started on the plasma membrane (cellular interactions), the actin
cytoskeleton interactions, to the nuclear compartment, culminating in the in-
tegration of some cellular pathways that lead to the generation of cancer, all
of which are analysed, in the ”Discussion” section of this chapter.
Figure 5.12: Adherens junction. E-cadherin is the main component of cell-cell
adherens junctions (AJs) which are important for maintaining tissue architecture,
cell polarity, cell movement and proliferation. E-cadherin interacts with β-catenin
which in turn binds α-catenin; α-catenin is then able to recruit F-actin. Cad-
herin may act as a positive or negative regulator of β-catenin. Highlighted in
red are the proteins found immunoprecipitating with Flag (Cdc42, RhoA, α/β-
catenin, Cadherin, LAR, Rac and p120ctn) and in blue boxes are the already known
interacting proteins with dystroglycan (Fyn, Src, Yes, Actin and ERK). Source:
http://www.kegg.jp/dbget-bin/www bget?pathway+hsa04520.
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Figure 5.17: Alzheimer’s disease. Alzheimer’s disease (AD) is associated
with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta),
a major component of senile plaques, is generated by from the amyloid precur-
sor protein by the consecutive cleavage of different enzymes including the gamma-
secretase complex. Highlighted in red are the proteins found immunoprecipitating
with Flag (SERCA, Calpain, PSEN, GAPD, ABAD, CX-I, -III and -V) . Source:
http://www.kegg.jp/dbget-bin/www bget?pathway+hsa05010.
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Figure 5.25: Ubiquitin mediated proteolysis. Ubiquitination functions as a signal
for 26S proteasome dependent protein degradation and other signalling processes.
This PTM is carried out by a process of sequential steps performed by a E1 ubiq-
uitin activating enzyme, a E2 ubiquitin conjugating enzyme, and a E3 ubiquitin
ligase. E3 ubiquitin ligases are classified into four groups: HECT type, U-box type,
single RING-finger type, and multi-subunit RING-finger type. Highlighted in red
are the proteins found immunoprecipitating with Flag (UBLE1A, UBE3C, HERC1,
NEDD4, ARF-BP1, UBE4B, PRP19 and PIAS). Source: http://www.kegg.jp/
dbget-bin/www bget?pathway+hsa04120.
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5.5. POST-TRANSLATIONAL MODIFICATIONS OF
BETA-DYSTROGLYCAN DETECTED BY MASS SPECTROMETRY
5.5 Post-translational modifications of beta-
dystroglycan detected by mass spectrom-
etry
The interactome analysis performed with flagged beta-dystroglycan allowed a
recovery of a great variety of proteins. In addition to this analysis, samples
immunoprecipitated with flag were subjected to a further mass spectrometry
analysis in search of PTMs, such as phosphorylation and ubiquitination, that
could be present on beta-dystroglycan. Under these conditions it was pos-
sible to recover both, a phosphorylated threonine (T790 in human, T788 in
mouse) and a ubiquitinated lysine (K794 in human, K792 in mouse) in beta-
dystroglycan. Ubiquitinated lysine was found enriched in both fractions, while
phosphorylated threonine was found in nuclear fractions only. An in silico
analysis using the NetPhosK 1.0 server (http://www.cbs.dtu.dk/services/
NetPhosK/) revealed PKC as the putative kinase responsible for T788 phospho-
rylation (Figures 5.27 and 5.28, and attached files: PTM/Phosphorylation
and PTM/Ubiquitination).
5.6 Discussion.
The translation of dystroglycan generates a pro-peptide that is further pro-
cessed into the alpha- and beta-dystroglycan subunits. Although they are
encoded by the same gene, and remain anchored on the plasma membrane, it
seems that the critical functions are performed by alpha-dystroglycan, render-
ing the beta subunit with functions restricted to supporting its counterpart
alpha subunit. This is reflected in the content of the published literature to
date; most papers are focused on finding the mechanisms that leads to hypo-
glycosylated alpha-dystroglycan, a core feature of the ”dystroglycanopathies”.
This author’s opinion does not intend to dispute the important role of alpha-
dystroglycan, but to highlight the fact that beta-dystroglycan is also an impor-
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Figure 5.27: Phosphorylation site detected in mouse beta-dystroglycan by
mass spectrometry. A schematic of mouse beta-dystroglycan is shown. High-
lighted in orange is the relative position of threonine found to be phosphory-
lated by mass spectrometry. The orange cloud represents PKC phosphorylat-
ing T788. The NLS is highlighted in green and the Flag tag in red.
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Figure 5.28: Ubiquitination site detected in mouse beta-dystroglycan by mass
spectrometry. Ubiquitination site detected in mouse beta-dystroglycan by
mass spectrometry. A schematic of mouse beta-dystroglycan is shown. High-
lighted in purple is the relative position of lysine found to be ubiquitinated by
mass spectrometry. The NLS is highlighted in green and the Flag tag in red.
190
5.6. DISCUSSION.
tant player in the integrity of the dystroglycan complex and that its functions
are far beyond a passive protein. This is based on the set of pathways presented
above and the discussion below.
5.6.1 The multiple functions of beta-dystroglycan in the
plasma membrane and vesicular trafficking
The hydrophobic amino acids found in the transmembrane domain render beta-
dystroglycan with the capacity to be inserted in membranous environments.
This means that beta-dystroglycan is typically found in two contexts: 1) most
of the organelles surrounded by membranes, contain beta-dystroglycan and, 2)
every physiological process involving membranes will always implicate, to some
extent, beta-dystroglycan. These ideas are represented in pathways such as
those related to adherens junctions, focal adhesions, endocytosis, phagosomes,
etc. Although an exquisite topic of discussion, pathways in Figures 5.12-5.16
and F.1-F.5, will be further analysed in the discussion section to this thesis.
5.6.2 The Alzheimer’s disease and WNT pathways, the
missing link in the role of nuclear beta-dystroglycan?
Despite the relatively low peptide count, nicastrin, the adaptor subunit of
the gamma-secretase complex (Shah et al., 2005), was identified by mass spec-
trometry analysis as an interacting protein with Flag-tagged beta-dystroglycan
(NCSTN in Figure 5.17, ”not highlighted in red”). This subunit, together
with presenilin, APH1 and PEN2, is an essential component of the gamma-
secretase complex (Hansson et al., 2004). Gamma-secretase cleaves the amy-
loid precursor protein (APP) in Alzheimer’s disease, Notch, EpCAM, CD44
and a myriad of other substrates in order to release active cytoplasmic frag-
ments (De Strooper et al., 1998, 1999; Lammich et al., 2002; Maetzel et al.,
2009; Murakami et al., 2003). With the evidence gathered from previous
DAPT experiments performed in this thesis (section 4.3.1), and the finding of
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nicastrin interacting with beta-dystroglycan, further corroborates that beta-
dystroglycan is subject to regulated intramembrane proteolysis mediated by
gamma-secretase.
Liberated fragments by RIP are able to perform different biological func-
tions, such as transcriptional regulation (Kopan & Ilagan, 2004), before they
are subject to proteasomal degradation. From section 4.4.2, it was shown
that the cytoplasmic fragment of beta-dystroglycan has a predominantly nu-
clear localisation. Furthermore, Mathew and colleagues have shown that beta-
dystroglycan translocates to the nucleus in an androgen receptor (AR) depen-
dent manner, and that its cytoplasmic fragment is able to modulate the tran-
scription of several genes, including the ETV1 transcription factor (Mathew
et al., 2013). However, based on in silico analysis, motifs that allow a DNA
interaction have not been clearly identified, with the exception of the BindN
algorithm (http://bioinfo.ggc.org/bindn/) which clearly states that the
NLS in beta-dystroglycan could be a potential DNA binding motif. Nonethe-
less, no further evidence stands to support this assumption and is therefore
likely to be indirect.
If the cytoplasmic fragment of beta-dystroglycan accumulates in the nu-
cleus (either, translocated from the cytoplasm to the nucleus or generated in
the nucleus as a a consequence of the cleavage of nuclear full-length beta-
dystroglycan) to exert a nuclear (gene) regulation, what is then the mecha-
nism(s) by which this very dynamic fragment orchestrates this new function?
The transmembrane epithelial cell adhesion molecule (EpCAM) is suscep-
tible to RIP, which releases a cytoplasmic fragment that is able to form a
complex with beta-catenin and the four and a half LIM domains protein 2
(FHL2), regulating the expression of target genes such as c-myc (Maetzel et
al., 2009). From the interactome analysis, the two main proteins significantly
enriched were members of the WNT pathway, catenins (alpha and beta) and
cadherin-1 (Figures F.1, 5.12 and 5.18). Then the possibility of a signalling
mechanism similar to that observed in EpCAM could be plausible.
In high grade prostate cancer, E-cadherin protein levels have been found
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to be reduced or absent (Morton, Ewing, Nagafuchi, Tsukita, & Isaacs, 1993;
Umbas et al., 1992), a process that clearly mirrors the reduction of full-length
beta-dystroglycan in the same disease (Henry et al., 2001; Hetzl, Fa´varo, Bil-
lis, Ferreira, & Cagnon, 2012; Losasso et al., 2000; Mathew et al., 2013).
Thus, the reduction of these two membrane receptors could cause the release
of anchored beta-catenin (Kypta & Waxman, 2012) and the increase in the
concentration of the cytoplasmic fragment of beta-dystroglycan, which in turn
are able to form a complex with FHL2. However, this does not explain the
concomitant translocation of beta-dystroglycan following androgen receptor
stimulation, nor the mechanism by which this dual translocation regulates the
gene expression of ETV1.
AR is able to interact with beta catenin and promote its nuclear translo-
cation (Mulholland, Cheng, Reid, Rennie, & Nelson, 2002; Truica, Byers, &
Gelmann, 2000). It has also been shown that, upon ligand stimulation, AR
binds the promoter region of ETV1, stimulating its gene expression (Cai et al.,
2007). It is therefore likely that such interactions exist among the cytoplasmic
fragment of beta-dystroglycan, beta-catenin and the androgen receptor. In this
scenario, beta-catenin associated with FHL2 (Wei et al., 2003) serves as a dock-
ing protein for the cytoplasmic fragment of beta-dystroglycan. Subsequently,
the cytoplasmic fragment enables, together with AR, the nuclear translocation
of beta-catenin. In the nucleus, by means of the AR, this complex is able to
bind to the TCF/LEF family of co-transcription factors (Behrens et al., 1996;
Molenaar et al., 1996), and then to the promoter region of ETV1. However,
experiments performed by Chesire and colleagues have shown that the AR
competes with the TCF co-transcription factor for its binding to beta-catenin
(Chesire & Isaacs, 2002). As a result, external signals may favour the forma-
tion of one or another complex. Hence, the interaction of beta-dystroglycan
with the complex containing AR and beta-catenin may modulate the interplay
between the two pathways (Kypta & Waxman, 2012). Along with the stim-
ulation of ETV1 transcription factor synthesis, this mechanism is a question
that clearly requires further research in order to understand the role of beta-
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dystroglycan in prostate cancer and other related cancers (Figures 5.23-5.24,
and (Cai et al., 2007)).
5.6.3 Beta-dystroglycan, a new player in DNA replica-
tion and the cell cycle?
The ability to interact with multiple proteins confers important roles on beta-
dystroglycan. From the interactome screening analysis, proteins associated
with DNA replication (Figure 5.19), the spliceosome (Figure 5.20), RNA trans-
port (Figure 5.21) and the cell cycle (Figure 5.22) were found immunoprecipi-
tating with Flag-tagged beta-dystroglycan.
A possible function of beta-dystroglycan in the cell cycle has been sug-
gested; however, the mechanisms behind this idea remain unknown. In this
regard, the knockdown of dystroglycan led to a delay in S-phase and to an
increase in the number of apoptotic cells in Swiss 3T3 cells (Higginson et al.,
2008) and HC11 mouse mammary epithelial cells (Sgambato, Di Salvatore, et
al., 2006). Importantly, increased protein levels of beta-dystroglycan during
the S-phase of the cell cycle have also been observed (Hosokawa et al., 2002;
Sgambato, Di Salvatore, et al., 2006).
Of the proteins involved in both DNA replication and the cell cycle, the
mini-chromosome maintenance complex (MCM) (MCM2, 4, 5 and 7) and
the structural maintenance of chromosome (Smc) (Smc1 and 3) proteins were
found to associate with Flag-tagged beta-dystroglycan.
The MCM DNA helicase complex, is a group of proteins implicated in DNA
replication. The proteins MCM2-7 are helicases able to interact with each other
and, together with other proteins, are recruited in a pre-replicative complex
to the initial stages of DNA synthesis, and persist throughout S-phase. The
components of this complex, which are assembled during the M-G1 transition
phase, are degraded once DNA replication is completed (Aladjem, 2007; Bell
& Dutta, 2002; Maiorano, Lutzmann, & Me´chali, 2006).
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A previous report demonstrated the association of beta-dystroglycan with
components of different nuclear compartments; however, an association be-
tween beta-dystroglycan and active replication sites was not observed (Mart´ınez-
Vieyra et al., 2013). This is in opposition to the interaction of the MCM com-
plex with Flag-tagged beta-dystroglycan observed in the interactome analysis
reported in this thesis (Figure 5.19). A possible explanation for this difference
could be that beta-dystroglycan associates with the MCM complex during the
pre-replication and pre-initiation stages of DNA replication, and then leaves
this complex once S-phase proceeds (active DNA synthesis). In favour of this,
it has been suggested that during the early stages of S-phase DNA replica-
tion is organized in 5-20 foci, and then, as S-phase proceeds, these initiating
foci are dispersed in to hundreds of foci throughout the nucleus (Kennedy,
Barbie, Classon, Dyson, & Harlow, 2000), a phenotype that is similar to that
reported by Mart´ınez and colleagues (Mart´ınez-Vieyra et al., 2013). Focal
replication sites co-localize with nuclear lamin A/C structures at early stages
of DNA synthesis (Kennedy et al., 2000; Shumaker, Kuczmarski, & Goldman,
2003). Given the reported interaction of beta-dystroglycan with lamin A/C
(Mart´ınez-Vieyra et al., 2013), it will be interesting to investigate the presence
of this complex (replication foci, Lamin A/C and beta-dystroglycan) during
early stages of the S-phase of the cell cycle, as means to establish a role of
beta-dystroglycan in DNA replication. This would also explain other reported
observations:
1. The increased expression of beta-dystroglycan during the S-phase of the
cell cycle and,
2. The delay in the S-phase of cells when dystroglycan levels are reduced.
If increased levels of beta-dystroglycan are required in order to assemble
the pre-replication complex and its disruption can be a triggering factor to stop
progression into S-phase. Further research aimed to investigate the association
of beta-dystroglycan with the MCM complex and their involvement in early
stages of the S-phase will provide support to this hypothesis.
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Another protein identified as interacting with Flag-tagged beta-dystroglycan
was the transcription factor STAT1. Because of its interaction with RNA poly-
merase II and STAT1, the MCM complex has been ascribed functions related
to transcription (Forsburg, 2004; Snyder, He, & Zhang, 2005). This further
supports a possible role of beta-dystroglycan in DNA replication and tran-
scription; however, the way in which beta-dystroglycan modulates these two
processes and the biological relevance remain unknown.
In light of these findings as a whole, it is clear then that if beta-dystroglycan
modulates nuclear processes, such as those related to DNA or RNA, it is
not through a direct interaction with nucleic acids, but through an indirect
association with adaptor proteins as mentioned above and discussed below.
Proteins involved with the spliceosome complex (Figure 5.20) and RNA
transport (Figure 5.21) were also immunoprecipitated with beta-dystroglycan.
The existence of these new interactions can be indirectly supported by a pre-
vious study reporting the association of beta-dystroglycan with nuclear bodies
such as the nucleolus, splicing speckles and Cajal bodies (Mart´ınez-Vieyra et
al., 2013).
Each one of these nuclear bodies is composed of different proteins and
develops different functions within the nucleus: the nucleolus, composed of
ribosome assembly factors, gives rise to the ribosome complex; the nuclear
speckles, a complex of pre-mRNA splicing factors, performs the storage and
recycling of splicing factors; and the Cajal bodies, of which the main compo-
nents are coilin and the SMN protein, allow the biogenesis, maturation and
recycling of small RNAs (Dundr & Misteli, 2010; Zimber, Nguyen, & Gespach,
2004).
This is really intriguing because the hypothesis stated in this thesis is that
beta-dystroglycan, as a co-transcription factor, regulates the transcription of
genes involved in cancer progression. However, the interaction with compo-
nents of the spliceosome suggests nuclear activities beyond gene transcription.
There may be different mechanisms by which beta-dystroglycan could be
coupled to the spliceosome machinery and subsequent events until the RNA is
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exported to the cytoplasm for its translation. Such mechanisms could involve:
1. Beta dystroglycan functions as a co-transcriptional factor.
2. Beta-dystroglycan modulates actin bridges, hence the positioning of nu-
clear bodies. The transcriptional activities of actin modulated by its
monomeric form are well known (Miralles, Posern, Zaromytidou, & Treis-
man, 2003). However, the possibility of a polymeric form of nuclear
actin (de Lanerolle & Serebryannyy, 2011; Pederson, 2008) has lead to
the suggestion of other actin-dependent regulation of gene and nuclear
body positioning (Dundr et al., 2007; Visa & Percipalle, 2010). In this
scenario, by means of its interaction with nuclear bodies, soluble beta-
dystroglycan recruits polymeric actin (Y. J. Chen et al., 2003), which in
turn position the DNA sequence to be transcribed.
3. Beta-dystroglycan acts as a scaffolding protein that modulates the trans-
port of nuclear bodies to the target DNA sequences ready to be tran-
scribed. In this regard, it has been shown that the internal nuclear
lamina is able to associate and regulate the positioning of the nuclear
bodies (Legartova´ et al., 2014; Shumaker et al., 2003). Additionally, it
is known that beta-dystroglycan and other components of the DAPC
associate with Lamin A/C, lamin B and Emerin (Fuentes-Mera et al.,
2006; Mart´ınez-Vieyra et al., 2013). Thus it is tempting to speculate
that beta-dystroglycan, together with the lamins, provides a framework
to modulate the location of nuclear bodies.
The idea of an association of beta-dystroglycan with the spliceosome ma-
chinery is indeed exciting; however, it has to be shown first that beta-dystroglycan
associates with this machinery before the theory can be tested.
Whatever the function of beta-dystroglycan is in the spliceosome complex,
if any, it seems that it has to remain anchored to the nascent RNA until it is
completely exported, as it is known that the spliceosome machinery is coupled
to the RNA export steps (Luo et al., 2001). It is interesting to highlight that
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beta-dystroglycan is able to interact with some components of the exportin
system such as CRM1 and exportin T. The presence of an NLS within the pri-
mary structure of beta-dystroglycan has been well documented (Lara-Chaco´n
et al., 2010; Oppizzi et al., 2008), yet, no DNA binding domains or an NES
have been reported so far. A quick in silico analysis confirms the lack of NES in
beta-dystroglycan; nonetheless, 4 leucines located in the second cadherin like-
domain of alpha-dystroglycan may have a potential role as a nuclear export
signal (http://www.cbs.dtu.dk/services/NetNES/). If this were true, then
it could imply that full dystroglycan (alpha and beta) is another mechanism
for the nuclear export of nascent RNA. Again, how this complex is assembled,
and its relevance within biological systems, is something that requires further
research.
It is hard to believe that a plasma membrane protein such as beta-dystroglycan
is able to perform such a multitude of functions. When first characterized
by Campbell and colleagues, it was thought that dystroglycan was only con-
fined to the plasma membrane for cell adhesion. However, the distribution of
beta-dystroglycan within a great variety of organelles, cell types and species,
suggests that there are more functions that await discovery.
Microscopy experiments performed by the Winder and Cisneros groups,
have shown that beta-dystroglycan is also localised to the cleavage furrow
and midbody during cytokinesis (Higginson et al., 2008; Villarreal-Silva et al.,
2011), and current research supports both observations. Importantly, recent
research findings support a role for beta-dystroglycan in the cell cycle before
the final stages of mitosis (note: the author did not perform any experiments to
support the following arguments; however, he was aware of the phenotype that
will be described below. Additionally, the following discussion will be based
on information and images kindly provided by Laura A. Jacobs in the Winder
lab). Also, although no further evidence has been gathered, there seems to be a
differential distribution between non-phospho and phospho-beta-dystroglycan
throughout the different stages of mitosis as described below.
During prophase phospho-beta-dystroglycan is homogeneously distributed
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throughout the cytosol. Then, there is a re-distribution to the edges of con-
densed chromosomes and, interestingly, a pool remains at the very centre of
condensed chromosomes. Later, in metaphase, phospho-beta-dystroglycan is
found surrounding the lined up chromosomes along the metaphase plate. The
most intriguing finding is that during anaphase, phospho-dystroglycan sur-
rounds the separating chromosomes. During telophase it still surrounds the
DNA, although the levels of protein are decreased. Finally, at the end of
telophase, it is again homogeneously distributed throughout the cytosol, but
a little amount remains associated to the midbody.
On the other hand, during prophase, non phospho-beta-dystroglycan is
strongly distributed on the plasma membrane and keeps the same association
during pro-metaphase, metaphase, anaphase and telophase. During metaphase
and anaphase, non phospho-beta-dystroglycan surrounds the aligned chromo-
somes; however, its levels are low compared to the phosphorylated counterpart.
By the time the cell starts dividing in telophase, normal beta-dystroglycan is
still strongly concentrated on the plasma membrane and a another pool starts
concentrating along the cleavage furrow. Finally, during cytokinesis, the lev-
els of normal beta-dystroglycan are reduced on the plasma membrane, but is
strongly concentrated in the midbody. From the observations above, it would
seem that beta-dystroglycan is not only present during late mitosis, but has
an important role during the condensation, alignment and separation of chro-
mosomes.
So far, we know that beta-dystroglycan is able to interact with F-actin
(Y. J. Chen et al., 2003), and, although not completely confirmed, is also
able to bind tubulin in human platelets (Cerecedo, Cisneros, Sua´rez-Sa´nchez,
Herna´ndez-Gonza´lez, & Galva´n, 2008). Additionally, it has been reported that
dystrophin, a direct interacting protein with beta-dystroglycan, is also able to
organize microtubules (Prins et al., 2009). Furthermore, beta-dystroglycan is
able to interact with ezrin and modulate fillopodia formation (Batchelor et al.,
2007; Spence, Chen, et al., 2004).
F-actin is an important player during all the stages of mitosis: it is re-
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distributed and localised to the cell cortex and is maintained until cytokinesis
(Field & Le´na´rt, 2011; Kunda & Baum, 2009). Also, through its interaction
with actin-binding proteins and moesin, a member of the ERM (Ezrin, Radixin
and Moesin) family of actin binding proteins, F-actin is able to modulate cel-
lular events that drive the correct spindle position, facilitating correct chro-
mosome segregation (Fehon, McClatchey, & Bretscher, 2010; Field & Le´na´rt,
2011; Kunda & Baum, 2009).
Thus, with the role of F-actin and moesin proteins in mitosis, and the con-
firmed interaction between beta-dystroglycan and F-actin, or beta-dystroglycan
and ezrin, it is tempting to formulate a possible explanation for the phenotype
observed for beta-dystroglycan. During interphase, a pool of beta-dystroglycan
interacts with F-actin leading to a direct regulation of the cytoskeleton (Fig-
ure 5.15). Once the cell enters mitosis, beta-dystroglycan is still embedded
in the plasma membrane and displays a high affinity for activated ERM pro-
teins which in turn bind F-actin. This results in increased cell stiffness in
the rounded cell, which consequently controls the correct positioning of the
mitotic spindle. During the separation of the two daughter cells, beta dystro-
glycan is re-located to the midbody in cytokinesis. In support of this, Notch,
whose signalling pathway was believed to be activated after mitosis, has been
recently shown to display functions before cell division in neuronal precursor
cells (K. M. Bhat, 2014; Pinto-Teixeira & Desplan, 2014). Then, it is possible
that, in addition to its anchoring activities, beta-dystroglycan may also be
able to modulate signalling events for the proper onset and positioning of the
cleavage furrow through its co-transcriptional activities.
This hypothesis fits well with non-phospho-beta-dystroglycan, although the
scenario with its phosphorylated counterpart seems to be rather different.
From the mass spectrometry analysis, the structural maintenance of chro-
mosomes (SMC) proteins, Smc1 (significantly enriched) and Smc3 (found in
two replicate Flag immunoprecipitations), which are core components of the
cohesin complex, and NCAPD2 (found in two replicate Flag experiments), the
regulatory subunit of the condensin complex, were found in Flag immunopre-
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cipitations (Figure 5.22).
The structural maintenace of chromosome complex includes members of the
cohesin, condensin and Smc5/6 complexes. These complexes play important
roles in sister chromatids cohesion, chromosome condensation, DNA replica-
tion, DNA repair and transcription. Cohesin’s function, is to maintain the two
sisters chromatides together, once they are generated in S-phase, until they
are separated during anaphase. Apparently, the binding of these complexes to
DNA does not require DNA binding domains (Jeppsson, Kanno, Shirahige, &
Sjo¨gren, 2014; Losada, 2014). The association of phospho-beta-dystroglycan
with cohesin and condensin complexes, and the phenotype above described,
suggests that beta-dystroglycan participates during the preparative stages of
chromosome condensation until they are completely separated in telophase.
Finally, as mentioned above, another plausible option could be the as-
sociation of phospho-beta-dystroglycan with microtubules. It may be that
phospho-beta-dystroglycan binds to microtubules through its interaction with
Smc1. This interaction may then provide a strong support to the suggested
interaction of Smc1 to the microtubules (Wong & Blobel, 2008).
These hypotheses fit well with the phenotype above described, however,
much work needs to be done in order to develop the protein interactions de-
scribed here, and importantly, the biological relevance of the participation of
beta-dystroglycan throughout the cell cycle.
5.6.4 The ubiquitin-proteasome system and beta-dystroglycan
Dystroglycan, a protein with a multitude of functions throughout its lifespan,
at some point has to be terminated. Whether it derives from the plasma
membrane, the cytosol, the nuclear membrane or the nucleoplasm, dystrogly-
can has to be subject to protein turnover by one or a combination of different
pathways in charge of protein destruction, such as endoplasmic reticulum asso-
ciated degradation (ERAD), lysosomes and the ubiquitin proteasome system
(Vellai & Taka´cs-Vellai, 2010).
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Ubiquitination is a multi-step process initiated by an E1 enzyme that acti-
vates ubiquitin, followed by the conjugation of the ubiquitin group to a target
substrate by an E2 enzyme, and completed by the ligation of the ubiquitin
group to the substrate by an E3 ligase (Hochstrasser, 2009; Lecker, Goldberg,
& Mitch, 2006). Each group is composed of different enzymes, but particularly
E3, which dictates the specificity of the ubiquitin pathway, comprises approx-
imately 600 enzymes divided in to HECT type, U-box type and RING-finger
type ligases (Figure 5.25) (Metzger, Hristova, & Weissman, 2012; Rotin &
Kumar, 2009). This PTM can enhance or prevent protein interactions, modu-
lating cellular processes such as transcription, signal transduction, membrane-
protein trafficking, endocytosis, DNA repair, and proteasomal binding and
degradation (Haglund & Dikic, 2012; Hochstrasser, 2009; Lecker et al., 2006).
Given the multiple functions attributable to ubiquitination, the discussion
presented here will focus on the ubiquitin-proteasome pathway; however, this
does not imply that the ubiquitination of beta-dystroglycan is purely related
to degradation. There may be other pathways where the ubiquitination of
dystroglycan (alpha and beta) modulates its interaction with other proteins,
its role in the cell cycle, localisation or its nuclear function.
In previous chapters it was shown that beta-dystroglycan is ubiquitinated
(Figure 3.21) and subject to proteasomal regulation (Figure 3.19 and 4.11),
indicating its potential degradation by the ubiquitin proteasome system. From
the mass spectrometry analysis, SAE1, an E1 ubiquitin activating enzyme was
found to immunoprecipitate with Flag-tagged beta-dystroglycan; however, it
was found in only two replicate experiments. Additionally, NEDD4L (also
known as NEDD4-2) and ARF-BP1 (also known as HUWE1), members of the
HECT type E3 ligases, were highly enriched in Flag IPs. Although there were
other protein candidates, they were in the group of significantly enriched pro-
teins with a low peptide count (UBE3C, HERC1), or proteins that were found
in only two replicate experiments, interacting specifically with Flag-tagged
beta-dystroglycan (PIAS and UBE4B) (Figures 5.6, 5.7, 5.25). Furthermore,
other candidate proteins were components of the proteasome. The components
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enriched are mainly members of the 19S regulatory particle (lid and base) and
only one component of the core regulatory particle was found (Figure 5.26).
This all confirms that, in LNCaP cells, the ubiquitin proteasome system may
be a pathway in charge of the rapid turnover of beta-dystroglycan.
Dystroglycan (alpha and beta) contains a multitude of lysines in its primary
structure that have been predicted to be subject to ubiquitination (http://
www.phosphosite.org); however, regardless of the potential implication that
the ubiquitin proteasome system plays in Duchenne and Becker muscular dys-
trophies (Bonuccelli et al., 2007; Gazzerro et al., 2010; Winder, Lipscomb, An-
gela Parkin, & Juusola, 2011) and in cancer (Acharyya et al., 2005; Acharyya
& Guttridge, 2007), there are no published studies aimed at understanding
the role that ubiquitination and ubiquitin enzymes play in the stability of
dystroglycan.
The interaction of SAE1, an E1 ubiquitin activating enzyme, with Flag-
tagged beta-dystroglycan could be plausible as there are only two E1 enzymes
in charge of activating ubiquitin groups; however, more research will be re-
quired to confirm this finding.
The cytoplasmic fragment of beta-dystroglycan has at least two identifi-
able PY motifs (http://elm.eu.org), which could be the motifs interacting
with the WW domain in NEDD4L in a similar way to that reported for the
epithelial sodium channel (Staub et al., 1996). A recent study suggested that
a phosphorylated tyrosine located in a PY motif in the very carboxy-terminus
of beta-dystroglycan could be an important signal triggering its proteasomal
degradation (Miller et al., 2012), further supporting the interaction of beta-
dystroglycan with NEDD4L. However, Pirozzi and colleagues showed that the
phosphorylation of a tyrosine within the PY motif prevented its interaction
with the WW domain (Pirozzi et al., 1997) and later reported, although not in
the context of tyrosine, that the binding of NEDD4L to SMAD7 is not depen-
dent on the phosphorylation of the PY motif (Arago´n et al., 2012) which is in
contrast to the interaction observed with SMAD3 (Gao et al., 2009). There-
fore, it will be important to determine to what extent the phosphorylation of
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Y890 in beta-dystroglycan modulates its putative interaction with NEDD4L
or HUWE1.
The identification of NEDD4L and ARF-BP1 as potential ubiquitin ligases
interacting with beta-dystroglycan leads the author to speculate that they are
responsible for the rapid turnover of beta-dystroglycan in cancers where its
expression has been shown to be reduced. In this regard, NEDD4L has been
ascribed functions such as endocytosis and sorting of transmembrane proteins,
whilst ARF-BP1 is associated with neuronal differentiation (by destabilizing
N-myc), and the regulation of p53 and Mcl-1 (Rotin & Kumar, 2009). More
research will be required in order to understand how these E3 ligases regulate
the internalisation, turnover or other cellular events of beta-dystroglycan.
Dystroglycan is a protein that is broadly present in different organelles
within the cell (plasma membrane, ER, nucleus), among different tissues (mus-
cle, prostate, brain, breast, etc.), and among different species. Therefore it
may be expected that more than one ubiquitin ligase targets dystroglycan for
degradation, as dictated by the organelle, cell type and the species. In this
regard, it was previously reported by Lee and colleagues that HRD1, a trans-
membrane RING E3 ubiquitin ligase resident in the endoplasmic reticulum,
the main function of which is to degrade misfolded or aberrant proteins (Bays,
Gardner, Seelig, Joazeiro, & Hampton, 2001), targets beta-dystroglycan for
ubiquitination (K. A. Lee et al., 2011). Another study provided evidence that
beta-dystroglycan is able to bind to WWP1 and WWP2 (Pirozzi et al., 1997),
and later, although not strictly linked, another study postulated WWP1 as
the causative ubiquitin ligase of muscular dystrophy in chickens (Matsumoto
et al., 2008). Furthermore, the ubiquitin ligases MAFbx and MuRF1 were
correlated to muscle atrophy (Bodine et al., 2001). This all indicates that the
ubiquitination of beta-dystroglycan may be mediated by different ubiquitin lig-
ases which may be determined by the cellular context; in the case of prostate
cancer ubiquitination is possibly mediated by HUWE1 and NEDD4L.
Further in-depth analysis will be required to show whether the ubiquitina-
tion of dystroglycan by NEDD4L and ARF-BP1 has a role in its stability; regu-
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lating in this way the amount of dystroglycan on the plasma membrane, which
in turn could lead to cancer progression (perhaps potentiating other related
processes such as those performed by MMPs). Additionally, having explained
the potential role of the co-transcriptional activity of the cytoplasmic frag-
ment of beta-dystroglycan, it will be required to investigate whether NEDD4L
and ARF-BP1 have a function regulating post-co-transcriptional events of this
fragment.
The mass spectrometry screening performed in this thesis identified K794
in human (K792 in mouse) as a lysine that could potentially be modified by
ubiquitination (Figure 5.28). The potential ubiquitination of this lysine was
already reported in large-scale mass spectrometry analyses aided to describe
ubiquitinated sites in murine tissues (Wagner et al., 2012) and the human
ubiquitinome (W. Kim et al., 2011). However, the role that this modified
lysine has in the different pathways wherein beta-dystroglycan is implicated,
and its relationship with the NEDD4L and ARF-BP1 ligases, is yet to be
determined.
The identification of phosphorylated T788 in beta-dystroglycan is intrigu-
ing. It may be that its presence modulates the interaction of beta-dystroglycan
with the importin complex, as it is located in the middle of the bi-partite NLS.
Additionally, it could be possible that this phosphorylated amino acid regulates
other PTMs, such as ubiquitination or sumoylation, as it is just three amino
acids away from the identified ubiquitinated lysine in this thesis. Furthermore,
its location near the plasma membrane could regulate the proteolytic events
mediated by Furin and gamma-secretase in beta-dystroglycan described earlier
in this thesis.
In the work presented in this thesis a Flag-tagged beta-dystroglycan im-
munoprecipitation strategy was used to identify possible interacting partners.
Interestingly, this strategy did not detect the common components of the
DAPC or non-muscle counterparts, such as utrophin, or the beta-syntrophins.
The following reasons, although not demonstrated, could explain why this was
the case.
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It could be that the DAPC members were at a low concentrations compared
with the immunoprecipitated proteins, so that they were masked by the most
abundant proteins. In this regard, utrophin, a dystrophin homologue and
core component of the DAPC in epithelial cells (Nguyen, Le, Blake, Davies,
& Morris, 1992), was found at low levels in the mass spectrometry approach.
Another possible explanation could be that, due to the conditions used in
the immunoprecipitation, other proteins presented a stronger interaction with
beta-dystroglycan than the typical DAPC members.
5.6.5 Summary
Through the results and analysis provided in this chapter it can be concluded
that:
1. Beta-dystroglycan may be implicated in RNA processing and transport.
2. Beta-dystroglycan may have roles during the S-phase of the cell cycle by
modulating DNA replication events.
3. Beta-dystroglycan may perform functional roles from the start of mitosis
until the completion of cytokinesis.
4. RIP in beta-dystroglycan may be mediated by the gamma-secretase com-
plex.
5. Beta-dystroglycan may have co-transcriptional properties in partnership
with components of the WNT pathway.
6. Beta-dystroglycan is phosphorylated on T788 and ubiquitinated on K792.
7. Beta-dystroglycan is subject to protein turnover by the ubiquitin-proteasome
system.
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6.1 Discussion
Dystroglycan is a protein subject to several post-translational modifications.
These PTMs are important in order to regulate its interaction with other
proteins, to control its targeting to different cellular compartments and for its
degradation. Therefore, the combination of post-translational modifications
with the cellular distribution, confer dystroglycan with properties to regulate
different cellular processes.
The data described in this thesis further confirmed that beta-dystroglycan
is subject to extensive phosphorylation and ubiquitination. Importantly, it
was observed that other post-translational modifications, such as RIP, are also
involved in the functionality of beta-dystroglycan. Furthermore, a dystrogly-
can interactome analysis showed that it may be possible that the interactions
of beta-dystroglycan with other proteins extend far beyond those already re-
ported. The main goal in this interactome analysis was to identify co-factors
and other proteins that could provide clues about the role of beta-dystroglycan
in the nucleus of LNCaP cells. It was exciting to find that, in addition to
some potential nuclear candidates, there are other proteins that, together with
beta-dystroglycan, may be modulating cellular functions outside of the nu-
cleus. There is still a lot of work that needs to be done in order to understand
those potential interactions and the questions that they raise.
This project centred around triggering events on the plasma membrane
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that could provide us with a logic explanation for how beta-dystroglycan is
transported to the nucleus. For this reason, the project was divided into three
main sections:
• Post-translational modifications affecting the integrity of beta-dystroglycan.
• Mechanisms leading to the proteolysis and nuclear translocation of beta-
dystroglycan.
• Protein interactions that could explain the function(s) of beta-dystroglycan
in the nucleus.
6.1.1 Post-translational modifications of beta-dystroglycan
From data presented in chapter 3 it is clear that beta-dystroglycan may be
subject to extensive phosphorylation and ubiquitination. The accumulation of
the cytoplasmic fragment of beta-dystroglycan in the nucleus led us to initially
propose that it has nuclear functions followed, by its ubiquitination, and then
degradation by the nuclear proteasome. Ubiquitination is a post-translational
modification that can have two different outcomes. The first is as an additional
modification involved in cell cycle, trafficking and nuclear functions. The sec-
ond one is to flag proteins for degradation by the proteasome (Hochstrasser,
2009; Komander, 2009).
In the first case, this modification could regulate the possible transport
and interactions of beta-dystroglycan with other nuclear proteins. Addition-
ally, modification with ubiquitin groups could lead to conformational changes
in the highly disordered cytoplasmic fragment of beta-dystroglycan that could
cause its activation (see below for discussion) or inactivation. The modifica-
tions of beta-dystroglycan in the second scenario represent the final stage of
regulation of nuclear beta-dystroglycan. In this regard, once beta-dystroglycan
has exerted its functions (whatever they are), the cell does not invest any un-
necessary energy by transporting beta-dystroglycan back to the cytoplasm.
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Although both are plausible ideas, further research is required in order to
identify any other amino acids subject to ubiquitination, how this modifica-
tion affects the transport of beta-dystroglycan, and if beta-dystroglycan is
indeed degraded in the nucleus, or transported back to the cytoplasm.
The nuclear localisation signal of beta-dystroglycan is rich in lysine and
arginine amino acids and is strategically located within the sequence contained
in the cytoplasmic fragment. Interestingly, the lysine that is shown to be
subject to ubiquitination in this project is located in the second stretch of
amino acids that belong to the NLS. Thus, it will need to be determined if
other lysines within the NLS are modified by ubiquitination (mono or poly) and
to what extent this modification affects protein interactions, nuclear transport
and the degradation of beta-dystroglycan. This could have several implications
as it is also known that this particular motif mediates the interaction with the
ERM proteins, rapsyn and ERK, and members of the importin system (see
section 1.5.5).
The reason why these questions have to be answered comes from the idea
that proteins are regulated differentially depending on whether the modifi-
cation is mono- or poly-ubiquitination and what type of linkage is involved.
Poly-ubiquitinated proteins are usually targeted for proteasomal degradation,
whilst mono-ubiquitination serves to target proteins for nuclear transport. In
this regard, a similar mechanism has been observed in the enzyme cytidylyl-
transferase, the enzyme that catalyses the synthesis of the phospholipid phos-
phatidylcholine. Its transport mediated by the importin system is disrupted
by the masking of its nuclear localisation signal by mono-ubiquitination once
this enzyme is targeted for lysosomal degradation (B. B. Chen & Mallampalli,
2009).
Additionally, an interesting paper has shown that PTEN (Phosphatase
and TENsin homologue) is differentially regulated depending on the type of
ubiquitination on its structure. This phosphatase usually antagonises the ef-
fects of phosphatidylinositol-3-kinase (PI3K) by converting phosphatidylinosi-
tol 3,4,5 phosphate (PIP3) to phosphatidylinositol 4,5 phosphate (PIP2) on the
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plasma membrane. The subsequent reports of its nuclear localisation led to
important discoveries. It was observed that poly-ubiquitination by NEDD4L
(NEDD4-1) targeted PTEN to proteasomal degradation. However, the mono-
ubiquitination by the same enzyme favoured its nuclear localisation. Addition-
ally, it was suggested that PTEN may had been subject to further deubiqui-
tination to perform its nuclear functions that maintain chromosome integrity
(Baker, 2007; Trotman et al., 2007). The opposite regulation by the same PTM
has been reported for p53. Mono-ubiquitination of p53 exposes its nuclear ex-
port signal, allowing further modification with SUMO groups which in turn
enhance nuclear export. The addition of poly-ubiquitin groups retains p53
in the nucleus with its consequent proteasomal degradation (Carter, Bischof,
Dejean, & Vousden, 2007).
The cytoplasmic fragment of beta-dystroglycan has other motifs, which
combined with ubiquitination, could provide other mechanisms of regulation.
A closer view of the primary structure of dystroglycan revealed other inter-
esting regulatory elements within its primary structure. It has five PEST
motifs distributed throughout alpha- and beta-dystroglycans (2 in alpha and
3 in beta). These motifs have a low hydrophobicity index indicating that they
are exposed and may mediate protein-protein interactions (http://emboss
.bioinformatics.nl/cgi-bin/emboss/epestfind) (Figure 6.1). The PEST
motifs are short sequences of proline (P), aspartic acid (E), serine (S) and
threonine (T) residues. These motifs are usually surrounded by lysine (K),
arginine (R) or histidine (H) amino acids and are approximately 12 amino
acids long. An important characteristic of proteins that have these motifs is
that they are, apparently, rapidly and efficiently degraded by the proteasome.
It has also been suggested that the presence of additional modifications, such
as phosphorylation and changes in the overall conformation of the substrates,
increase the turnover of proteins targeted for proteasomal degradation(Garc´ıa-
Alai et al., 2006; Rechsteiner & Rogers, 1996).
The presence of these PEST motifs could be the point of convergence
between the extensive phosphorylation and ubiquitination present in beta-
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     1 MRMSVGLSLLLPLSGRTFLLLLSVVMAQSHWPSEPSEAVRDWENQLEASMHSVLSDLHEA 60!
                                                                !
    61 VPTVVGIPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSWLHWDSQSHTLEGL 120!
      !
   121 PLDTDKGVHYISVSATRLGANGSHIPQTSSVFSIEVYPEDHSELQSVRTASPDPGEVVSS 180!
      !
   181 ACAADEPVTVLTVILDADLTKMTPKQRIDLLHRMRSFSEVELHNMKLVPVVNNRLFDMSA 240!
      !
   241 FMAGPGNAKKVVENGALLSWKLGCSLNQNSVPDIHGVEAPAREGAMSAQLGYPVVGWHIA 300!
      !
   301 NKKPPLPKRVRRQIHATPTPVTAIGPPTTAIQEPPSRIVPTPTSPAIAPPTETMAPPVRD 360!
                      +++++++++++++++++++++!
!
   361 PVPGKPTVTIRTRGAIIQTPTLGPIQPTRVSEAGTTVPGQIRPTMTIPGYVEPTAVATPP 420!
        !
   421 TTTTKKPRVSTPKPATPSTDSTTTTTRRPTKKPRTPRPVPRVTTKVSITRLETASPPTRI 480!
                    +++++++++++++                                  !
!
   481 RTTTSGVPRGGEPNQRPELKNHIDRVDAWVGTYFEVKIPSDTFYDHEDTTTDKLKLTLKL 540!
!
   541 REQQLVGEKSWVQFNSNSQLMYGLPDSSHVGKHEYFMHATDKGGLSAVDAFEIHVHRRPQ 600!
!
   601 GDRAPARFKAKFVGDPALVLNDIHKKIALVKKLAFAFGDRNCSTITLQNITRGSIVVEWT 660!
       !
   661 NNTLPLEPCPKEQIAGLSRRIAEDDGKPRPAFSNALEPDFKATSITVTGSGSCRHLQFIP 720!
       !
   721 VVPPRRVPSEAPPTEVPDRDPEKSSEDDVYLHTVIPAVVVAAILLIAGIIAMICYRKKRK 780!
             ++++++++++++                                          !
!
   781 GKLTLEDQATFIKKGVPIIFADELDDSKPPPSSSMPLILQEEKAPLPPPEYPNQSVPETT 840!
! ! ++++++++++++++ ! ! ! ! !+++++++++++++++++!
!
   841 PLNQDTMGEYTPLRDEDPNAPPYQPPPPFTAPMEGKGSRPKNMTPYRSPPPYVPP 895!
       +++++++++++++ +++++++++++++++++++++                    !
!
A 
B 
E 
D 
C 
D 
F 
Figure 6.1: Dystroglycan has different potential PEST motifs. The PEST mo-
tifs are characterised by short stretches of proline (P), aspartic acid (E), serine
(S) and threonine (T) amino acids surrounded by basic residues. Alpha- (dark
green) and beta-dystroglycan (blue) have two (A and B) and three (C, D and
E) potential PEST motifs (red crosses) respectively. The motif identified by
Piggot is highlighted in pink crosses (F) (Piggott, 2014), and the amino acids
that belong to the cytoplasmic fragment of beta-dystroglycan are underlined.
dystroglycan. Apparently, the deletion of a PEST motif in human NANOG, a
gene that regulates pluripotency of embryonic stem cells, decreased its ubiq-
uitination and extended its half life (Ramakrishna et al., 2011). Furthermore,
the phosphorylation of two key serines within a PEST sequence in the vascular
endothelial growth factor receptor 2 is important in modulating its ubiquiti-
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nation and consequent degradation by the proteasome (Meyer et al., 2011).
Thus, these PEST motifs could correspond to the minimal sequences, the
definition of ”degrons” (Ravid & Hochstrasser, 2008), that are recognised by
the NEDD4L and HUWE1 E3 ligases in order to target beta-dystroglycan for
degradation. A speculative idea is that the hydrophilic PEST motifs mediate
the interaction of beta-dystroglycan with both ligases, which in turn are able
to ubiquitinate adjacent lysines.
Although the idea looks feasible, it seems that this putative interaction is
more complicated in reality. In agreement with this thesis, a previous report
showed that phosphorylated beta-dystroglycan was subjected to ubiquitina-
tion (Piggott, 2014). In vitro experiments aimed to identify the E3 ubiquitin
ligase responsible for this PTM suggested that the WW1 and WW2 domains of
NEDD4L interacted with the LEDQATFIKKGVPI peptide sequence of beta-
dystroglycan (see region F in Figure 6.1). However, further in vivo characteri-
sation by immunoprecipitation assays was not able to identify any interaction
between NEDD4L and beta-dystroglycan in H2K myoblasts (Piggott, 2014).
This is contrary to the mass spectrometry results obtained in chapter 5, where
NEDD4L was identified as one of the putative ubiquitin ligases interacting with
beta-dystroglycan. Because of the characteristics of the sequence previously
identified by Piggott, it can be argued that the interaction between NEDD4L
and beta-dystroglycan was not detected, because two internal lysines are part
of the second stretch of amino acids that conform the nuclear localisation sig-
nal in beta-dystroglycan. Thus, it can be speculated that the competitive
binding of these amino acids to the importin alpha/beta complex, avoided the
subsequent interaction with NEDD4L in the pull-down experiment.
Furthermore, a pull-down assay using the recombinant cytoplasmic frag-
ment of beta-dystroglycan in an importin free system, did not show any binding
to the WW1 and WW2 motifs of NEDD4L (Piggott, 2014), indicating that
the hypothesis of a possible competition with importins is not feasible. How-
ever it is also possible that despite the presence of WW interaction motif in
dystroglycan and four WW domains in NEDD4L, that NEDD4L does not in-
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teract with beta-dystroglycan via a WW domain interaction. As discussed in
chapter 5, it may be that the type of ligases implicated in the ubiquitination
of beta-dystroglycan depend on the cellular type. The interaction of NEDD4L
with beta-dystroglycan, detected by mass spectrometry analysis in this thesis,
has also been observed in other in vitro systems (Steve Winder personal com-
munication, and (Piggott, 2014)). Although the interaction between NEDD4L
and beta-dystroglycan still has to be confirmed in LNCaP cells, the evidence
above suggests a possible indirect interaction.
Investigating the possibility that NEDD4L and HUWE1 are the ubiqui-
tin ligases of beta-dystroglycan is important, because the activity of these
ligases could be modulated in order to prevent the pathological loss of beta-
dystroglycan from the plasma membrane in certain diseases. Previous studies
have used the inhibition of the proteasome as a strategy to restore components
of the DAPC to the plasma membrane. However, this strategy has been crit-
icized by the fact that the abolishing of the proteasome activity affects the
turnover of proteins that have to be normally degraded by this pathway: it is
not ”substrate specific”, or it fails to improve the dystrophic phenotype of the
mdx mice (Perkins & Davies, 2012; Selsby, Morris, Morris, & Sweeney, 2012).
Therefore, the option of inhibiting these E3 ubiquitin ligases would be a more
specific means of preventing the ubiquitination of beta-dystroglycan. In this
regard, it is interesting to note that in colorectal cancer the levels of NEDD4L
were found to be downregulated at the mRNA and protein levels (Tanksley,
Chen, & Coffey, 2013). In prostate cancer, on the other hand, there seemed
to be no definite correlation as two independent groups have found increased
(Hellwinkel et al., 2011) and also reduced (Hu, Xu, Fu, Yu, & Huang, 2009)
levels of NEDD4L.
More research is required in order to determine the way in which the above
E3 ubiquitin ligases and beta-dystroglycan interact, either by means of the
sequence identified by Piggott or the PEST motifs proposed here. Also, it will
be necessary to investigate the role of pY890 and the role of pT788 (which is
situated in the middle of the binding sequence identified by Piggott) in this
213
CHAPTER 6. DISCUSSION, CONCLUSIONS AND FUTURE WORK
interaction. These investigations will help develop our understanding of how
ubiquitination controls the stability of beta-dystroglycan.
6.1.2 Regulated intramembrane proteolysis of beta-dystroglycan
The results provided in this thesis add more evidence to the modification of
beta-dystroglycan by regulated intramembrane proteolysis that occurs by a
series of events initiated in the extracellular environment. By combining pre-
vious reports with the information gathered in this thesis, a general mechanism
of the events initiated on the plasma membrane leading to RIP can be pos-
tulated as follows. High cell density and PDBu stimulation are two potential
factors that may initiate downstream proteolytic events in beta-dystroglycan.
The apparent hypo-glycosylation of alpha-dystroglycan because of decreased
expression on LARGE2 and β3GnT1 (Bao et al., 2009; Esser et al., 2013) ren-
ders a ”naked” protein that is susceptible to a first cleavage by furin (Singh et
al., 2004). These events are followed by further proteolytic events by MMP-2
and -9 on the extracellular domain of beta-dystroglycan which in turn gen-
erate a membrane-anchored fragment (Yamada et al., 2001). The proteolytic
activities mediated by gamma-secretase within the plasma membrane produce
a smaller fragment that is still attached to this lipid bi-layer by the palmi-
toyl modification in a cysteine group immediately below the transmembrane
domain (Kang et al., 2008). The final cut at the interface of the plasma
membrane and NLS, carried out by furin, releases this small fragment into
the cytosol. The released cytoplasmic fragment is then transported to the
nucleus by passive diffusion (see section 1.5.4 and Figure 1.7), where it accu-
mulates and regulates gene transcription and is finally degraded by the nuclear
ubiquitin-proteasome system (Figure 6.2).
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The localisation in the nucleus of the same key players mediating the pro-
teolysis of beta-dystroglycan on the plasma membrane leads to the hypothesis
that the same mechanism could apply in the nucleus. RIP in the nuclear mem-
brane could explain some discrepancies between the pool of beta-dystroglycan
anchored to the nuclear membrane and the pool observed moving freely in the
nucleoplasm. In this model, full-length beta-dystroglycan is anchored to the
nuclear membrane and the released cytoplasmic fragments are free moving in
the nucleoplasm. The processing of beta-dystroglycan by RIP may also influ-
ence further processing by the nuclear ubiquitin proteasome system. Although
the PTMs and the potential nuclear functions of beta-dystroglycan were sep-
arated from the RIP mechanisms described in this thesis, all three of these
mechanisms have to be thought of as a continuous process.
There are different enzymes with the potential to cleave membrane-anchored
proteins: some cleave type II transmembrane proteins, others multi-pass pro-
teins (Lemberg, 2011; Wolfe & Kopan, 2004). However, if nuclear beta-
dystroglycan is subject to proteolysis, the question then arises of how this
process could be carried out. The possibility of a mechanism mediated by
nuclear gamma-secretase (J. Li et al., 1997) was previously discussed in this
thesis, but there is still the question of whether other enzymes could perform
the same function. In this regard, one of the critical steps in the processing
of prelamin A consists of its proteolytic cleavage by the seven transmembrane
zinc metalloprotease ZMPSTE24. This protease, which is located in the ER
and the inner nuclear membrane, helps with the maturation of lamin A, and is
implicated in the Hutchinson-Gilford Progeria Syndrome due to its inability to
cleave a mutant form of prelamin A (Davies, Fong, Yang, Coffinier, & Young,
2009).
The processing of prelamin A by ZMPSTE24 teaches us that there could
be a similar processing for beta-dystroglycan, as it has been demonstrated
that the nucleus is not exempt from proteolytic regulatory activities. In this
regard, after being transported to the nucleus and inserted in the plasma
membrane, beta-dystroglycan could be cleaved by gamma-secretase or similar
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enzymes, such as ZMPSTE24 (Barrowman, Hamblet, George, & Michaelis,
2008; Barrowman, Hamblet, Kane, & Michaelis, 2012). Understanding the
way that beta-dystroglycan is processed within the nucleus could explain the
possible hypothesis of a liberated cytoplasmic fragment that is able to function
as a transcriptional co-factor. It remains to be determined if the purpose of this
cleavage is intended to initiate turnover of dystroglycan, if it has a significance
in cellular signalling, if it has functions and then it is immediately degraded
by the proteasome, or a combination of all three.
The answers to these questions are important because they could influence
the design of therapies aimed to prevent the cleavage of beta-dystroglycan.
Given the fact that beta-dystroglycan is reduced from the plasma membrane
in cancer and in muscular dystrophies via mechanisms that involve the pro-
teasome, PTM and gamma-secretase, a sensible therapeutic strategy could
be to inhibit the activity of gamma-secretase. However, like the proteasome,
gamma-secretase is not specific to beta-dystroglycan, and it inhibition will
inhibit other pathways as a consequence.
By analogy, it is known that the inhibition of the proteasome leads to the
restoration of the DAPC components to the plasma membrane. However, this
therapeutic strategy has been questioned by the fact that proteins have to be
subject to proteasomal degradation as part of normal cell function. There-
fore inhibiting proteasomal activity has off-target effects that are potentially
harmful, limiting its use as a therapy (Perkins & Davies, 2012).
The same rationale can be applied to the development of therapeutic strate-
gies that inhibit the activity of gamma-secretase in order to stop the cleavage
of plasma membrane proteins. Inhibiting gamma-secretase could stop the fur-
ther processing of beta-dystroglycan, but also of other proteins that have to be
cleared because of alterations in their sequences which are potentially harmful
to the cell (Selkoe & Wolfe, 2007). In this regard, the development of thera-
pies that are highly specific in preventing the processing of beta-dystroglycan
by gamma-secretase could be more useful. Although this could be a sensi-
ble strategy, in proteins subject to the same proteolytic events by gamma-
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secretase it has been observed that the use of such strategies can lead to
other unwanted effects, such as the stimulation of tumourigenesis, alteration
of stem cell signalling pathways, and effects associated with the inhibition of
the Notch signalling pathway (Purow, 2012). It has to be considered that the
proteolytic activation of beta-dystroglycan is merely a consequence of an up-
stream activation. As mentioned previously, it can be activated under normal
conditions or started by defective glycosylation of alpha-dystroglycan followed
by the proteolytic cleavages of furin, on alpha- and, subsequently, MMPs on
beta-dystroglycan (Figure 6.2). Again, further research is required to show
that this process is caused by an event initiated on alpha-dystroglycan and
that it is not an independent mechanism concerning beta-dystroglycan alone.
If the first scenario is true, then a therapy aimed to restore the glycosyla-
tion of alpha-dystroglycan could be enough to restore the components of the
DAPC to the plasma membrane. However, if gamma-secretase cleavage is an
independent mechanism, other strategies aimed at protecting the cleavage of
beta-dystroglycan within the plasma membrane will have to be developed.
So far, the discussion has been focused on the possible consequences of the
liberated cytoplasmic fragment of beta-dystroglycan. However, it should not
be forgotten that, upon cleavage, alpha- and beta-dystroglycan fragments are
released to the extracellular environment. A simple conclusion about these re-
leased fragments is that, they are degraded, but the consequences of generated
fragments seem to be far more complex than this.
Different research groups have focused their attention on the potential use
of released cleaved fragments as biomarkers in neurodegenerative diseases and
cancer. By measuring the concentrations of various secreted proteins in cere-
brospinal fluid (CSF), Yin and colleagues identified specific secreted proteins
that were increased in patients with Alzheimer’s and Parkinson diseases. One
of the proteins identified was alpha-dystroglycan, and even though the number
of patients under study was low, its use as a biomarker of neurodegenerative
diseases was suggested (Yin, Lee, Cho, & Suk, 2009). In addition to that
study, increased levels of the N-terminal domain of alpha-dystroglycan have
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also been observed in the CSF of patients with Lyme neuroborreliosis (Hesse et
al., 2011). The secretion of the N-terminal fragment of alpha-dystroglycan has
also been reported for various different cell lines (Saito, Saito-Arai, Nakamura,
Shimizu, & Matsumura, 2008; Saito et al., 2011).
The other scenario that has to be taken into account is the possibility
that the released fragments could be affecting adjacent interactions e.g. by
means of the formation of homophilic interactions or by affecting other cellular
processes. In this regard, it has been reported that the N-terminal domain
of alpha-dystroglycan retains its ability to interact with extracellular matrix
components, such as lamins, fibronectin and fibrinogen. Perhaps the most
interesting result reported by the authors was the fact that the N-terminal
domain was able to induce neurite extension in PC12 cells (Hall, Bozic, Michel,
& Hubbell, 2003).
Together, these results highlight the potential use of secreted cleaved frag-
ments of dystroglycan as biomarkers; however, large scale screening is still re-
quired to find a correlation between the concentration of extracellular secreted
cleaved dystroglycan in body fluids and the onset/progression of muscular dys-
trophies and cancer. Furthermore, if the cleavage of dystroglycan is a common
event in disease, it will be interesting to determine if there are additional cel-
lular events initiated by the liberation of the secreted fragments e.g. by the
formation of homophilic interactions.
6.1.3 The function of nuclear dystroglycan
The function of nuclear beta-dystroglycan is an emerging and exciting topic.
With its important function on the plasma membrane to protect the sar-
colemma from damage during muscle contraction and relaxation, or its role
in controlling and co-ordinating the growth of epithelial cells, it is hard to
believe that dystroglycan is also present in the nucleus of cells (either alone
or accompanied by alpha-dystroglycan) where it has a function within this
very controlled environment. In this thesis, evidence indicating that beta-
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dystroglycan may have different roles inside the nucleus was found. Some of
the information discussed below will be based on the findings gathered in this
project, but caution has to be taken as most of the putative functions and
interactions of beta-dystroglycan have to be further confirmed.
The localisation of beta-dystroglycan in the nucleus of different cell lines
and in human prostate cancer has been well documented. However, there are
no studies reporting the nuclear presence of its counterpart, alpha-dystroglycan.
This study is the first to show evidence that alpha-dystroglycan is also present
in the nucleus. There are several reasons why this observations seems counter-
intuitive. Alpha-dystroglycan is a secreted protein, it does not have a nuclear
localisation signal, and it does not have a transmembrane domain that could
direct its insertion into the nuclear membrane. Furthermore, a previous report
using an antibody directed against the glycan groups of alpha-dystroglycan
concluded that beta-dystroglycan was the only subunit present in the nucleus
(Oppizzi et al., 2008). Also, the only evidence presented thus far corresponds
to that of a biochemical cell fractionation of an over-expressed construct pre-
sented in this thesis (Chapter 3, Figure 3.10). Although attempts were made in
order to detect alpha-dystroglycan by immunofluorescence and western blot-
ting by using antibodies against core and glycosylated alpha-dystroglycan,
they were not successful. The idea of nuclear alpha-dystroglycan can not be
completely discarded and the following elements provide some insights into
how this protein could be transported to the nucleus and its potential roles.
The results shown in section 3.5 correspond to three independent experi-
ments, which, in part, could discard the possibility of an experimental artefact.
Also, it is thought that during the biosynthesis of dystroglycan, both alpha-
and beta-subunits remain non-covalently attached, suggesting that this inter-
action could provide a route for the transport of alpha-dystroglycan. Addi-
tionally, glycosylation has also been observed to modify the nucleocytoplasmic
transport of heat shock proteins-40 and -70 (Zachara et al., 2004), and to con-
fer the properties of a nuclear localisation signal as was observed with BSA
(Guinez, Morelle, Michalski, & Lefebvre, 2005; Rondanino, Bousser, Monsigny,
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& Roche, 2003; Hart & West, 2009). Furthermore, phosphorylation modulates
the glycosylated status of proteins which in turn affects their nuclear transport
as has been observed with Tau proteins (Lefebvre et al., 2003). Interestingly,
the transport of some glycosylated proteins occurs in a cell cycle-dependent
manner (Rondanino et al., 2003) and apparently, this modification, enhances
the interaction between some transcription co-factors (Gewinner et al., 2004).
Given the extensive glycosylation of alpha-dystroglycan and the data from
the reports cited above, it can be hypothesized that alpha-dystroglycan trav-
els to the nucleus by means of its multiple glycan groups, which mediate un-
known nuclear regulations. However, this is contradicted by the fact that in
the data reported in this thesis, alpha-dystroglycan was apparently void of
glycosylation. Therefore, if alpha-dystroglycan is transported to the nucleus,
it has to occur via a novel, glycan-independent mechanism. In support of
this, Chuderland and colleagues identified a new motif that is able to translo-
cate cytoplasmic proteins to the nucleus in an importin-independent pathway.
This SPS/TPT (Ser-Pro-Ser / Thr-Pro-Thr or S/T-P-S/T) motif, upon phos-
phorylation and interaction with importin-7, was able to mediate the nuclear
transport of the extracellular signal-regulated kinase-2 (ERK-2), SMAD3 and
MEK1 (Chuderland, Konson, & Seger, 2008). Thus, in a speculative scenario,
hypo-glycosylated alpha-dystroglycan exposes its major TPT domains, which
are then phosphorylated, bound by importin-7 and transported to the nucleus.
Much research is required to fully characterise the nuclear localisation of alpha-
dystroglycan and the significance of this. Some elements have been provided
that suggest possible pathways to the nucleus and testing these, with the help
of newly developed antibodies (Fortunato et al., 2014; Humphrey et al., 2015),
will further support or discard the running hypothesis of a separate pool of
nuclear alpha-dystroglycan.
The information provided above, although limited for alpha-dystroglycan,
leads to the question of whether the N-glycosylation on the globular domain
of beta-dystroglycan could confer additional properties to this subunit, and it
may be by modulating its interaction with other proteins in the lumen of the
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nuclear envelope.
The nuclear lamina, in addition to the known components lamin-A/C,
lamin-B and emerin (a lamin-binding protein), is composed of proteins that are
part of the LINC complex (Linker of Nucleoskeleton and Cytoskeleton), which
connects the nucleoskeleton to the cytoskeleton (Crisp et al., 2006; Dechat,
Adam, Taimen, Shimi, & Goldman, 2010; Starr, 2011; K. L. Wilson & Berk,
2010). The main components of the LINC complex are SUN and KASH pro-
teins. SUN proteins are transmembrane proteins immersed in the inner nu-
clear membrane, with the N-terminal oriented towards the nucleoplasm and
the C-terminal facing the nuclear membrane lumen. On the other hand, KASH
proteins span the outer nuclear membrane, with the N-terminal facing towards
the cytosol and the C-terminus in the lumenal space of the nuclear membrane.
The localisation and the way these two proteins interact resemble a nuclear
bridge, able to transmit signals and forces between the nucleoskeleton, the
cytoskeleton and the extracellular matrix (Crisp et al., 2006; Hodzic, Yeater,
Bengtsson, Otto, & Stahl, 2004; Starr, 2011; Wang et al., 2012)
SUN proteins interact with chromatin-associated proteins, with compo-
nents of the nuclear lamina in the nucleoplasm, and with KASH proteins in
the nuclear membrane lumen. KASH proteins are able to interact with dif-
ferent cytosolic proteins, including actin filaments, microtubules, intermediate
filaments and others, and regulate different cellular process in a great variety
of organisms. The mutations of KASH proteins have been associated with
various diseases, such as Emery-Dreifuss muscular dystrophy, cancer (colorec-
tal, gastrointestinal, ovarian and breast), autism disorders, hearing problems,
mental disorders and others (Luxton & Starr, 2014; Starr, 2011; Turgay et al.,
2014).
The mass spectrometry analysis identified, SUN2, kinesin, dynein and
torsin A (component of the nuclear membrane lumen) as potential binding
partners of nuclear beta-dystroglycan. Incorporating these finding with the
model suggested by Tadayoni and colleagues (Tadayoni et al., 2012), it is pos-
sible to hypothesize that beta-dystroglycan is able to interact with SUN2 and
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KASH proteins, which in turn triggers the formation of other complexes in
the cytosol, depending on the cellular context. During the development of
this thesis and in support of the above hypothesis, SUN1 and emerin nuclear
proteins, were found interacting with dystroglycan (Cisneros and Winder labs,
Steve Winder personal communication) (Figure 6.3).
Further research is required to confirm the proposed interaction between
beta-dystroglycan, SUN and KASH, and its biological and clinical significance.
Perhaps this new association will help to explain the molecular basis for the
centralised nuclei usually observed in muscular dystrophies, and alterations in
the nuclear shape and positioning of the centrosomes which have been reported
in different cancers (Gundersen & Worman, 2013).
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6.2 Future perspectives
The broad distribution in cellular organelles of differing tissues and species,
confers multiple functions on dystroglycan: whether they are advantageous or
disadvantageous, is something that has to be determined. During the course
of this thesis there were many questions that arose and these require answers
in order to have a better understanding of the effects of phosphorylation-
ubiquitination, RIP and the nuclear localisation of dystroglycan, particularly
in diseases, such as cancer and muscular dystrophies, and other cellular pro-
cesses, namely development. Those questions are described in the previous
chapters, but the most relevant, are enumerated in the objectives below:
1. To fully characterise the localisation and functionality of alpha-dystroglycan
in the nucleus.
2. To determine the effects of the over-expression of the cytoplasmic domain
of beta-dystroglycan in heterologous systems. Does it inhibit or stimulate
tumour progression?
3. To determine the effects of the extracellular domain of beta-dystroglycan
on adjacent and distant cells.
4. To determine the function of beta-dystroglycan in mitosis.
5. To further confirm that NEDD4L and HUWE1 are the ligases implicated
in the ubiquitination of beta-dystroglycan.
6. To further characterise the interaction of beta-dystroglycan with mem-
bers of the LINC complex.
7. To characterise the cross-talk between Notch and dystroglycan signalling
pathways.
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6.3 Conclusions
This work highlights the possibility that beta-dystroglycan may be subject to
multiple phosphorylation and ubiquitination post-translational modifications.
It also provides new evidence about another post-translational modification
mediated by gamma-secretase, regulated intramembrane proteolysis, that is
responsible for the further processing of beta-dystroglycan. The triggering of
these three PTM (ubiquitination, phosphorylation and RIP) seems to be ini-
tiated by extracellular events affecting the glycosylation of alpha-dystroglycan
in disease. The signals initiating these PTM appear to converge on the nucleus,
where the cytoplasmic fragment of beta-dystroglycan initiates and regulates
downstream events (Figure 6.4).
Although this work has provided more information about the post-translational
modifications and interacting partners of beta-dystroglycan, the question still
remains: what is the function of nuclear beta-dystroglycan in prostate cancer
cells?
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C
List of plasmids
Plasmid Features Antibiotic
resistance
Reference
pcDNA3.1-αDg-
myc/hisB
Encodes alpha-
dystroglycan with a
myc/his tag in its C-ter
Ampicillin Jane Hewitt,
University of
Nottingham
(unpublished).
pcDNA3.1(+)-
αβDg-myc/his
Encodes full length
αβDg with a myc/his
tag in its C-ter
Ampicillin Winder lab
(Thompson,
2007).
pcDNA2-αβDg Encodes full length
αβDg
Ampicillin Winder lab.
pcDNA2-
αβDgFlag
Encodes full length
αβDgFlag
Ampicillin This study.
pcDNA3.1(+)-
αβDgFlag
Encodes full length
αβDgFlag
Ampicillin This study.
pcDNA3.1(+)-
cdβDgFlag
Encodes cytoplasmic
domain of βDgFlag
Ampicillin This study.
pcDNA3.1(+)-
αβDgFlag-Y890F
Encodes full length
αβDgFlag with the
mutation Y890F
Ampicillin This study.
pcDNA3.1(+)-
αβDgFlag-
K806R
Encodes full length
αβDgFlag with the
mutation K806R
Ampicillin This study.
pGST-MD Encodes MultiDsk Ampicillin (M. D. Wilson et
al., 2012).
pKA417 Encodes GST Ampicillin Gift from K.R.
Ayscough.
Table C.1: List of plasmids
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D
Preparation of resolving and stacking gels
Separating gel (10 ml) Stacking gel (5 ml)
Concentration 7.5% 10% 12.5% 15% 5%
Acrylamide 2.5 3.35 4.15 5.0 0.8
Gel stock 3.75 3.75 3.75 3.75 0.625
Water 3.65 2.85 2.0 1.2 3.525
TEMED 5 µl 5 µl 5 µl 5 µl 15 µl
10% APS 100 µl 100 µl 100 µl 100 µl 50 µl
Table D.1: Volumes used to prepare Laemmli SDS-PAGE gels (Biorad appa-
ratus).
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Figure F.4: N-glycan biosynthesis. N-glycans or asparagine-linked glycans are
major constituents of glycoproteins in eukaryotes. N-glycans are covalently attached
to asparagine with the consensus sequence of Asn-X-Ser/Thr by an N-glycosidic
bond, GlcNAc b1- Asn. Highlighted in red are the proteins found immunoprecip-
itating with Flag (DPM1, OST and GANAB). http://www.kegg.jp/dbget-bin/
www bget?pathway+hsa00510.
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